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Parathyroid Localization
Nis Schmidt, MD, MSc, FRCSC
Member, Editorial Board, Canadian Journal o f  Surgery. Clinical Professor, Department o f  
Surgery, University o f  British Columbia, St. Paul’s Hospital, Vancouver, BC
Increased success in the surgical management of primary hyper­
parathyroidism results not from ad­
vances in localization, but from cer­
tainty of the diagnosis. After that 
the experience of the operator is 
the best guarantee for success in 
locating and removing overactive 
parathyroid tissue, bringing the 
clinical problem under control. In 
spite of great biochemical, isotopic 
and technical advances, the best 
preoperative localization techniques 
for discovering a parathyroid adeno­
ma are optimistically not better 
than 80% accurate in pointing to 
the offending parathyroid gland, or 
glands, when that organ is incrimi­
nated as the cause of the patient’s 
hypercalcemia.1 If all available in­
vestigative tools for locating an 
enlarged parathyroid or detecting 
increased parathormone concentra­
tion were brought to bear on every 
patient suspected of having primary 
hyperparathyroidism, the inconve­
nience, morbidity and cost factors 
would be unreasonable and the in­
creased sensitivity and specificity 
would still fall short of 100%.
Much has been written on the 
subject of preoperative parathyroid 
localization. Of historical interest 
only is the once-used barium swal­
low to locate a retroesophageal or 
retropharyngeal parathyroid tu­
mour. Selenium-methionine scan­
ning, thallium-technetium subtrac­
tion scanning, computed tomogra­
phy and and magnetic resonance
imaging have a specificity at best of 
80% and a sensitivity of 80%, in­
creasing as the gland diameter in­
creases over 1 cm.2 Arteriography 
and venous parathormone sampling 
are individually no more sensitive 
than the above investigative proce­
dures, but are much more invasive 
and therefore risky. Currently the 
least invasive and most widely avail­
able preoperative investigative tool 
used to locate a parathyroid tumour 
is real-time ultrasonography.
Wexler and associates in this 
issue of the Journal (pages 175 to 
180) give a thoughtful prospective 
evaluation of preoperative parathy­
roid ultrasonography versus para­
thyroid nuclear scanning. Their 
findings in a small series of 27
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patients treated at the Royal Victo­
ria Hospital in Montreal, an institu­
tion with experienced and skilled 
radiologists and surgeons, are bet­
ter than the literature would sup­
port — 78% sensitivity and 100% 
specificity to locate a parathyroid 
adenoma preoperatively to one side 
or other of the neck.
Once the hypercalcemic patient is 
considered to have primary hyper­
parathyroidism of significant mag­
nitude to justify surgical treatment, 
the failure to cure that patient 
through surgery depends on four 
factors: the size, location and num­
ber of the glands, and the experi­
ence of the operating surgeon.
Glands smaller than 1 cm in 
diameter (about 30% in our experi­
ence), unless they are located at the 
inferior poles of the thyroid lobes, 
are poorly seen by ultrasonography, 
and they are rarely seen if located 
deep to the thyroid lobes, adjacent 
or under the tracheoesophageal 
groove, or behind the superior thy­
roid poles. Glands in the thymic 
extension into the neck and those 
located deep to the clavicular heads 
and along the common carotid ves­
sels are rarely visualized. Large 
glands are easier to find at all 
locations in the neck. Glands great­
er than 2.5 cm in diameter are rare. 
Double adenomas are infrequently 
found by localization techniques be­
cause they are seldom of equal size, 
whereas hyperplasia of all the 
glands, especially in tertiary hyper­
parathyroidism of renal disease, is 
often well visualized. Parenthetical­
ly, the glands most easily visualized 
preoperatively by ultrasonography 
are usually easily found on explora­
tion of the neck. False-positive ul­
trasonographic findings for the 
most part are thyroid nodules or 
occasionally large lymph nodes. 
The bottom line of parathyroid sur­
gery is that in 85% of situations the 
parathyroid adenoma or hyperplasia 
is easily found by any surgeon
comfortable with operating in the 
neck. Careful bloodless dissection is 
the friend of success. It’s the 15% 
of cases that present difficulty, forc­
ing the parathyroid surgeon to stay 
longer, search deeper and use all 
the tricks known through experi­
ence to find the elusive tumour. 
The failure rate of parathyroid ex­
ploration should not exceed 5%.
Unilateral exploration cannot be 
advocated generally because preop­
erative localization does not yet 
give us that level of confidence. 
Admittedly once a parathyroid ade­
noma is located, the possible pres­
ence of a second adenoma is about 
2% on either side of the neck in our 
experience. If both parathyroid 
glands on one side are enlarged and 
diseased, there is a high chance 
that hyperplasia exists, and the sec­
ond side has to be explored. In spite 
of the preoperative ultrasonograph­
ic findings, if the suspected tumour 
is not found during neck explora­
tion the other side of the neck must 
be explored.1 If one satisfactory 
parathyroid tumour is located, it is 
not necessary to do a biopsy on all 
parathyroid tissue since the chance 
for ectopic parathyroid tumours or 
mediastinal tumours occurs in only 
1% to 2% of cases (personal unpub­
lished data).
For the most part, when a para­
thyroid exploration is being con­
templated, ultrasonography, in spite 
of its mediocre value in preoperative 
investigation, should be done. Even 
with a positive report from an expe­
rienced and confident radiologist, a 
bilateral neck exploration is still the 
best plan. If the radiologist is not 
confident, a marginal report can be 
disadvantageous to the surgeon 
with infrequent parathyroid experi­
ence. One must explore that patient 
with caution since a failed parathy­
roid exploration greatly increases 
the morbidity, risk and difficulties 
for the subsequent control of hyper­
calcemia of parathyroid disease.
Since the advent of accurate, 
widely available, multichannel bio­
chemical analysis, hypercalcemia is 
becoming uncovered within the 
general population quite often. This 
means that parathyroid exploration 
will be performed increasingly fre­
quently. It also means that with 
infrequent experience, the failed ex­
ploration rate will climb unless sur­
geons confronted with the clinical 
problem seek some advice and expe­
rience in finding the often hidden 
parathyroid adenoma. Until a better 
localization method is available, 
probably a tagged monoclonal anti­
body, practical help is available.
Intraoperative localization using 
methylene blue is of practical value, 
although few experienced parathy­
roid surgeons find it necessary; 500 
ml of dextrose and normal saline 
containing 5 m g/kg of methylene 
blue, infused rapidly over 30 min­
utes just after the induction of 
anesthesia, will in almost all cases 
stain the parathyroid adenoma a 
deep purple. The thyroid gland will 
stain a grey-blue, and normal para­
thyroid tissue rarely changes its tan 
brown hue. It amazes me how often 
a deep colour change speeds up the 
exploration and localization of para­
thyroid adenomas in the primary 
and in the repeat neck exploration 
and adds to the surgeon’s confi­
dence that abnormal parathyroid 
tissue has indeed been adequately 
removed.3
In my experience with parathy­
roid surgery, which has grown ex­
tensively in the past few years, a 
solid history and physical examina­
tion to rule out causes of hypercal­
cemia other than primary hyper­
parathyroidism, an accurate repeat­
ed determination showing an elevat­
ed calcium level, ionized calcium 
and parathormone measurements 
that are elevated or of high-normal 
values are sufficient to recommend 
parathyroid exploration by an expe­
rienced surgeon. Localization help
168 CJS, VOL. 33. NO. 3. JUNE 1990
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in addition to ultrasonography, 
through the use of intravenous 
methylene blue during surgery, 
should give even the occasional 
parathyroid surgeon confidence to 
explore and find most abnormal 
glands, and give them the satisfac­
tion which comes through treating
this interesting clinical problem 
successfully.
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Microvascular Reconstruction 
of the Hand
Ralph T. Manktelow, MD, FRCSC
Head. Division o f Plastic Surgery. Department o f Surgery, Toronto General Hospital. Toronto, 
Ont.
W hen I see a patient in the emergency department who 
has a serious hand injury or a 
finger or hand amputation I am 
often unsure of what is the best 
approach to treatment. From the 
technical standpoint there are usu­
ally several options available, from 
simple amputation closure to the 
most complex procedure — replan­
tation. It is technically feasible to 
repair, with varying degrees of 
functional success, tendons, bones, 
nerves, vessels, joints and skin. 
However, just because a technique 
of repair or reconstruction is avail­
able does not necessarily mean that 
it should be carried out.
The surgeon dealing with a badly 
mangled hand must look at what 
can be accomplished in terms of 
regaining the two main hand func­
tions — pinch and grip. Whether to 
repair and reconstruct depends on 
both biologic and psychosocial fac­
tors. The degree of damage to the 
various tissues and structures deter­
mines the extent of recovery. Can 
bones that are fixed or replaced 
unite, can tendons be repaired or 
replaced and develop good gliding, 
can nerves be repaired and have
useful sensibility and motor func­
tion, and will joints move again? 
Will skin coverage be adequate to 
handle the functional needs of the 
patient and provide not only dura­
ble, sensate coverage but adequate 
cosmesis? There are many variables 
that make functional recovery un­
predictable. However, the biology 
cannot be viewed in isolation from 
the patient and the patient’s unique 
psychosocial factors. The hand 
therapist who spends many hours 
with the patient postoperatively will 
find each one unique in the way 
that they pursue their therapy pro­
gram and cope with disability. 
These two factors — rehabilitation 
compliance and coping — are criti­
cal to the outcome of hand recon­
struction. Some patients pursue the 
tedious repetitions required in the 
therapy program with diligence and 
perseverance. Others do not have 
the motivation, endurance and abili­
ty to tolerate discomfort that are 
needed for successful therapy. In 
some situations the patient who is 
unable to pursue the therapy pro­
gram manually may be assisted with 
dynamic splints.
When sensory nerve injuries are
present even the best of repairs will 
never allow recovery of normal sen­
sibility. It is always difficult for the 
therapist and the surgeon to under­
stand why a patient who has poor 
sensibility will use the extremity 
well, but others who have minimal 
measurable loss of sensibility find 
this enough of a handicap to pre­
vent them from using the finger or 
hand. When the surgeon sees a 
patient in the emergency depart­
ment with a severe hand injury or 
amputation, how that person is 
going to cope and how vigorously 
they are going to pursue their exer­
cise programs are unknown factors. 
However, in the initial discussion 
with the patient, the surgeon may 
be able to make a tentative assess­
ment.
The patient with a hand amputa­
tion described in this issue by Ewart 
and Zuker (pages 239 to 242) illus­
trates the decision-making problem 
faced by the surgeon in the emer­
gency setting: The hand is almost 
completely severed with division of 
all structures except for extensor 
tendons. The wrist is destroyed ne­
cessitating shortening of the ex­
tremity and fusion of the metacar-
CJS, VOL. 33, NO. 3. JUNE 1990 169
MANKTELOW
pals to the distal radius. Will the 
loss of the wrist and loss of the 
normal mobility of the base of the 
thumb be of such functional disad­
vantages that the patient is better 
off with a prosthesis? There is no 
sure answer to this question be­
cause the biologic and psychologi­
cal factors, which determine the 
value of the surgery, are largely 
hidden from the surgeon at the time 
of the preoperative emergency con­
sultation.
The final factor that affects deci­
sion-making is the patient’s func­
tional requirements for the hand. 
These requirements include self- 
care, hobbies, sports and vocation. 
A man who uses his hand in the 
northern bush to cut trees needs a 
hand which is strong and pain free, 
with good sensibility and one that 
can tolerate cold weather. A seam­
stress who uses her hand for meti­
culous activities needs good sensi­
bility in the fingers but may not 
need a lot of strength. Cold sensi­
tivity will not be a problem. The 
watchmaker who works with jewel­
ler’s forceps needs extreme sensibil­
ity but does not need a lot of 
movement. The mechanic or tool 
and die maker needs a strong grasp 
for tools such as a wrench or a 
screwdriver and needs full wrist 
movements so that the hand can be 
placed in awkward positions about 
machinery. For some persons, play­
ing squash, skiing or bicycling are 
very important activities in bringing 
satisfaction to their lives. For oth­
ers the requirements are more ba­
sic. What do they need to be able to 
eat, wash and clothe themselves? 
For all patients function will be 
adversely affected by pain.
The effect of a hand injury on 
body image is usually considered 
relatively unimportant compared 
with its effect on pinch or grip. 
Obviously the appearance of a per­
son’s face is important to them in 
their ability to relate to people
socially. However, the appearance 
of the hand has long been underap­
preciated in terms of its psychoso­
cial effect on the patient. Many 
patients will not use an ugly hand 
which has good pinch or grip capa­
bility because they do not want the 
hand to be seen, believing that it 
makes them look deformed. The 
effect of this factor varies with 
psychosocial background; for exam­
ple, a patient from a Third World 
country who has had an amputation 
may not allow the extremity to be 
seen because in that country an 
amputation would indicate the pres­
ence of a socially unacceptable con­
dition. Occasionally, the psychoso­
cial effect of an amputation will be 
so severe that a replantation may be 
beneficial even if the hand is of little 
functional use. Conversely, a man 
who works in a shipyard or other 
occupation where many people have 
lost fingers may find an amputation 
a “badge of respect” among his 
fellow workers.
The advent of microvascular sur­
gery has given us the technical 
feasibility to reattach amputated 
parts. The decision to reattach de­
pends upon the functional contribu­
tion of the amputated part in terms 
of grip and pinch capability and of 
psychosocial value. The latter is 
extremely difficult to evaluate in the 
emergency situation. Generally, sur­
geons believe that a single finger 
should not be reattached because it 
will not have a normal range of 
motion or normal sensibility and 
will tend to be bypassed in favour of 
the rest of the hand for many 
functional activities. Furthermore, a 
finger which is stiff tends to get in 
the way and limits the overall use­
fulness of the hand. Therefore, for 
a labourer a single digit replanta­
tion may be more of a liability than 
an asset. Replantations which are 
distal to the proximal interphalan- 
geal joint are usually better than 
more proximal replantations, be­
cause the joint is functioning and 
composite finger motion is good. 
When two to four fingers have been 
amputated the usefulness of replan­
tation becomes much greater, be­
cause the possibility that total hand 
function will be improved by replan­
tation increases with the number of 
fingers that have been injured. 
When the thumb has been amputat­
ed replantation is almost always 
worthwhile, because the thumb is 
so important for both pinch and 
grip. The carpometacarpal joint is 
almost always preserved, allowing 
the thumb to be positioned for most 
of these activities. Amputations 
proximal to the palm are often 
associated with severe tissue injury 
which greatly limits the functional 
result.
Surgeons doing replantation 
must have a good understanding of 
the sophistication of prosthetic 
limbs. Dynamic hooks, myoelectric 
hands and “functional” cosmetic 
prostheses have improved greatly in 
recent years. Proximal level ampu­
tations through the palm, wrist and 
distal forearm are often useful lev­
els for replantation. Amputations in 
the proximal forearm usually do not 
lend themselves well to replantation 
because the fine motor nerves and 
vessels to the forearm musculature 
often cannot be repaired. Amputa­
tions of the upper arm are some­
times useful between the elbow and 
middle part of the humerus. More 
proximally there is usually unrepai­
rable injury to motor nerves to the 
upper arm musculature, poor rein­
nervation of forearm and hand mus­
culature and poor return of hand 
sensibility. Nevertheless, there are 
no fixed rules for replantation. The 
decision on each patient must be 
made on the basis of the injury, the 
patient’s personality and the func­
tional requirements of the hand. 
For this, the benefits of an experi­
enced team approach are invalua­
ble. ■
170 CJS, VOL. 33, NO. 3, JUNE 1990
f
k A
U - A 
, A
k,, k
k •
V i
►* > 
►
Laparoscopy has been a standard form of treatment for 
gynecological diseases, but is now showing promise in the treatment 
of general surgical disorders such as cholelithiasis, appendicitis, and 
intra-abdominal adhesions. Laparoscopy allows outpatient or 
overnight stays in the hospital and enables the patient to return to 
normal activity in a few days instead of a few weeks.
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CORRESPONDENCE
Atypical Tuberculosis 
Discovered in a Breast 
Nodule
To the editors. Atypical mycobac­
teria have been given increased at­
tention recently because of the fre­
quent development of infections due 
to Mycobacterium avium-intracel- 
lulare in patients with acquired im­
mune deficiency syndrome. Other 
nontuberculous myycobacteria 
have, however, been associated with 
human infections. In Ontario Myco­
bacterium xenopi is the second 
most commonly isolated such myco­
bacterium.1'2 These organisms may 
be resistant to first-line an- 
timycobacterial antibiotics.3 Al­
though usually a commensal in pa­
tients who have chronic obstructive 
lung disease, M. xenopi can pro­
duce cavitary pulmonary disease 
and has been isolated from bone, 
the urinary tract, epididymis, lymph 
nodes and a prosthetic joint.3
Case Report
An asymptomatic 25-year-old im­
migrant woman from Iran was 
found to have a breast nodule dur­
ing routine physical examination. 
Chest radiographs appeared normal. 
The 3-cm nodule, which was tender 
and mobile, was removed. Histolog­
ic examination of the nodule 
showed benign fibrocystic disease. 
The breast tissue sent for culture 
yielded M. xenopi. No acid-fast ba­
cilli were seen in the histologic 
specimens. The patient has re­
mained well and has not needed 
chemotherapy.
Comment
Mycobacterium xenopi was first 
isolated by Schwabacher in 19594 
from a cutaneous lesion of a South 
African toad. It has been associated 
with disease in humans, the most 
common of which is pulmonary 
infection. This case report is 
thought to be the first in which M. 
xenopi was cultured from breast 
tissue.
P. Murat, MD
P. Thomas, MB, FRCP(Lond),
FRCPC, FCCP
Department o f Medicine,
Division o f Respirology,
St. Michael’s Hospital,
University o f Toronto,
Toronto, Ont.
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Human Umbilical Vein 
Grafts
To the editors. I find it necessary to 
respond to the conclusion reached 
by Batt and colleagues in their 
reported experience with 52 human 
umbilical vein grafts placed in 48 
patients over a span of 9 years (Can 
J Surg 1990; 33: 61-65) to discon­
tinue use of this graft material as 
an arterial substitute.
My 16-year experience with over 
1000 implants reported in part in 
the Journal o f Vascular Surgery 
(1988; 7: 336-346) indicates the 
efficacy of the material as an arteri­
al conduit in properly selected cases 
and when attention is paid to specif­
ic technical details. We have not 
found it necessary, for example, to 
use a distal autologous venous in­
terposition, which may contribute 
to failure by adding composite anas­
tomosis. More importantly, Batt 
and colleagues stated that prior 
failure of lower limb bypasses had 
occurred in 22 of their cases (42%), 
but they did not emphasize the 
salvage role of the umbilical vein in 
these cases and in those with poor 
runoff, as suggested by the “rel­
atively large numbers of patients 
with far-advanced ischemia” . For 
the authors to cast blame on the 
umbilical vein graft in the form of 
their conclusion to discontinue its 
use is not warranted by the data.
Failure of revascularization is a 
complex phenomenon, probably 
multifactorial and frequently misun­
derstood. It is simplistic to blame a 
graft when the capacitance of the
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system may be limited, the resist­
ance significantly elevated, rheolog­
ic components not appreciated, pro­
coagulant factors not analysed and 
other factors that could have been 
investigated or considered were not.
Finally, the authors would have 
given their paper a better balance if 
they had referenced articles with 
contrary views.1-7 There must be 
something else amiss (other than 
the graft material) when different 
groups obtain conflicting results 
using the same material.
Herbert Dardik, MD, FACS
Chief, Department o f  Surgery.
Englewood Hospital.
Englewood. NJ
Using the same human umbilical 
vein graft with a different sample of 
patients would be expected to lead 
to a different experience. Such is 
the nature of clinical studies. No 
one study on its own can provide 
definitive conclusions. However, 
when sufficient weight of evidence 
points from a variety of different 
sources to the wisdom of discontin­
uing use of the human umbilical 
vein graft, we believe it is our 
responsibility as clinicians and re­
search scientists to report our con­
clusions.
Dr. Dardik is correct in challeng­
ing us to ensure a sound balance of 
references describing conflicting ex­
periences in each of our reports. We
believe we have followed his exam­
ple in this regard.
It is perhaps worth noting that, 
regardless of the clinical experience 
of any one hospital or clinical cen­
tre, the highly respected, successful 
corporation and former manufac­
turer of the chemically processed 
human umbilical vein graft, Meadox 
Medicals Inc., would not have aban­
doned this bioprosthesis recently 
had it foreseen a strong, expanding 
market.
R. Guidoin, PhD
Laboratory o f  Experimental Surgery,
Pavilion de Services,
Universite Laval,
Quebec, PQ
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To the editors. We appreciate Dr.
Dardik’s interest in our article, but
we respectfully suggest that there is
nothing “amiss” with our study.
SESAP VI Question
Item 121
A 19-year-old man is taken to the operating room urgently after an 
automobile accident. At celiotomy, he has a subcapsular hematoma of 
the liver that appears to be expanding, a pulverized spleen, and a jagged 
5- to 7-cm laceration of the left colon at the peritoneal reflection with 
moderate fecal contamination.
Treatment of the liver injury would best be accomplished by
(A) incising the capsule and directly ligating the bleeding vessels
(B) packing the liver and returning to the operating room in 48 to 
72 hours
(C) leaving the hematoma intact and draining the area thoroughly
(D) extending the incision into the chest and inserting an inferior 
vena cava shunt via the right atrium
(E) hepatic artery ligation
For the incomplete statement above select the best of the five 
completions.
For the critique of Item 121 see page 228.
(Reproduced by permission from SESAP VI Syllabus; Surgical Educa­
tion and Self-Assessment Program No. 6. For enrolment in the Surgical 
Education and Self-Assessment No. 6, please apply to the American 
College of Surgeons, 55 East Erie St., Chicago, IL 60611.)
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Preoperative Parathyroid Localization: a Prospective Evaluation 
of Ultrasonographyand Thallium-Technetium Scintigraphy in Hyperparathyroidism
Barry L. Stein, MD, CM; Marvin J. Wexler, MD, CM, MSc, FRCSC, FACS
To assess the ability of ultrasonography (US) and dual tracer thallium-technetium 
subtraction scanning (NS) to localize abnormal parathyroid glands, these two 
investigations were carried out preoperatively in 27 consecutive patients who 
underwent surgery for hyperparathyroidism. Nineteen patients had adenomas and 8 
hyperplasia. Of 23 US procedures 2 were inadequate, and of 26 NS procedures 1 
was inadequate.
Ultrasonography was found to be superior to NS for preoperative localization of 
abnormal parathyroid glands (sensitivity per gland 53% versus 36%); detection rates 
for hyperplasia were poor for both techniques (sensitivity per gland 36% and 25%). 
However, when positive, both techniques were extremely accurate (positive 
predictive value of 100% for both). There was no correlation between the weight of 
the gland or degree of physiological hyperfunction (parathyroid hormone level) and 
detection rates for the two techniques. False-positive results were rare for both, so a 
positive result was highly predictive of an abnormality at that location.
Ultrasonography had sufficient accuracy to suggest its routine use when adenoma 
is suspected, particularly to detect the side of the lesion (sensitivity 78% and 
positive predictive value 100%). The addition of subtraction scintigraphy does not 
appear to be warranted.
Dans le but d’evaluer la capacite de l’echographie (EG) et celie de la scintigraphie a 
double definition par soustraction au thallium-technetium (SG) pour localiser les 
parathyroides anormales, ces deux examens ont ete pratiques avant la chirurgie 
chez 27 patients consecutifs qui ont ete operes pour hyperparathyroidie. Dix-neuf 
patients etaient porteurs d’adenomes, alors que 8 souffraient d’hyperplasie. Sur 23 
EG pratiquees, 2 ont ete insatisfaisantes comparativement a 1 sur 26 pour les SG.
L’echographie s’est montree superieure a la SG pour la localisation preoperatoire 
des parathyroides anormales (taux de sensibilite par glande de 53% par rapport a 
36%); le taux de detection des hyperplasies a ete mauvais pour les deux techniques 
(sensibilite par glande de 36% et de 25%). Toutefois, lorsqu’elles etaient positives, 
les deux techniques etaient extremement precises (pouvoir predictif positif de 100% 
pour les deux). On n’a observe aucune correlation entre le poids de la glande ou le 
degre d’hyperfonctionnement physiologique (le niveau d’hormone parathyroidienne) 
et les taux de detection des deux techniques. Les faux positifs ont ete rares avec les 
deux techniques. En consequence, un resultat positif etait fortement predictif d’une 
anomalie au foyer localise.
L’echographie possedait une precision suffisante pour suggerer son emploi 
systematique quand un adenome est soupfonne, particulierement lorsqu’il s ’agit de 
localiser la lesion (sensibilite de 78% et pouvoir predictif de 100%). L’ajout de la 
scintigraphie de soustraction ne parait pas justifie.
Primary hyperparathyroidism can be effectively treated in 
90% to 95% of cases at first opera­
tion by an experienced parathyroid 
surgeon by excision of the diseased 
glands.1 In the other 5%, a missed 
abnormal parathyroid gland is the 
most common cause of failure.2 The 
operation is often difficult. Unusual 
and ectopic locations are common, 
and supranumerary glands occur in 
5% to 8% of patients. Extensive 
dissection with exposure and biopsy 
of all glands has been advocated3 
but carries a risk of complications. 
For the occasional neck surgeon, 
location of the four parathyroid 
glands can be tedious, and failures 
of primary exploration are not un­
common.
To facilitate exploration, reduce 
operating time and increase the
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success rate for the occasional sur­
geon, numerous techniques for pre­
operative localization of abnormal 
parathyroid glands have been tried. 
They include thermography, galli­
um and selenium nuclear scanning, 
cine-esophagography, lymphogra­
phy and various intraoperative 
staining techniques. None has been 
consistently successful. We report­
ed an unsatisfactory experience 
with high-resolution computed to­
mography.4 Selective angiography 
and venography with venous hor­
mone assay are time-consuming, 
technically difficult and risky,5 and 
are usually reserved for reoperation. 
Thallium-technetium subtraction 
scanning (NS) and ultrasonography 
(US) are newer, readily available, 
noninvasive localization techniques, 
and recent reports of their use have 
been encouraging.6' 8 In this paper, 
we report the results of a prospec­
tive study using these two investi­
gations in 27 patients who under­
went surgery for hyperparathyroi­
dism.
Patients and Methods
Between January 1986 and July 
1988, 27 consecutive patients (19 
women, 8 men), ranging in age 
from 16 to 70 years (mean 51 
years) and scheduled to undergo 
surgery for hyperparathyroidism, 
had preoperative localization 
studies; 25 had both US and NS 
and 2 had NS only. Preoperative 
parathyroid hormone levels were 
measured for all patients using a 
C-terminal assay.9 The results of 
the localization studies were known 
to the surgeon preoperatively. All 
patients underwent neck explora­
tion by the same surgeon. All para­
thyroid glands were identified at 
surgery and detailed records were 
kept of the location, size and 
weight of the abnormal glands. The 
operative findings were compared
with the preoperative US and NS 
findings, and the studies were then 
collectively reinterpreted by a single 
nuclear radiologist or ultrasonogra- 
pher to assess their reproducibility.
Ultrasonography was performed 
using a real-time scanner (Diasonic 
DRF 400; Diasonics Inc., Milpitas, 
Calif.) with a 10 MHz small-parts 
probe. The patients were examined, 
in transverse and longitudinal 
planes, supine with the neck slight­
ly hyperextended. Acoustic gel was 
used as a couplant.
Nuclear scanning of the neck, 
including a portion of the superior 
mediastinum, was done with the 
patient supine and the head and 
neck extended and immobilized. 
Thallium-201 (2 mCi) was injected. 
Five frames of 5 minutes each were 
taken immediately after the injec­
tion with a low-energy all-purpose 
collimator in magnification mode. 
Technetium pertechnetate (1 mCi) 
was then injected. A single frame of 
5 minutes was taken after a 
5-minute waiting period. At the 
termination of scanning, the neck 
was palpated and the presence or 
absence of any nodularity was not­
ed. Subtraction of the technetium 
from the thallium image was then 
carried out by computer.
Operative findings were the stan­
dard against which the localization 
studies were compared. A true-posi­
tive result correctly predicted an 
abnormality found at surgery. A 
false-negative one implied a failure 
of the technique to detect disease 
confirmed operatively. The results 
of the studies were tabulated in 
three ways: (a) the ability of the 
technique to predict correctly 
whether each parathyroid gland was 
normal or abnormal; (b) its ability to 
detect correctly the side of the neck 
on which each abnormal gland was 
located; and (c) its ability to make 
the correct predictions overall, con­
sidering all four parathyroid glands 
as one unit.
Statistical Analysis
This was carried out using the 
following standard definitions: sen­
sitivity =  true positives/true posi­
tives + false negatives; specificity = 
true negatives/true negatives + 
false positives; positive predictive 
value = true positives/true posi­
tives + false positives; negative pre­
dictive value = true negatives/true 
negatives + false negatives. Stu­
dent’s t-test was used to analyse the 
differences.
Results
From the operative and histologic 
findings, 19 patients were found to 
have solitary adenomas and 8 hy­
perplasia (6 tertiary, 2 secondary). 
Of the 25 US procedures, 2 were 
technically inadequate, and of the 
27 NS procedures, 1 was inade­
quate. The operative location of the 
abnormal glands and results of the 
localization tests are shown in 
Table I, together with the weight of 
the abnormal glands for adenoma 
and hyperplasia.
Ultrasonography
Ultrasonography (Table II) cor­
rectly predicted 18 glands as being 
abnormal and 56 as normal; howev­
er, 16 abnormal glands were missed 
and there were 2 false-positive pre­
dictions. Sensitivity and specificity 
were 53% and 97% respectively per 
gland. These values increased to 
61% and 100% when only the side 
of the neck was considered (Table 
III). When the data were reanalysed, 
separating the adenomas from hy­
perplasia, the sensitivity per gland 
was 67% and 36% respectively (Ta­
ble IV). Considering only the side of 
the neck, these values were 78% for 
adenomas and 30% for hyperplasia. 
The positive predictive value was 
100% for both adenoma and hyper-
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plasia per side of the neck.
Nuclear Scanning 
Comparable results for NS are
shown in Tables V to VII. Of 104 
glands examined, this technique 
correctly identified 14 as being ab­
normal and 65 as normal. There 
were no false-positive results, but 
25 surgically abnormal glands were
Table 1. S u m m a ry  o f P a tie n ts
^  v -
Location Prediction
• ¥■ Patient no. at surgery Ultrasonography Nuclear scanning Wt, gt
A de n o m as
1 LU LU N o rm a l 0 .49
* - 2 LL LL LL 1.03
3 LL N o rm a LL _
C k 4 RL RL RL 0 .64
5 LL LU LL 1.68
■ 6 RL RL N o rm a l 2 .25
7 LU LL N o rm a l 2 .29
8 LL LL N o rm a l _
9 RU N o rm a N o rm a l _
10 RL - N o rm a l 0 .4 9
11 RL N o rm a N o rm a l 0 .22
12 RL ND RL 1.26
13 RL RL N o rm a l -
14 RL RL RL 1 0 .47
15 LL LL N o rm a l ND
k A 16 RL RL RL 0 .53
17 RU N o rm a N o rm a l 0 .4 6
*  > 18 LL LL LL 2 .13
19 RL RL RL 1.38
H yp e rp las ia *
20 R U .LU N o rm a LU 1 .3 8 ,3 .0 8
21 R U ,R L RL ND 0 .2 ,0 .6
L U .L L 0 .5 ,0 .2 4
i  . 22 R U ,R L - N o rm a l 0 .5 7 ,0 .3
L U .L L 0 .2 ,0 .3 5
23 R U ,R L ND N o rm a l -
LU
24 RL RL RL 1.1
25 R U .R L R L .LL RL 1 .9 ,0 .2 8
L U ,L L 0 .4 4 ,0 .1 3
26 R U ,LU RU LU 0 .7 6 ,0 .7
► . 27 R U ,R L R U ,R L RL 1 .0 2 ,0 .7
L U .L L 0 .6 7 ,0 .0 2
’ A lth o u g h  h yp e rp la s ia  p a th o lo g ic a lly  in vo lves  a ll 4  g la n d s , if, a t su rg e ry , a g la n d  w as m in im a lly
en la rged  and d id  n o t re q u ire  re m o va l, it w as co n s id e re d  n o rm a l fo r  th e  p u rp o se  o f  th is  s tu d y .
k '  ^ fW e ig h t  o f th e  lig h te s t g la n d , in  cases w ith  4  w e ig h ts  p ro v id e d , re f le c ts  o n ly  a pa rtia l (b io p s y )
w e ig h t fro m  th a t g la n d , w h ic h  w a s  le ft in s itu  o r  t ra n s p la n te d  and d o e s  n o t re f le c t  th e  to ta l w e ig h t
o f th a t g land.
LU =  le ft u p per neck , L L  =  le f t  lo w e r neck , RL =  r ig h t lo w e r neck , RU =  r ig h t u p p e r neck ,
N o rm a l =  no a b n o rm a l g la n d  d e tec te d , ND =  n o n d ia g n o s tic .
• / Table II. U ltra s o n o g ra p h y : R e su lts  A c c o rd in g  to  T h re e  C a tego ries
*  *■ Per patient, Per side of neck, Per gland,
Pathologic type n =  23 n =  46 n =  92
of abnormality TP FP FN TP TN FP FN TP TN FP FN
P "  A A de n o m as 12 2 4 14 18 0  4  12 52  2 6
H ype rp las ia 0 0  5 3  0 0  7  6 4  0  10
T o ta ls 12 2 9 17 18 0  11 18 5 6  2  16
TP =  tru e  p o s itive , TN =  tru e  n e g a tive , FP =  fa ls e  p o s it iv e , FN =  fa ls e  nega tive .
erroneously predicted as normal 
(i.e., no parathyroid seen after sub­
traction scanning). The sensitivity 
per gland, which was 36%, in­
creased only slightly to 38% when 
only the side of the neck was 
considered (Table VI). Specificity 
and positive predictive value were 
both 100%. When considered ac­
cording to pathologic type (Table 
VII), the sensitivity per gland was 
47% for adenoma and 25% for hy­
perplasia, and the specificity and 
positive predictive value were 100% 
for both.
Gland weight was used as an 
indirect, reproducible measure of 
the size of the gland. When US 
correctly identified an abnormal 
parathyroid, weights ranged from 
0.2 g to 10.47 g (mean 1.67 g) 
(Table VIII). The technique failed to 
identify abnormal glands that 
ranged in weight from 0.2 g to 3.08 
g (mean 0.98 g). There was no 
correlation between the weight of 
the abnormal gland and the ability 
of US to detect it correctly (p > 
0.05). As was the case with US no 
correlation was found between 
gland weight and detection rate for 
NS (mean = 2.06 g versus 1.00 g).
In 25 of the patients the serum 
parathyroid hormone level was de­
termined before the localizing pro­
cedures were performed (Table IX). 
Of the patients who had an elevated 
level (> 30 pg/ml), 8 were correct­
ly identified by US as having abnor­
mal glands and 9 had false-negative 
results. Nuclear scanning gave 10 
true-positive results and 9 false­
negative ones. Again, no correlation 
could be found between detection 
rate and parathyroid hormone level 
for either US or NS [x = 0.15 for 
US and 0.37 for NS, kappa index of 
concordance10).
Six patients were identified on 
palpation as having multinodular 
goitre. Two tests of US were non­
diagnostic, three gave true-positive 
results and one a false-negative re-
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suit. On NS, three tests gave false­
negative results and three true-posi­
tive.
Discussion
Since all patients with hyperpara­
thyroidism have at least four para­
thyroid glands with one or more 
abnormal glands, a true test of a 
localizing technique is not only its 
ability to detect an abnormal gland 
but to predict the status of each 
parathyroid gland. Normal glands 
usually cannot be detected either by 
US or subtraction scanning; there­
fore, neither technique should have 
detected an abnormal focus in the 
location of a normal gland. If an 
abnormal gland is present, it should 
be detected and correctly localized. 
If an abnormality is predicted in the 
upper neck and is found at surgery 
to be in the lower neck, then the 
technique is in error. However, for 
the surgeon, the side of the abnor­
mality is perhaps of greater impor­
tance. We chose, therefore, to ana­
lyse our data in three ways: accura­
cy per gland (assuming four 
glands), accuracy per side of the 
neck and accuracy per patient as a 
whole (all four glands taken togeth­
er as one unit).
For both techniques, false-posi­
tive results were rare; there were 
none for NS, only two for US and 
none per side of the neck for either 
technique. Thus, the specificity was 
almost 100% in all instances. The 
failures were the result of the tech­
nique not finding the abnormality 
that existed.
Ultrasonography had a sensitivity 
of 53%. This increased to 61% 
when only the side of the neck was 
considered. Nuclear scanning’s sen­
sitivity was inferior to US in all 
categories.
The histologic type of the abnor­
mality is thought to play an impor­
tant role in the localization abilities
of both US and NS. The sensitivity 
of US for adenomas was far greater 
than that for hyperplasia (67% ver­
sus 36%) even though our patients 
were an unusually select group with 
secondary and tertiary hyperplasia, 
often with very large glands. Simi­
larly, NS was almost twice as effec­
tive in detecting adenomas as hy­
perplasia (47% versus 25%). This 
trend has been observed for both 
techniques by others11-14 and re­
mains unexplained. It is not neces­
sarily related to the size of the 
abnormal glands. In our series, 
weight as an indirect measure of
Table III. Ultrasonography: Sensitivity and Specificity According to the Three Categories 
Per patient, % Per side of neck, % Per gland, %
Sensitivity 57 61 53
Specificity - * 100 97
Positive predictive value 86 100 90
Negative predictive value - * 62 78
'Since all patients had diseased glands, true-negative results are not possible when considering 
the patient as a whole, and specificity and negative predictive values do not apply. However, this 
is not so when a single gland or side of the neck is considered.
Table IV. Ultrasonography: Sensitivity and Specificity According to Pathologic Type of
Abnormality
Per patient, % Per side of neck, 0/o Per gland, %
A H A H A H
Sensitivity 75 0 78 30 67 36
Specificity - - 100 - 96 100
Positive predictive value 86 0 100 100 86 100
Negative predictive value - - 82 - 90 29
A =  adenoma, H =  hyperplasia.
Table V. Nuclear Scanning: Results According to Three Categories
Per patient, Per side of neck, Per gland,
Pathologic type n =  26 n = 52 n = 104
TP FP FN TP TN FP FN TP TN FP FNof abnormality
Adenoma 9 0 10 9 19 0 10 9 57 0 10
Hyperplasia 1 0 6 3 1 0 10 5 8 0 15
Totals 10 0 16 12 20 0 20 14 65 0 25
Table VI. Nuclear Scanning: Sensitivity and Specificity According to the Three Categories
Per patient, °/o Per side of neck, % Per gland, %
Sensitivity 38 38 36
Specificity - 100 100
Positive predictive value 100 100 100
Negative predictive value 50 72
Table VII. Nuclear Scanning: Sensitivity and Specificity According to Pathologic Type of
Abnormality
Per patient, % Per side of neck, % Per gland, %
A H A H A H
Sensitivity 47 14 47 23 47 25
Specificity - - 100 100 100 100
Positive predictive value 100 100 100 100 100 100
Negative predictive value - - 66 9 85 35
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size did not correlate with detection 
ability for either US and NS or 
adenoma and hyperplasia. This is 
contrary to the findings of some. 
For example, Gimlette and col­
leagues15 found that 25 of 26 para­
thyroid glands having a mass great­
er than 1 g were correctly located; 
none of 10 glands having a mass 
less than 0.3 g was correctly locat­
ed by scanning. Thallium-201 up­
take (%/g) did not differ between 
hyperplastic and adenomatous 
glands. Kim and associates16 per­
formed subtraction scintigraphy on 
33 patients; 22 of 29 adenomas 
were correctly localized, but only 1 
of 4 patients who had multigland 
enlargement had all the enlarged 
glands localized. However, 50% of 
the lesions weighing less than 0.3 g 
were successfully identified.
Parathyroid hormone levels did
not correlate with detection rates 
for either technique. For US this 
finding may reasonably be expected, 
since the technique detects struc­
ture and not function. Nuclear 
scanning, however, may be func­
tionally dependent. The thallous ion 
is an analogue of the potassium ion 
and, like potassium, is extracted by 
cells upon perfusion. The high cel- 
lularity and vascularity in function­
ing lesions may be a factor in its 
uptake17 and perhaps more likely to 
increase with increased production 
and secretion of parathyroid hor­
mone. The facts that such secretion 
is periodic and serum levels were 
not measured concurrently with 
NS, may explain the lack of correla­
tion noted.
Dual tracer scintigraphy with 
thallium and technetium is reported 
by some1112 to have a localization
sensitivity as high as 70% to 90%. 
Our lower rate may be due to the 
dose of 1 mCi of technetium we 
used, which is lower than that 
recommended by others.16 Thallium 
accumulates in both parathyroid 
and thyroid tissue, technetium only 
in the thyroid. The subtraction of 
the two scans shows the location of 
abnormal parathyroid tissue. With a 
lower dose of technetium, the thy­
roid is not as “hot” , so the poten­
tial difference on digital subtraction 
is minimized, resulting in a lower 
sensitivity. However, our results are 
almost identical to those of Attie 
and colleagues14 who used a 5 mCi 
dose in 62 adenomas, ranging in 
size from 1 to 4 cm in diameter, and 
had only 59% sensitivity.
Many thyroid nodules do not ac­
cumulate technetium but do accu­
mulate thallium. Thus, when the 
technetium scan is subtracted from 
the thallium scan, a thyroid nodule 
might give a false-positive result.18 
This can be avoided by palpating 
the neck and thyroid to detect such 
nodules for consideration when in­
terpreting the scan. This was not a 
problem in our study, because we 
had no false-positive results in our 
six patients with multinodular 
goitre. Likewise, nodules or cysts 
within the thyroid gland may be 
erroneously interpreted by US as an 
abnormal parathyroid or conversely 
create difficulties in detecting a con­
tiguous enlarged parathyroid. Three 
of four adenomas missed by US in 
the series of Dwarakanathan and 
colleagues13 are explained thus. 
Again, this was not the case in our 
experience.
Our results compare favourably 
with those of early studies indicat­
ing the accuracy of US for preoper­
ative localization of adenomas and 
its superiority over NS. No modality 
is ideal, each gives some false-nega­
tive results, but we have found few, 
if any, false-positive results when 
the findings in patients with nod-
Tab le  V III.  C o rre la tio n  o f W e ig h t (g ) o f A b n o rm a l G la n ds  and D e tec tio n  A b ility
U ltrason ograph y N uc lear scann ing
TP FN TP FN
0 .2 8 0 .2 0 0 .2 8 0.30
0 .49 0 .2 4 0 .5 3 0.35
0 .5 3 0 .4 4 0 .6 4 0.44
0 .6 0 0 .4 6 0 .7 0 0.46
0 .6 4 0 .6 7 0 .7 0 0.49
0 .7 0 0 .7 0 1 .38 0.49
0 .7 6 1 .38 1 .68 0.57
1.02 1.68 2 .1 3 0.67
1.03 1.90 1 0 .4 7 0.76
1.10 2 .29 1.02
1.38 3 .0 8 1.10
2 .13 1.18
2 .25 1.90
10 .47 2.25
3.08
M ean  1 .67 0 .9 8 2 .0 6 1.00
In ca se s  o f 4 -g la n d  h yp e rp las ia , th e  w e ig h t o f  an in c o m p le te ly  e xc ised  o r  p a r t ia lly  t ra n s p la n te d  
fo u r th  g land  is  n o t in c lu d e d  in  th is  ta b u la tio n .
T a b le  IX . C o rre la tio n  o f P a ra thy ro id  H o rm o n e  Leve l and D e tec tio n  A b ility
P ara th yro id  horm one  
le v e l, pg /m l
U ltraso n o g rap h y N u c lear scanning
TP FN TP FN
0 - 3 0  (n o rm a l) 4 2 0 7
3 0 - 6 0 2 1 3 1
60  - 1 0 0 3 5 4 4
> 1 0 0 3 3 3 4
T o ta ls 12 11 10 14
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ules in the thyroid are interpreted 
with care. Although greater accura­
cy may be obtained by combining 
two or three modalities, this does 
not appear to be cost effective. In 
our hands, the contribution of sub­
traction scintigraphy in addition to 
US was minimal. Both studies, car­
ried out in 18 patients with adeno­
mas, correctly localized the lesion 
in 7 patients; in 3 neither study was 
effective. In eight patients, only one 
modality was positive and in six of 
these it was US that detected the 
lesion. Similar findings have been 
reported by Attie and colleagues.14 
Of 32 patients in their series who 
underwent three imaging studies 
(including magnetic resonance im­
aging), the adenoma in 13 cases 
was accurately imaged by two mo­
dalities but not by the third. In 12 
of the 13 the test that failed was 
subtraction scintigraphy.
Ultrasonography for parathyroid 
glands requires a radiologist skilled 
in this application. In such a set­
ting, it provides an effective, safe, 
noninvasive and inexpensive localiz­
ing procedure for parathyroid ade­
nomas. At present, our data sug­
gest that US is useful in directing 
the surgeon to the appropriate side 
of the neck in the case of adenomas 
(sensitivity 78%, specificity 100%). 
We believe, as do Mattar and associ­
ates17 and Attie and colleagues,14 
that this will decrease operating 
time by limiting the extent of dis­
section. It can allow the surgeon to 
plan the dissection preoperatively 
and direct attention to the affected 
side of the neck. Previously, we 
have strongly advocated that all
parathyroid glands should be ex­
plored and biopsied.3 It may now be 
reasonable to reconsider the conser­
vative approach of unilateral neck 
exploration. If US (with or without 
NS) localizes an abnormality to only 
one side and if, at surgery, an 
abnormal gland is found on that 
side, together with a normal gland, 
then perhaps the opposite side of 
the neck need not be explored. The 
reported incidence of hypocalcemia 
varies depending upon the extent of 
parathyroid dissection and biopsy.19 
Arguments favouring a conservative 
approach are strengthened if preop­
erative US also demonstrates no 
abnormality on the contralateral 
side. It follows that preoperative 
localization of an adenoma could 
reduce the extent of dissection and 
the morbidity without significantly 
increasing the risk of persistent 
hypercalcemia.
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Feeding Jejunostomy: 
a Safe Adjunct to Laparotomy
It is well established that a feeding jejunostomy is an invaluable adjuvant for use in 
critically ill and malnourished patients. What is not well known are the 
complications of inserting these tubes. Some surgeons are reluctant to insert 
feeding tubes unless the indications are very clear. From their experience with the 
insertion of 133 feeding jejunostomy tubes during a 3-year period, the authors 
conclude that the complications associated with the insertion of such tubes are few 
and that the procedure is justified even if the tube is never used.
II est bien etabli que la jejunostomie d’alimentation constitue un adjuvant 
incomparable pour le patient gravement malade souffrant de denutrition. Ce qu’on 
connait moins bien, ce sont les complications relatives a l’insertion de ces tubes. 
Certains chirurgiens hesitent a poser des tubes d’alimentation a moins que les 
indications en soient tres claires. Apres avoir inserer 133 tubes d’alimentation au 
cours d’une periode de 3 ans, les auteurs concluent que les complications reliees a la 
pose de ces tubes sont peu nombreuses et que l’intervention est justifiee, meme si le 
tube n’est jamais utilise.
There has been a resurgence of interest recently in jejunosto­
my feeding to provide nutritional 
support.1-3 This has been precipitat­
ed, in part, by the expenses and 
potential complications associated 
with parenteral nutrition.4 Current 
opinions favour the administration 
of nutrients through the gut, a 
route that is more physiological and 
efficient.5 There have also been 
great improvements in the formula­
tion and techniques of enteral feed­
ing. Nasogastric tube feeding is 
clearly the safest and least compli­
cated method of delivering enteral 
nutrients. Yet there are a number of
Accepted for publication June 22, 1989
clinical situations in which surgical­
ly inserted feeding tubes have cer­
tain advantages. In this paper we 
review the experience at the Ottawa 
General Hospital with feeding jeju­
nostomy.
Patients and Methods
We reviewed the records of all 
patients in whom a feeding jejunos­
tomy tube was inserted at the Otta­
wa General Hospital between 1981 
and 1984. There were 133 patients 
(56 men 77 women).
The indications for the procedure
are shown in Table I: 93 patients 
underwent major upper gastrointes­
tinal procedures and a feeding jeju­
nostomy was inserted at the same 
time to ensure adequate nutritional 
support distal to the operative site; 
33 patients had a feeding jejunosto­
my inserted in anticipation of a long 
or potentially complicated postoper­
ative recovery period; 7 patients had 
neurologic disorders.
The feeding jejunostomy was ins­
erted in conjunction with other ab­
dominal surgical procedures in 110 
cases, but in 23 cases the jejunosto­
my was inserted as a separate oper­
ative procedure; 10 of the 23 were 
done under local anesthesia because 
of the poor general condition of the 
patient.6 Approximately 75 of the 
133 tubes were inserted by one 
surgeon (J.B.F.).
We inserted jejunostomy tubes in 
13 patients with frank intra-abdomi­
nal sepsis, including perforated vis- 
cus, anastomotic dehiscence or dis­
placed, leaking gastrostomy tubes.
The standard Witzel technique 
was used in all patients.7 A 3 mm 
cautery incision was made through 
the serosa and muscularis on the 
antimesenteric border. The bowel 
wall was grasped firmly between 
thumb and forefinger to make the
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mucosa pout outward. The mucosa 
was touched with the cautery and 
the bowel swabbed with povidone- 
iodine solution. The catheter was 
inserted through this enterotomy 
and secured with a 3-0 Vicryl purse­
string suture. A 5 cm serosal tunnel 
was constructed with 3-0 Vicryl or 
silk. The catheter was brought 
through the abdominal wall away 
from the primary incision, with the 
proximal end of the bowel located 
superiorly. It is useful to record this 
technical information in case rein­
sertion of the catheter is ever neces­
sary. Care was taken to fix the 
entire 5 cm tunnel to the abdominal 
wall to prevent kinking, bowel her­
niation and dislodgement of the 
tube. The average time for the 
procedure, when done in conjunc­
tion with other operations was 10 
minutes.
Three types of catheter were used 
— red rubber (in 78 cases), Silastic 
(in 35) and Foley (in 20). Their 
sizes ranged from 8 to 16 French 
but a no. 10 French red rubber 
catheter was used in the majority of 
patients.
Results
The catheter was used for nutri­
tional support in 120 of the 133 
patients (90%); enteral feeding was 
considered unnecessary in 13 pa­
tients.
The average length of use was 38 
days (range from 1 to 285 days). 
More than half the patients contin­
ued to use the feeding jejunostomy 
at home. There were no operative 
deaths or morbidity related to inser­
tion of the tube. After removal of 
the tube the fistula closed spontane­
ously in all patients. Two patients 
had aspiration pneumonia. Tube 
blockage was a frequent problem, 
particularly when the smaller Silast­
ic catheter was used. This problem 
was easily rectified by irrigation
techniques in all but two patients in 
whom percutaneous tube replace­
ment was necessary. The tube was 
accidentally pulled out in 18 pa­
tients. It was replaced percutane- 
ously in 10 of these. Whenever 
percutaneous repositioning was re­
quired, the tube’s position was con­
firmed radiologically using soluble 
contrast material. In one patient 
this radiologic examination con­
firmed that the tube was outside the 
bowel. The tube was removed be­
fore feeding was started. Wound 
infection at the tube exit site oc­
curred in 10 patients (8%). All the 
infections were minor and respond­
ed to simple wound care.
Intolerance to the feeding for­
mula (diarrhea, cramping, abdomi­
nal distension, nausea and vomit­
ing) occurred in 45 (33%) patients. 
This was managed by reducing the 
flow rate and gradually reinstituting 
the enteral feeding according to a 
written protocol. The liberal use of 
antidiarrheal agents and constant 
infusion pumps were also helpful in 
controlling the diarrhea. In six pa­
tients, the symptoms were so severe 
that the enteral feeding had to be 
stopped.
Discussion
Although the feeding tube was 
often placed for prophylaxis, it was 
actually used in 120 of the 133 
patients for an average of 38 days. 
The technique is rapid, safe and 
simple. Very few deleterious side 
effects were reported even when the 
tube was not used for feeding. The 
time required and the paucity of 
complications suggests that feeding 
jejunostomy can be an integral 
component of many major abdomi­
nal procedures even in the absence 
of definite indications that enteral 
feeding will be required.
Feeding jejunostomies avoid the 
expense and potential hazards of
parenteral nutrition if feeding can 
be carried out distal to the site of 
the diseased area and as long as the 
gastrointestinal tract is functioning. 
An additional benefit of feeding je­
junostomy is the possibility of out­
patient feeding, which was carried 
out in more than half of the 133 
patients in this series. This had an 
obvious salutary effect upon the 
length of hospital stay.
One surgeon inserted most of 
these catheters. Conceivably, the 
relative paucity of complications 
was attributable to his individual 
experience. We reviewed the surgi­
cal literature related to complica­
tions associated with feeding cathe­
ters (Table II2'38' 12). It seems clear 
that feeding jejunostomy is a safe 
procedure in the hands of abdomi­
nal surgeons. Decision-making re­
garding its use is analogous to the 
consideration often given to inci­
dental appendectomy during other 
operations. The surgeon should be 
concerned about adding a proce­
dure which is marginally indicated. 
When such operations go awry, the 
surgeon may find it difficult to 
justify his decision. However, our 
experience and that in the literature 
supports the tenet that the risks are 
minimal but the potential benefits 
are great.
Our major catheter-related com­
plications included diarrhea and 
skin infections around the tube. 
The latter occurred in 10 (8%) of 
our patients, but these skin infec­
tions were superficial and easily 
managed. All jejunostomy fistulas 
closed after tube removal. The inci­
dence of tube dislodgement into the 
peritoneal cavity ranges from 1% to 
4% in the literature.3-81012 This 
complication occurred in only one 
patient in our series and fortunately 
was discovered before feeding be­
gan. The use of fluoroscopy and 
dye injection to confirm catheter 
position after any manipulation of 
the tube is recommended to prevent
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this potentially dangerous complica­
tion. This problem can also occur 
when dislodged tubes are reinserted 
percutaneously. After reinsertion 
and before feeding is reinstituted, it 
is mandatory to confirm, using 
contrast material, that the tube is in 
the bowel lumen.
Recently several patients of ours 
whose gastrostomy tubes became 
dislodged complained of diarrhea at 
low infusion rates. This symptom 
combined with mild abdominal pain 
led to a diagnostic contrast study. 
All had few, if any, abdominal 
symptoms. This may be an impor­
tant clinical spectrum to remember 
when caring for such patients.
Formula intolerance was the 
major problem encountered in our 
series. This reflects the known in­
ability of the small bowel to control 
osmolarity, in contrast to the stom­
ach. Formula intolerance has been 
the most common problem in most 
of the papers we reviewed. It seems 
to occur in direct proportion to the 
severity of the patient’s illness. 
Hence, critically ill patients in the 
intensive care unit, particularly 
those on respirators and receiving 
muscle relaxants, are the most diffi­
cult to feed enterally. These data 
emphasize the importance of using 
the stomach whenever possible and 
of taking great care to eliminate the 
risks of aspiration. The recent de­
velopment and refinements of per­
cutaneous endoscopic gastrostomy 
will probably outdate feeding jeju-
nostomy as a separate procedure. 
As well, during laparotomy, one can 
consider insertion of both a gastros­
tomy and jejunostomy.
Diarrhea occurred in 28 (21%) 
patients, bloating and cramping in 
10 (8%), and nausea and vomiting 
in 7 (5%). These were managed by 
first reducing or discontinuing en­
teral feeding, which was gradually 
reinstituted according to a written 
nursing protocol. The use of an- 
tidiarrheal agents and constant in­
fusion pumps were helpful in con­
trolling the diarrhea. These prob­
lems were severe enough to discon­
tinue the feeding in only 6 (4%).
Aspiration occurred in two pa­
tients. Just as formula intolerance is 
more common with jejunal versus 
gastric feeding, a relative advantage 
of jejunal feeding is a presumed 
reduced rate of aspiration. The cur­
rent study and previous experience 
in our institution confirms that, 
while uncommon, aspiration can 
occur even when feeding distal to 
the pylorus. Presumably, the je ju ­
nal feeding stimulates gastric secre­
tion and dilatation. This may cause 
aspiration particularly in elderly, de­
bilitated or critically ill patients.
Of note were the jejunostomy 
tubes inserted in the presence of 
abdominal sepsis without leaks or 
fistula formation. In this series je ju ­
nostomy tubes were inserted in 18 
patients who suffered from sepsis or 
who had dislodged percutaneous or 
surgical gastrostomies. Each had a
perforated viscus with fluid collec­
tions and peritoneal fibrin forma­
tion. An area of stomach or je ju ­
num, or both, was prepared by 
removing as much fibrin as possible 
and rubbing the serosa with a dry 
gauze. The enterotomy and tunnel 
were constructed as described 
above. No leakage occurred.
Conclusions
Feeding jejunostomy is a simple, 
safe procedure which adds less than 
10 minutes of operating time. It 
permits nutritional access without 
the expense and potential complica­
tions of parenteral nutrition, and is 
easily adapted to home use. Tube 
insertion has a low complication 
rate and can be performed in the 
presence of intra-abdominal sepsis. 
The tubes can be reinserted or 
removed easily and without signifi­
cant morbidity. The risk of aspira­
tion pneumonia is much lower than 
with gastric feeding although diar­
rhea is more common. Feeding je ju ­
nostomy can be performed under 
local anesthesia in selected high- 
risk patients or when percutaneous 
endoscopic gastrostomy is contrain­
dicated.6
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C a th e te r  
d is lo d g e m e n t, 
no. (% )
D ia rrh e a
no . (% )
N a u s e a , 
vom iting , 
no. (% )
B lo a tin g , 
no. (% )
D e lany, e t a l7 115 19 1 (0 .8 ) 0 3  (2 .6 ) 2 ( 1 0 .5 ) _ 3 ( 1 5 .7 )
F loover, e t a l2 26 2 6 0 0 0 9  (3 4 .6 ) - 1 (3 .8 )
S m ith , e t a l8 25 20 2 ( 8 ) - - 1 0 ( 5 0 ) 3 ( 1 5 ) 1 (5 )
Page, e t al3 199 161 1 (0 .5 ) 0 2 ( 1 ) -
H eberer, e t a l9 42 39 1 (2 .3 ) 0 1 (2 .3 ) 11 (2 8 ) 0 3 ( 8 )
D a ly , e t a l10 20 20 - - 4 ( 2 0 ) 7 ( 3 5 ) 7 ( 3 5 )
A d a m s , e t a l " 73 48 2 (2 .7 ) - 3 ( 4 ) 8 ( 1 1 ) - -
P re se n t s tu d y 133 120 1 0 (7 .5 ) 0 1 (0 .7 ) 2 8  (2 3 ) 7 ( 5 .2 ) 1 0 ( 7 .5 )
*N o . o f  p a tie n ts  in s tu d y  in w h o m  feed ing  w a s  a c tu a lly  s ta rte d . -  =  N o t reco rded .
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COMPLICATIONS IN SURGERY 
AND TRAUMA. 2nd ed. Edited by 
Lazar J. Greenfield. 981 pp. Illust. J.B. 
Lippincott Co., Philadelphia. 1989. 
$95 (US). ISBN 0-397-50904-9
This well-written book covers a wide 
range of specialties within the broad 
field of surgery. Each specialty section 
is written by recognized experts in their 
field.
The book comprises 10 sections: 
wound healing, plastic surgery, thoracic 
surgery, cardiovascular surgery, alimen­
tary tract surgery, endocrine system 
surgery, nervous system surgery, geni­
tourinary surgery, musculoskeletal sur­
gery and, finally, a synopsis of surgical 
complications. The sections emphasize 
the problems most likely to be encoun­
tered by the surgical resident or practis­
ing surgeon.
The chapters on my area of special 
interest and expertise, hepatobiliary and 
pancreatic surgery, were written by 
well-known, experienced surgeons and 
cover the major areas in a concise yet 
comprehensive manner.
This book should be useful for resi­
dents and surgeons in any field of 
surgery, but particularly those in the 
fields of trauma, thoracic and cardiovas­
cular surgery, orthopedics and neuro­
surgery. It is also a useful reference 
text for surgical libraries. 1 highly rec­
ommend it as a reference text for 
medical school libraries and tertiary 
care hospitals.
Sherif S. Hanna, MD, FRCSC, FACS
Department o f Surgery,
Sunnybrook Medical Centre,
2075 Bayview Ave.,
Toronto, Ont.
CONTROVERSIES IN THE MAN­
AGEMENT OF VENOUS DISOR­
DERS. Edited by Bo Eklof, Jan Erik 
Gjores, Olav Thulesius and David 
Bergqvist. 327 pp. Illust. Butterworth 
& Co. (Publishers) Ltd., London. 1989. 
$185 (US). ISBN 0-407-01566-3
This book, the fifth publication by the 
Societas Phlebologica Scandinavica, will 
be of particular interest to vascular 
physicians, surgeons and radiologists. 
The text is aptly entitled “Controver­
sies”. Each chapter is written by well- 
known Scandinavian authors, followed 
by discussions written by equally re­
nowned world experts. This arrange­
ment makes for interesting reading as it 
presents varying opinions from both 
sides of the Atlantic.
The anatomy, physiology, diagnosis 
and treatment of systemic venous disor­
ders are covered. The only major weak­
ness is a lack of discussion on the role 
of duplex scanning; this undoubtedly 
will become the method of choice for 
assessing venous disease. Nevertheless, 
the book presents objective and concise 
information and would be a valuable 
addition for any surgeon interested in 
venous disorders.
York Hsiang, MD, FRCSC
Assistant Professor,
Department o f Surgery,
Faculty o f Medicine,
University Hospital, UBC Site,
2211 Wesbrook Mali,
Vancouver, BC
VASCULAR DISORDERS OF THE 
UPPER EXTREMITY. 2nd ed. Edited 
by Herbert I. Machleder. 409 pp. Futu- 
ra Publishing Company, Inc., Mount 
Kisco, NY. 1989. $55 (US). ISBN 0- 
87993-347-X
Vascular disorders of the upper extrem­
ity pale in comparison with conditions 
affecting the lower limbs. However, for 
the discerning clinician there is a wealth 
of interesting innovation in the diagno­
sis, assessement and management of
continued on page 188
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General Surgical Procedures After Heart 
T ransplantation
John Yee, MD; Dimitri Petsikas, MD; Michael A. Ricci, MD;* Albert Guerraty, MD, FRCSCf
Seventy-eight cardiac transplantations were performed between July 1982 and 
March 1989. The perioperative death rate was 10%. Overall survival was 86%.
Among the long-term survivors, 14 patients underwent 16 noncardiac surgical 
procedures. Seven of them required emergency laparotomy, four for biliary tract 
disease, one for ruptured abdominal aortic aneurysm, one for suspected abdominal 
sepsis and one for enterocolitis. Elective surgical interventions included repair of 
symptomatic abdominal wall hernia, treatment of hemorrhoids or perianal 
condylomas, total hip arthroplasty, maxillary sinus drainage and resection of a 
duodenal villous adenoma.
Preoperatively, all patients received cyclosporine orally. Ten of the 14 patients 
were on triple-drug immunosuppression (cyclosporine, azathioprine and low-dose 
prednisone [less than 0.20 m g/kg daily]). The remaining four patients took 
cyclosporine with either azathioprine or prednisone.
There were no deaths. Complications were limited to residual choledocholithiasis 
treated by percutaneous removal, two cases of wound infection and an incisional 
hernia. The authors’ experience indicates that noncardiac surgical procedures may 
be safely performed in patients who have received a heart transplant.
The past decade has witnessed a marked increase in heart trans­
plantation accompanied by a steady 
improvement in survival rates. 
There is a large population of pa­
tients who have undergone trans­
plantation and who therefore re­
quire comprehensive medical care.1 
It is inevitable that some of them 
will need emergency or elective sur­
gery for noncardiac problems. To 
determine the risk for noncardiac 
surgery in this patient group, we 
reviewed our experience with 78 
cardiac transplant recipients.
Soixante-dix-huit transplantations cardiaques ont ete effectuees entre juillet 1982 et 
mars 1989. La mortalite perioperatoire a ete de 10% et la survie globale de 86%. 
Parmi les survivants de longue date, 14 patients ont subi 16 interventions 
chirurgicales pour des causes non cardiaques. Sept d’entre-eux ont necessity une 
laparotomie d’urgence, quatre pour des affections biliaires, un pour rupture d’un 
anevrisme de l’aorte abdominale, un pour suspicion de sepsie abdominale et un pour 
une enterocolite. Les interventions chirurgicales non urgentes comprenaient la 
reparation d’une hernie symptomatique de la paroi abdominale, le traitement 
d’hemorroldes ou de condylomes perianaux, une arthroplastie totale de la hanche, le 
drainage d’un sinus maxillaire et la resection d’un adenome villeux du duodenum.
Tous les patients avaient re?u en preoperatoire, de la cyclosporine par voie orale. 
Dix des 14 patients recevaient une immunosuppression triple (cyclosporine, 
azathioprine et prednisone a faible dose [moins de 0.20 m g/kg par jour]). Les 
quatre autres patients recevaient de la cyclosporine avec soit de l’azathioprine, soit 
de la prednisone.
II n’y a eu aucun deces. Les complications se sont limitees a une 
choledocholithiase traitee par voie percutanee, a deux cas d’infections de plaie et a 
une hernie d’incision. L’experience des auteurs indique que les operations non 
cardiaques peuvent etre pratiquees sans danger chez les greffes cardiaques.
From the Department o f General Surgery and Department o f  Cardiovascular and Thoracic 
Surgery, Royal Victoria Hospital, McGill University, Montreal, PQ
Presented at the 12th annual meeting o f  the Canadian Association o f General Surgeons, held in 
conjunction with the 58th Annual Meeting o f the Royal College o f Physicians and Surgeons o f  
Canada, Edmonton, Alta., Sept. 22, 1989
*Present address: University o f  Vermont College o f  Medicine, Vascular Surgery, Burlington, Vt
fPresent address: Medical College o f Virginia, Cardiovascular Surgery. Richmond, Va
Reprint requests to: Dr. J. Yee, Resident in General Surgery, Royal Victoria Hospital, 687 Pine 
Ave. W, Montreal, PQ H3A 1A1
Patients and Methods
We reviewed the medical records 
of all patients who underwent or­
thotopic cardiac transplantation at 
the Royal Victoria Hospital, Mon­
treal, between January 1985 and 
March 1989. The records of anoth­
er seven patients who received 
transplants at Hopital Notre-Dame, 
Montreal, between July 1982 and 
January 1985, were also reviewed 
because they were followed up at 
the Royal Victoria Transplant Clin­
ic. We paid particular attention to 
the management and outcome of 
noncardiac surgical problems.
Seventy-eight cardiac transplants 
had been performed by our group 
during the study period. There were 
68 men and 10 women. The mean 
age of the group was 49 ±  9 years. 
The overall survival was 86% with a 
mean follow-up of 22 months. Ac­
tuarial survival at 1 year was 88%. 
The early postoperative death rate, 
(up to 30 days) was 10%. No deaths 
were attributed to abdominal com­
plications.
Immunosuppressive therapy con­
sisted of azathioprine (400 mg) pre-
YEE, ET AL.
operatively and methylprednisolone 
(500 mg) and azathioprine (125 mg) 
intraoperatively. Maintenance im­
munosuppression consisted of anti­
thymocyte globulin (10 m g/kg dai­
ly) and azathioprine (at doses ad­
justed according to the peripheral 
blood leukocyte count). Steroids, 
prednisone at 0.20 m g/kg or less 
daily, were used only in patients 
with recurrent rejection. Cyclospo­
rine (1 m g/kg daily) was started on 
the postoperative day 3, and the 
dose was subsequently adjusted to 
maintain a serum level of 150 to 
300 ng/m l. Antithymocyte globulin 
was discontinued as adequate levels 
of cyclosporine were achieved.
Results
Fourteen patients (12 men, 2 
women) (18% of the total) under­
went 16 surgical procedures after 
cardiac transplantation.* The mean 
age of this group was 50 years 
(range from 37 to 62 years) at the 
time of the transplantation. The 
average time between transplanta­
tion and subsequent noncardiac sur­
gery was 10 months (range from 1 
to 51 months).
Seven patients (9%) had emergen­
cy laparotomy, done for biliary tract 
disease in four and for a ruptured 
abdominal aortic aneurysm in one. 
Severe enterocolitis and presumed 
appendicitis accounted for the other 
two emergency cases. Only one ab­
dominal complication had developed 
within 30 days of transplantation.
Indications for the seven elective 
procedures included symptomatic 
inguinal or incisional hernias, peria­
nal disease, osteonecrosis of the 
hip, recurrent sinusitis and duode­
nal villous adenoma.
*Readers wishing to obtain full clinical de­
tails o f  these patients in table form should 
contact Dr. J  fee.
Most patients received isoflurane 
for general anesthesia. All patients 
received antibiotics prophylactically. 
Endomyocardial biopsy after major 
abdominal procedures revealed no 
significant rejection.
All patients had continued to re­
ceive their immunosuppressive med­
ication during and after surgery. 
When oral medication was contrain­
dicated cyclosporine was adminis­
tered by intravenous infusion over 4 
hours at 25% of the daily oral 
dosage. Prednisone was replaced 
with an equivalent dose of methyl­
prednisolone intravenously. Azathi­
oprine was given intravenously at 
the same dose as had been given 
orally. Hydrocortisone succinate 
(100 mg) was administered intraop­
eratively, followed by three postop­
erative doses at 8-hour intervals to 
provide sufficient corticosteroids to 
meet the metabolic stresses of intra­
abdominal surgery. Antibiotics and 
ranitidine were used prophylactical­
ly during these procedures.
Before 12 of the 16 surgical 
procedures the patients received tri­
ple drug immunosuppression (cy­
closporine, azathioprine and predni­
sone). In three procedures only cy­
closporine and prednisone were so 
used, and in one the patient re­
ceived only cyclosporine and azathi­
oprine. Adjustment of immunosup­
pression was minimal. Monitoring 
for rejection was done by endomyo­
cardial biopsy when the patient was 
kept in hospital for more than 5 
days. Cyclosporine levels were mon­
itored daily and maintained in the 
therapeutic range.
There were no deaths. Four com­
plications occurred in three pa­
tients: residual choledocholithiasis, 
wound infection (two patients) and 
an incisional hernia.
Discussion
The special features of heart-
transplant patients all pose chal­
lenges for the general surgeon: the 
possibility that there were low-flow 
states during and immediately fol­
lowing cardiopulmonary perfusion, 
the threat of infection and impaired 
wound healing, and the effects of 
continued immunosuppression.
The results at several centres 
suggest that cardiac transplant pa­
tients are at high risk for serious 
and potentially lethal abdominal 
complications. Jones and col­
leagues,2 for instance, described a 
group of post-transplant patients, in 
which the rate of general surgical 
complications was 13%. Over half 
the patients who suffered abdomi­
nal complications did so within 30 
days of transplantation, and among 
them the death rate was more than 
40%. Pancreatitis or peptic ulcer 
disease was implicated in all of 
these deaths. Furthermore, 70% of 
the patients with early complica­
tions had pathologic findings relat­
ed to perforated ulcer or pancreati­
tis. Disesa and colleagues3 reported 
a similarly high rate, with 11 of 14 
general surgical complications oc­
curring within 30 days of transplan­
tation. Pancreatitis or perforated 
peptic ulcer was the preoperative 
diagnosis in 45%.
At the University of Pittsburgh4 
12% of cardiac transplant patients 
subsequently underwent general 
surgical procedures. Nine emergen­
cy laparotomies and eight elective 
procedures were reported. Patients 
with acute abdominal complications 
requiring surgery had a death rate 
of 33%. No deaths occurred after 
elective surgery. Steroid therapy 
was not reported as having masked 
signs of peritoneal irritation.
Colon and associates5 reported a 
34% rate of complications requiring 
general surgical consultation. One- 
third of these required surgery. 
Pancreatitis and gallbladder disease 
accounted for two-thirds of the gen­
eral surgical consultations. The
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death rate for patients who required 
laparotomy for severe pancreatitis 
and its complications was 40%. 
Elective cholecystectomy was un­
complicated.
In the another series6 there were 
22 elective and 7 emergency intra­
abdominal operations. The death 
rate (there were five deaths among 
those who underwent emergency 
laparotomy) was 17%. Twelve elec­
tive cholecystectomies were per­
formed without complication. One 
laparotomy was performed for pan­
creatic disease and four for compli­
cations of peptic ulcer disease.
Merrell and associates7 reported a 
15% rate of acute abdominal com­
plications. Pancreatitis and gas­
trointestinal bleeding accounted for 
a large proportion of them. No 
predisposing factors could be identi­
fied, except that recent pulses of 
high-dose antirejection steroid ther­
apy was associated with 33% of the 
abdominal complications. This sug­
gested to them that steroid-sparing 
immunosuppression might lead to a 
lower rate of abdominal complica­
tions.
In our series, 9% of post-trans­
plant patients underwent emergency 
procedures. Cholecystitis was com­
monly encountered, but none of the 
laparotomies was performed for 
peptic ulcer disease or pancreatitis, 
described as frequent by other cen­
tres. Only one of our patients re­
quired operation within the early 
post-transplant period. Those who 
had elective surgery had an uncom­
plicated postoperative course except 
for one who had a late wound 
infection after herniorrhaphy. En­
doscopy was performed without 
complication. Like Merrell and col­
laborators,7 we detected no cases of 
“rebound” graft rejection. Al­
though we did not find any associa­
tion between abdominal complica­
tions and the higher dose steroids 
used to treat episodes of rejection, 
our death rate and low incidence of
early abdominal complications, es­
pecially the absence of pancreatitis 
and peptic ulcer, may be related to 
the low doses of maintenance cor­
ticosteroids we used.
Previous reports8-12 have docu­
mented a 0.3% to 1% incidence of 
abdominal complications after ex­
tracorporeal circulation and routine 
cardiac surgery. Gastroduodenal he­
morrhage was encountered most 
frequently. Pancreatitis, well de­
scribed following cardiopulmonary 
bypass,1314 has been associated with 
the administration of azathioprine 
and corticosteroids after cardiac 
transplantation.1516 The high ab­
dominal morbidity after general car­
diac surgery has been attributed to 
pre-existing disease in middle-aged 
patients with concomitant heart dis­
ease, perioperative splanchnic hypo­
perfusion often exacerbated with 
vasopressors, and difficulties inher­
ent in the clinical assessment of 
sedated and ventilated patients. 
These same factors, combined with 
the side-effects of immunosuppres­
sive medication and increased sus­
ceptibility to sepsis, may contribute 
to death among patients in the early 
post-transplant period.
The risk of death after cardiac 
transplantation is highest immedi­
ately after transplantation and de­
clines rapidly to a constant level by 
the third month.17 Patients are es­
pecially vulnerable in this period 
and require close surveillance with 
aggressive investigation of potential 
complications, particularly those re­
lated to pancreatitis and peptic ul­
ceration. Endoscopy, shown to be 
safe after heart transplantation,18 
and ultrasonography are particular­
ly useful. Late complications, 
though less frequent, demand a 
similar diagnostic approach. Early 
laparotomy should be considered 
when careful clinical examination 
suggests that abdominal disease is 
evolving.
Elective abdominal surgery can
be performed safely. Our data, to­
gether with that published by other 
groups, show that morbidity is min­
imal. Perianal disease, which often 
represents a potential source of sep­
sis, may be treated by elective sur­
gery. Cholelithiasis may reflect bile 
metabolism altered by cyclospo­
rine.19 Total joint arthroplasty is a 
safe and effective means of rehabili­
tating transplant patients with ste­
roid-induced osteonecrosis.20 Suc­
cess with major plastic and recon­
structive procedures has also been 
described among transplant recipi­
ents.21
For optimal care there should be 
close communication between the 
treating surgeon and the transplant 
team. Effective treatment will in­
clude a thorough but directed d.^^, 
nostic approach with early interven­
tion when indicated. Disease in the 
pancreaticobiliary system is com­
mon and should be actively sought. 
The surgeon should not delay treat­
ment or deny elective surgery be­
cause of previous heart transplanta­
tion. Adequate immunosuppression 
must be maintained and monitored. 
Appropriate antibiotic prophylaxis 
and meticulous wound care may 
minimize the potential for septic 
complications among these pa­
tients.
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dents who wish to obtain complete, 
current information about the diagnosis 
and management of conditions they see 
infrequently. The contributions of inter­
nists to this book may even make it 
acceptable reading for non-surgeons.
John L. Provan, MS, FRCS, FRCSC, 
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Professor of Surgery,
Faculty of Medicine,
University of Toronto,
Toronto, Ont.
CURRENT OPERATIVE UROLOGY. 
Edited by E. Douglas Whitehead. 400 
pp. Illust. J.B. Lippincott Company, 
Philadelphia. 1989. $75.50 (US).
ISBN 0-397-50991-X
An unusual feature of this surgical 
textbook is its format. It is divided into 
25 topics of interest to urologists in 
particular, but also to other surgical 
specialists such as gynecologists and 
general surgeons.
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Second Annual W.R. Ghent Lecture on 
Trauma. Abdominal Organ Injury: 
Diagnosis, Treatment and Education
Charles E. Lucas, MD
In this lecture the author reviews aspects of education in the care of traumatized 
patients, with particular attention to abdominal injuries. He notes the lack of 
education in this aspect of medical care during the medical school years and the 
variable quality of trauma care education during residency training. The author 
outlines an organized approach to the teaching of trauma care, focusing on 
cognitive, psychomotor and affective education and the establishment of a uniform 
core curriculum for residents with the ultimate goal of enhancing patient care.
L’auteur passe en revue dans cette communication, divers aspects de la formation 
relative aux soins aux victimes de trautismes, une attention particuliere etant 
accordee aux blessures abdominales. II note le manque de formation specifique a ce 
type de soins medicaux durant les annees du cours de medecine, ainsi que la qualite 
inegale de la formation en traumatologie re?ue durant la residence.
L’auteur decrit les grandes lignes d’une approche structuree pour l’enseignement 
des soins aux traumatises, centree sur une formation cognitive, psychomotrice et 
affective, ainsi que l’etablissement d’un programme academique uniforme pour les 
residents, le tout etant destine a ameliorer les soins aux patients.
I t is an honour to receive any invitation to present scientific 
data and personal biases to a distin­
guished group of professional 
peers. This honour is enhanced 
when the presentation is a named 
lectureship, in this instance, the 
Ghent Lecture. When this honour 
revolves around the combination of 
abdominal trauma, education and
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science, my personal pleasure is 
unsurpassed. Although I did not 
know Dr. Ghent personally, all men 
(and women) are known by their 
acts, personal interactions and writ­
ten word.1-3 Dr. Ghent’s writings 
define, for me, a man desirous of 
coordinating divergent skills among 
many peers into a common goal 
which is then nurtured for the
betterment of the common good, in 
this instance, better emergency 
medical care for the injured Canadi­
an citizen.1 His good name is re­
membered by this lectureship; his 
good works can only be fulfilled by 
the continued efforts of each of you 
working together to provide ongo­
ing re-evaluation and improved care 
to the traumatized patient.3
My objective today is to review 
one aspect of this effort, namely, 
education in the care of injured 
patients with special emphasis on 
abdominal injury.
Premedical Education
This education begins long be­
fore our experiences in medical 
school;4 everyone is exposed to 
some aspects of trauma from the 
earliest years. When health care 
represents 10% of a nation’s gross 
national product, many people have 
family or relatives involved in some 
aspect of the health care industry. 
Discussions with these relatives 
often centre around the care of 
traumatized patients since to the 
layman this is the most exciting 
aspect of the health care worker’s 
daily activity. The dramatic and 
exciting aspects of trauma care 
have reached the communications 
industry4 through such television 
heroes as Dr. Kildare and Dr. Ben 
Casey. Recent television contribu­
tions have highlighted the dynamic
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activities of the emergency medical 
service teams working in the field. 
Unfortunately, some recent contri­
butions have highlighted the inade­
quate physician whose knowledge is 
deficient or who is unavailable, a 
reflection of the serious problem 
faced today by physicians in the 
area of professional liability. The 
already serious malpractice problem 
within the United States is one 
which appears to be growing in 
Canada. The effects of the malprac­
tice crisis within the state of Florida 
have ruined a well-established emer­
gency medical service system in 
Dade County. In the state of Michi­
gan, a general surgeon with no 
malpractice settlements or suit loss­
es currently pays over $40 000 an­
nually in order to have $200 000 to 
$600 000 coverage.
Editorial comments in the daily 
newspapers often attack the effica­
cy of the medical profession and, 
more specifically, emergency medi­
cal services. All of these factors, 
which are a part of our premedical 
school educational system within 
North America have led to a reduc­
tion in the number of applicants to 
medical schools in the US. Current­
ly, over 60% of applicants to medi­
cal schools in the US are accepted. 
Such a lowering of standards will 
ultimately lead to a lower quality of 
care. Let us hope that Canada does 
not follow the same path. Our re­
sponsibility as educators in the area 
of trauma necessitates that we re­
verse the stance perpetuated by the 
above factors and remember the 
advice given by Dr. Ghent in 1981 
when he stated ’’The public good is 
the higher law”.1
Medical School Education
The next phase of education in 
care of the traumatized patient 
takes place in medical school.56 
Unfortunately, the medical school
curriculum in this area often is 
haphazard or absent.7 8 Part of the 
deficiency relates to the faculty con­
flict with personal and institutional 
needs. Typically, the medical school 
faculty is involved in the areas of 
research, patient care and educa­
tion,69 with education receiving low 
priority and being assigned to the 
more junior faculty. Following the 
ideals of Dr. Ghent, we must insist 
that our alma maters provide for 
our medical students an organized, 
comprehensive curriculum on all 
aspects of trauma, the number one 
killer of young people in North 
America.
Residency Education
Following medical school, educa­
tion in the treatment of trauma 
takes place in the surgical residency 
programs, especially those of gener­
al surgery, orthopedic surgery, tho­
racic surgery and plastic surgery. 
The quality of this education, how­
ever, continues to vary between 
training institutions.10 Until recent­
ly, there was no well-defined mini­
mal requirement of exposure to the 
care of severely injured patients to 
meet the qualifications for sitting 
the specialty board examinations. 
Furthermore, stimulation for facul­
ty to become involved in the teach­
ing of trauma care is lacking in our 
residency training programs. Junior 
faculty members often learn how to 
teach while working on the trauma 
service, where they are encouraged 
to promote clinical investigations 
and write clinical reviews in order to 
be promoted to other more lucrative 
and “less dirty” services.6 How 
many full professors of surgery 
have the honour of being called to 
help treat a seriously injured patient 
involved in a motor vehicle accident 
at 02:00 hours?11 What reward sys­
tems exist within most of our train­
ing programs to encourage our best
teachers to continue to be involved 
on the trauma service? How many 
of the dynamic, creative and effec­
tive surgeons maintain a presence 
in the emergency department? Dr. 
Ghent emphasized, “The most im­
portant component of an effective 
emergency department is person­
nel.”2 By this statement, I am sure 
that he meant all personnel — 
physicians, nurses, attendants, floor 
sweepers and administrators.
The objective of an excellent edu­
cational program during the surgi­
cal residency years requires that 
specific emphasis be placed on all 
three of the educational domains — 
cognitive, psychomotor and affec­
tive.9 The development of a specific 
curriculum outlining learning objec­
tives enhances successful imple­
mentation of these objectives. The 
cognitive objectives define the 
knowledge base or the decision­
making skills required for the care 
of traumatized patients; the psycho­
motor objectives identify the techni­
cal skills which must be learned 
while caring for injured patients; 
the affective domain delineates the 
attitudinal characteristics which 
need to be enhanced or developed in 
the caring but effective maturing 
surgeon.
Cognitive Education
Instruction in the cognitive do­
main takes place in many different 
settings. Most of the knowledge is 
gained during daily rounds.56-910 
Bedside teaching allows not only 
for recitation of the published con­
cepts regarding a particular injury 
but permits the elucidation of sub­
tle facts which can be brought forth 
by the mature surgeon. A drawback 
of bedside teaching is the episodic 
experience for a particular resident 
who is exposed to many interesting 
problems but may not be exposed 
to other, critical areas.
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Establishment of a Uniform 
Core Curriculum
Definition of a core curriculum is 
enhanced by some of the packaged 
programs which deal with all as­
pects of general surgery, including 
trauma. The American College of 
Surgeons has provided excellent 
leadership with their Surgical Edu­
cation and Self-Assessment Pro­
gram (SESAP). The American Col­
lege of Surgeons Committee on 
Trauma provides a good cognitive 
base with their course on Advanced 
Trauma Life Support (ATLS) which 
specifically addresses multisystem 
injury. The in-training examinations 
for residents also address the care 
of traumatized patients. These 
packaged programs are augmented 
by the weekly lecture sessions. It is 
to be hoped that every trauma ser­
vice throughout North America will 
develop such lectures for the trau­
ma team and identify specific cogni­
tive objectives to be met during a 1 
or 2-year cycle. The specific cogni­
tive objectives of such lectures are 
then reinforced by identifying edu­
cational needs during morbidity and 
mortality conferences. A journal 
club assigned to deal with unusual 
cognitive objectives in trauma care 
will help fill some educational gaps, 
and special assignments to residents 
with perceived deficiencies will pre­
pare them for later examinations.
Stagnation is the curse of all 
established educational programs. 
Education in trauma care is no 
exception. The maintenance of an 
excellent base of knowledge is dy­
namic and fluid, constantly slough­
ing outdated facts and incorporat­
ing new techniques, studies and 
procedures as they are introduced.6 
Healthy care of this living body of 
knowledge requires yearly input 
from many trauma experts through­
out Canada and the US.
I foresee a time when each region 
will be assigned an area of study.
Besides collating and making pre­
sentations to a central committee, 
the regional centres would be re­
sponsible for yearly updates on 
what is new and, more importantly, 
what new research projects are ap­
propriate. No one group is an island 
possessing the cognitive skills to 
achieve this objective in all areas of 
care. Dr. Ghent emphasized this 
when he stated, ’’The input by all 
specialty groups has been sought 
during revisions and the new incor­
porates many changes.”2 Although 
space does not permit a complete 
discussion of all challenging ques­
tions within this cognitive base, the 
following examples will highlight 
the need for a living body of knowl­
edge filtering from different regions 
of North America into a central 
committee.
In 1989, a 37-year-old man was 
seen in the emergency department 
following a motor vehicle accident. 
He had a systolic blood pressure of 
50 mm Hg, a pulse rate of 120/min 
and inadequate perfusion as indicat­
ed by a weak, thready pulse and 
cold, clammy skin. His immediate 
resuscitation with a balanced elec­
trolyte solution led to an increase in 
the systolic blood pressure to 90 
mm Hg and a fall in the pulse rate 
to 105/min within 15 minutes. 
Rapid examination revealed a prob­
able fracture of the right femur, 
bilateral rib fractures, a scalp lacer­
ation, abdominal and chest-wall ten­
derness and normal breath sounds. 
While he was receiving electrolytes, 
his systolic blood pressure fell to 80 
mm Hg as the pulse rate rose. 
Internal bleeding was diagnosed. 
Laparotomy was performed immedi­
ately, but no injuries were seen. 
While the patient was in the operat­
ing room, the systolic blood pres­
sure fell further to 60 mm Hg. A 
left thoracotomy was performed in 
an effort to identify a thoracic 
source for the continued bleeding 
and to provide internal cardiac mas­
sage. Minimal bleeding was identi­
fied from the left thorax. The main 
injury was severe pulmonary contu­
sion. The patient died, despite con­
tinued intraoperative attempts at 
resuscitation.
During the discussion of this case 
at the morbidity and mortality con­
ference, the surgical resident and 
many of the trauma surgeons 
praised the decision to perform a 
laparotomy. When the role of diag­
nostic peritoneal lavage or abdomi­
nal computed tomography scanning 
was questioned, the surgical resi­
dent rightly pointed out that an 
unstable patient should never be 
taken to the radiology department 
for prolonged x-ray studies and that 
this patient was too unstable to 
undergo diagnostic peritoneal la­
vage. When the resident was ques­
tioned about diagnostic peritoneal 
lavage in the operating room, he 
responded that the patient needed 
immediate full laparotomy. These 
questions led to a long discussion 
of the recent studies comparing 
diagnostic peritoneal lavage and ab­
dominal computed tomography 
scanning after blunt trauma. Many 
important cognitive points were ad­
dressed and the resident team was 
well educated regarding a number 
of facts which will certainly appear 
on their subsequent examinations. 
Unfortunately, the role of diagnos­
tic paracentesis, which takes ap­
proximately 10 seconds to perform, 
was ignored. Although this tech­
nique has been well documented as 
an excellent means for identifying 
hemoperitoneum, the advent of new 
techniques (diagnostic peritoneal la­
vage and abdominal computed to­
mography) seems to have blinded 
today’s residents to the value of the 
technique, which is an important 
aspect of recent medical history.
A regional trauma centre as­
signed the task of collating data on 
early diagnostic evaluation for blunt 
abdominal trauma would address
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both old and new techniques to 
provide a compendium of data for a 
uniform trauma curriculum.
For our younger surgical col­
leagues who missed the era of diag­
nostic paracentesis, I recommend 
that bihemispheric diagnostic para­
centesis be performed just lateral to 
the recti muscles.12 Using a 
20-gauge needle and a 10 ml sy­
ringe, this procedure takes approxi­
mately 10 seconds to complete and 
can be done during resuscitation. 
When any amount of blood is re­
trieved in the aspirating needle, one 
can predict the findings of diagnos­
tic peritoneal lavage, thus preclud­
ing its need. When no blood ap­
pears on aspiration, the likelihood 
of a life-threatening hemoperito- 
neum approaches zero.
Despite a long discussion outlin­
ing the benefits of diagnostic para­
centesis in unstable patients, the 
lesson was not perceived by all. 
More recently, a patient presented 
with a gunshot wound to the poste­
rior abdomen and posterior chest. 
This patient had a low systolic 
blood pressure and paralysis below 
the level of the eighth thoracic 
vertebra. Because of the unstable 
vital signs and the potential for a 
life-threatening intrathoracic or in­
tra-abdominal hemorrhage, the pa­
tient was treated immediately with a 
balanced electrolyte solution, then 
taken to the operating room. The 
systolic blood pressure remained 
marginal, so a left thoracotomy was 
done. It revealed a moderate hemo­
thorax as the cause of the hypoten­
sion. At laparotomy it was apparent 
that the posteriorly located gunshot 
wound had not entered the perito­
neal cavity. The righteous resident 
in this instance defended his deci­
sion on the basis that his patient 
was unstable and had a potentially 
lethal hemorrhage which precluded 
delay in operative intervention. 
When questioned about the role of 
diagnostic paracentesis to rule out
intra-abdominal hemorrhage, the 
resident indicated that the hemorrh­
age was thought to arise from the 
left thorax and that was the cavity 
first explored. He indicated that the 
threat for rapid hemorrhage was 
too likely to permit left tube thora­
costomy, which would take too 
long. When questioned about the 
role of diagnostic thoracentesis 
while the patient was on the operat­
ing table, he replied that he had 
never considered that possibility 
and had not seen it in any of his 
readings.
Clearly, the regional team as­
signed to deal with the diagnostic 
approach to abdominal injury 
should also be prepared to revise 
standards for approaching patients 
with penetrating thoracic wounds.
The resident was further advised 
that after he performed a negative 
thoracotomy, a diagnostic para­
centesis followed by diagnostic peri­
toneal lavage would have precluded 
the need for opening a second 
major body cavity. Hopefully, he 
now knows that thoracotomy and 
laparotomy are not the ideal treat­
ment for paraplegia.
Initial Evaluation and Diagnosis
A regional committee assessing 
initial evaluation of patients with 
abdominal trauma would collate 
data on these tests for both blunt 
and penetrating trauma from either 
gunshot or stab wounds. There are 
subtle differences between the dif­
ferent types of penetrating wounds, 
and they need a different approach 
to diagnosis and treatment. The 
regional committee would also iden­
tify the exact criteria for a positive 
peritoneal lavage in patients with 
pelvic fracture in whom there is a 
high frequency of false-positive 
findings on diagnostic peritoneal 
lavage.
Possibly, a new degree of he- 
moperitoneum should be indicated
for operative intervention in pa­
tients with pelvic fracture. Our pedi­
atric surgical peers no longer per­
form diagnostic peritoneal lavage 
for blunt injury because they have 
elected to observe, nonoperatively, 
patients with known hemoperito- 
neum. The current guidelines in 
many centres suggest that a posi­
tive peritoneal lavage will make lap­
arotomy mandatory when the pa­
tient can be treated by observation. 
This reasoning has no logic. A 
negative peritoneal lavage reassures 
the surgeon that there is no he- 
moperitoneum and, thus, circum­
vents the need for observation in a 
special care unit. On the other 
hand, a positive peritoneal lavage 
could be used as a baseline against 
which subsequent diagnostic com­
puted tomography scans or a subse­
quent peritoneal lavage could be 
compared during observation. The 
criterion that any patient who has a 
positive peritoneal lavage must un­
dergo laparotomy must be put to 
rest.
Liver Injuries
A review of the recent treatment 
of liver injury identifies many para­
doxes whereby currently popular 
recommendations discount a wealth 
of previous experiences and publica­
tions. Consequently, the regional 
centre assigned the task of setting 
the optimal treatment regimens for 
liver injury would have a full agen­
da. Most surgeons currently recom­
mend exploratory laparotomy for 
patients with penetrating abdominal 
stab wounds thought to have in­
jured the liver, regardless of wheth­
er the patient’s condition is stable 
or hypovolemic shock is present. 
Despite these recommendations, we 
now see many patients with stab 
wounds to the abdomen in whom 
peritoneal penetration is neither es­
tablished nor ruled out. Presum­
ably, many patients with liver inju-
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ries are successfully treated nonop- 
eratively.
What is the current recommen­
dation for the treatment of pa­
tients with penetrating gunshot 
wounds to the right upper quad­
rant? Many of these patients have 
stable vital signs but the trajectory 
of the bullet clearly transgresses 
the liver. When there are no perito­
neal signs, should the patient be 
observed rather than explored? 
Many such patients who undergo 
exploration have nonbleeding, 
through-and-through gunshot 
wounds which are not even drained. 
Should not the same policy of care­
ful observation applied to patients 
with right upper quadrant stab 
wounds also be applied to patients 
with similar gunshot wounds? 
When patients present with blunt 
abdominal trauma following a 
motor vehicle accident, a positive 
diagnostic paracentesis or diagnos­
tic peritoneal lavage leads to opera­
tive intervention. Some centres ob­
tain abdominal computed tomogra­
phy scans but omit paracentesis and 
peritoneal lavage. When the source 
of bleeding is from a probable liver 
injury, stable patients are observed 
nonoperatively.
Hemoperitoneum and Liver Injuries
What are the current guidelines 
for successful observation of pa­
tients with hemoperitoneum and 
liver injury confirmed by computed 
tomography? Hepatic artery ligation 
was once considered to be a techni­
cal mishap associated with inevita­
ble death. During the 1960s, hepat­
ic dearterialization became an ac­
ceptable treatment for refractory 
bleeding from the injured liver. Dur­
ing the 1970s, hepatic dearterializa­
tion was used as prophylaxis 
against postoperative bleeding in 
patients with large liver wounds not 
bleeding at laparotomy. Our own 
experience has shown that in a
small but significant number of pa­
tients hepatic necrosis develops fol­
lowing hepatic dearterialization for 
trauma. What are the current 
guidelines for hepatic dearterializa­
tion and should this procedure be 
used in conjunction with liver su­
tures, intrahepatic packing or in 
patients with associated peritonitis 
from hollow viscus injury?13 In­
trahepatic and parahepatic packing 
for liver injury, once considered the 
technique of an inadequate sur­
geon, has matured and is now a 
respectable procedure in certain cir­
cumstances.13 The questions that 
need to be answered regarding liver 
packing include the timing intraop- 
eratively, the technique (intrahepat­
ic or parahepatic), the value of a 
rubber dam between the liver and 
pack, and the timing of pack re­
moval.14
Hepatorrhaphy, the technique I 
prefer for the closure of most liver 
injuries, has been proposed by 
many as the cause of the hepatic 
necrosis. Does this so-called hepatic 
necrosis following hepatorrhaphy 
reflect inappropriate technique or 
unusually tight tieing of the hepa­
torrhaphy sutures? The type of 
drainage following treatment of 
liver injury continues to be contro­
versial. Many years ago, T-tube 
choledochostomy was the recom­
mended treatment for the most se­
vere liver injuries to decompress the 
extrahepatic and, therefore, the in­
trahepatic biliary system.13 Our 
studies showed that not only does 
T-tube choledochostomy not pre­
vent complications following the 
treatment of liver injury but it is 
associated with an increased risk of 
new complications related to biliary 
tract sepsis. Currently, the contro­
versy regarding drainage centres 
around the need to use closed 
drainage as opposed to none at all, 
with the result that some young 
surgeons provide no drainage for 
very severe liver injuries which need
to be drained to the outside in order 
to prevent the infrequent but fatal 
complications such as bile peritoni­
tis. The regional centre studying 
liver injury would address these 
questions and even design prospec­
tive randomized projects to identi­
fy the best modalities for treatment.
Splenic Injury
The optimal treatment of splenic 
injury is forever changing. The as- 
plenic state was known to be associ­
ated with infection in rodents in 
1920.15 The modern techniques for 
successful splenorrhaphy were well 
described in adults by 1930.15 The 
increased incidence of post-splenec­
tomy sepsis in children was known 
in the 1950s.15 Despite this knowl­
edge, the standard in the 1970s was 
splenectomy for all injured spleens. 
This policy was so ridiculous that 
surgical residents would “hide” tiny 
avulsions from their attending staff 
to prevent unnecessary splenecto­
my. The popularization of splenorr­
haphy was a big step forward but 
was severely criticized when applied 
to adult patients.
Fortunately, the surgical world 
has accepted splenorrhaphy and has 
even moved a step further toward 
nonoperative treatment of splenic 
injury observed by abdominal com­
puted tomography. Although the 
current surgical literature suggests 
that splenic disruption observed by 
abdominal computed tomography 
should be treated by operative inter­
vention in order to avoid missing 
associated hollow viscus injury, I 
am confident that this lack of wis­
dom will be corrected during the 
next decade. I look forward to a 
time when the criteria for nonopera­
tive treatment of splenic disruption 
confirmed by computed tomography 
are well defined and followed by 
most North American surgeons. 
Clearly, the regional centre as­
signed to evaluate splenic injury
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would have an exciting agenda re­
solving these issues. Additional is­
sues that the centre must resolve 
relate to the wound breaking- 
strength in patients with splenorr­
haphy and those treated nonopera- 
tively for splenic injury.15
Pancreatic and Duodenal 
Injuries
Pancreatic and duodenal injuries 
continue to be a challenge.16 The 
regional trauma centre designated 
to update treatment of pancreatic 
injury could address the role of 
serial serum amylase determinations 
and abdominal computed tomogra­
phy scans in patients with a nega­
tive diagnostic peritoneal lavage. 
Recently, we reported that patients 
with negative peritoneal lavage and 
a positive abdominal computed to­
mography scan showing probable 
pancreatic disruption are candidates 
for endoscopic retrograde cholangi­
opancreatography (ERCP) to identi­
fy the degree, if any, of pancreatic 
disruption.17 We have observed a 
patient with blunt abdominal injury, 
a rising serum amylase, and “tran­
section” of the body of the pancre­
as on abdominal computed tomog­
raphy scan when the ERCP showed 
integrity of the primary, secondary 
and tertiary pancreatic ducts.17 The 
centre assigned to updating the 
criteria for surgery of pancreatic 
injury would need to encourage 
prospective studies designed to 
identify the value of ERCP in this 
setting.
The centre working with the 
guidelines for treatment of duode­
nal injury will need to identify the 
current status of abdominal com­
puted tomography with contrast 
after a negative diagnostic peritone­
al lavage. Is this test better than 
simply looking for scoliosis and 
decreased visualization of the right 
psoas shadow on an abdominal
plain film? This centre would also 
need to address the current guide­
lines for treatment of duodenal he­
matoma in adults. Should these 
patients be observed for 3 weeks as 
is currently popular with children?
The Regional Centres
Each specialty area within the 
field of trauma could be reviewed by 
a regional centre annually to define 
the objective criteria for surgical 
intervention and to develop ques­
tions which will test the cognitive 
domain of surgical residents caring 
for such patients. The guidelines 
for treatment and the questions 
designed to test these guidelines 
would be sent to a central commit­
tee from which they would be dis­
tributed to other regional commit­
tees for constructive criticism and 
revision.6 The materials would then 
come back to the central committee 
for collation and return to the re­
gion of origin. Since this approach 
requires a consensus, one would 
have to discount those questions 
for which no consensus could be 
reached. Whenever the questions 
are too controversial to produce a 
consensus, further research and 
further prospective studies would 
be necessary to identify the best 
approach. This type of involvement 
of multiple centres annually would 
create a sense of excitement in all 
participants and lead to a living 
body of knowledge which would be 
revitalized each year. Maintenance 
of this living body of knowledge 
would require the frequent replace­
ment of experienced surgeons with 
new surgeons responsible for the 
yearly maintenance of the data 
bank. Since the American College 
of Surgeons Committee on Trauma 
is already organized in a regional 
framework, one could logically rec­
ommend that this be the central 
committee to which each region 
would forward data annually.6
Psychomotor and Affective 
Education
The psychomotor domain is criti­
cal to the successful care of injured 
patients. Surgeons are physiologic 
mechanics, working on the human 
chassis. A skilled hand is as impor­
tant as experience with that particu­
lar injury. A proper residency pro­
gram needs to define which experi­
ences are appropriate at the differ­
ent levels of surgical training. 
There are many procedures which 
are minor and should be included 
into the mandatory core curriculum 
of junior residents, whereas the 
more major surgical procedures 
would fit into the core curriculum 
of the more mature residents.818 
Although each resident would not 
get to do each major procedure in 
injured patients, an absolute mini­
mum of major procedures which 
each resident needs to perform dur­
ing his surgical training must be 
identified. This curriculum for the 
psychomotor domain should be co­
ordinated and be in concert with the 
guidelines established by the boards 
testing surgical proficiency.
The evolution of new surgical 
procedures mandates that the prac­
tising surgeon have some mecha­
nism whereby a refresher course 
would provide the new cognitive 
materials and psychomotor skills 
required to remain up to date with 
the treatment of various injuries. 
Successful care of the injured pa­
tient requires that the surgeon 
show leadership, courage and deci­
siveness.19 These affective traits 
need to be encouraged as part of 
our core curriculum so that the 
mature surgeon has the ability to 
make life and death decisions even 
though the database is inadequate. 
The surgeon needs to be taught 
that sins of omission are much 
worse than sins of commission. The 
importance of teamwork in the care 
of the injured patient cannot be
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over stressed. The maturing resi­
dent must learn to avoid peer pres­
sure while carrying out the proper 
order of priorities. Avoidance of turf 
battles between the surgical special­
ties requires the presence of a team 
captain who is responsible for up­
dating and maintaining the appro­
priate emergency medical services 
and schedules, and resolving dis­
putes between different surgical 
specialties. This team captain would 
really function as the chairman 
(chairwoman) of a large trauma 
committee designed for the optimal 
care of injured patients. Nobody 
can say it better than Dr. Ghent, 
”As chairman of the committee, I 
know from bitter experience that 
the buck stops here, with me.” 1
Conclusions
The actual care of an injured 
patient cannot be separated from 
education. The proposed guidelines, 
briefly outlined herein, for the de­
velopment of an organized ap­
proach to a uniform core curricu­
lum for residents and practising 
physicians alike reflects this union 
of patient care with education. 
Clearly, multiple disciplines must be 
involved in the input, which should 
be constructively criticized by all 
parties in order to enhance the 
quality of the yearly revisions. The 
ultimate goal of this intricate sys­
tem of living education would be 
enhanced patient care. The chal­
lenge is there. We surgeons must 
accept the task lest others of less 
skill and less idealism pick up the 
gauntlet.
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Inflammatory Aneurysms of the 
Abdominal Aorta
The treatment of inflammatory aneurysms of the abdominal aorta presents a 
formidable challenge to the surgeon. The retroperitoneal inflammatory reaction 
obliterates normal tissue planes, limiting access to the infrarenal aorta. During a 
70-month period 25 (6%) of 439 patients operated on for abdominal aortic 
aneurysms were found to have the inflammatory type. These patients were more 
likely to be symptomatic than patients with noninflammatory aneurysms and they 
were more likely to be male. Although surgical repair of the aneurysms required 
longer aortic occlusion time and more blood replacement, the outcome was similar to 
that for patients treated for noninflammatory aneurysms.
Le traitement des anevrismes inflammatoires de l’aorte abdominale represente un 
formidable defi pour le chirurgien. La reaction inflammatoire retroperitoneale efface 
les plans normaux des tissus, limitant de la sorte faeces a l’aorte sous-renale. Au 
cours d’une periode de 70 mois, 25 (6%) des 439 patients operes pour un anevrisme 
de l’aorte abdominale avaient un anevrisme de type inflammatoire. Ces patients 
etaient plus sujets a etre symptomatiques que les patients souffrant d’anevrismes 
non inflammatoires et il y avait plus de chance que ce soit des hommes. Meme si la 
reparation chirurgicale necessita une occlusion aortique plus prolongee et davanta- 
ge de transfusions sanguines, Tissue fut comparable a celle des patients traites pour 
un anevrisme non inflammatoire.
I nflammatory aneurysm, a proc­ess that involves the aortic wall 
and surrounding retroperitoneal 
structures, is a well-recognized vari­
ant in the spectrum of aneurysmal 
disease. The cause is poorly under­
stood. Because of the pathologic 
differences between these aneu­
rysms and the noninflammatory va­
riety there may be a different pat­
tern of symptoms, and the involve­
ment of adjacent structures in the
inflammatory process presents tech­
nical problems for the vascular sur­
geon. The technical difficulty and 
associated complications, which 
may include enterotomy or major 
venous or ureteral injury, have 
prompted some to recommend no­
noperative treatment for inflamma­
tory aneurysms. Understanding the 
potential operative hazards and 
adopting a modified technique to 
control the aorta in an area free
from the inflammatory process ap­
pears to allow for safe surgery with 
results that are comparable to those 
for noninflammatory aneurysms.
Methods
A prospectively collected vascular 
database was used to identify all 
patients operated on for an abdomi­
nal aortic aneurysm during the 70 
months from March 1981 to De­
cember 1986. Aneurysms were clas­
sified as inflammatory or noninflam­
matory by their gross appearance at 
surgery as recorded in the operative 
notes. In addition to patient demo­
graphics, the following variables 
were compared with respect to in­
flammatory and noninflammatory 
aneurysms: aneurysm size, manner 
of presentation, symptoms, type of 
reconstruction, hospital course and 
outcome. The hospital records of 
patients with inflammatory aneu­
rysms were further reviewed for 
details regarding radiologic investi­
gations. Long-term patient outcome 
was determined from clinic records 
and direct patient and family con­
tact.
Statistical analysis between the 
groups was carried out using x2 
and Student’s f-tests as appropriate.
Findings
During the review period 439 
patients were operated upon for 
abdominal aortic aneurysm; 25 (6%)
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of these were classified by the oper­
ative findings as having inflammato­
ry aneurysms. Patient demograph­
ics, manner of presentation and 
operative results are outlined in 
Table I.
The majority of patients with 
inflammatory aneurysms were 
symptomatic, most commonly suf­
fering from back or abdominal pain. 
Twelve of the 25 patients under­
went excretory urography before 
operation; ureteral obstruction was 
demonstrated in 4 of them. Urete- 
rolysis was carried out in one and 
the obstructive uropathy resolved 
spontaneously in the remainder.
Tube grafts were used in 20% of 
patients with noninflammatory an­
eurysms and in 3 of the 25 with 
inflammatory aneurysms. Nine of 
the patients with inflammatory an­
eurysms required placement of at 
least one limb of the bifurcation 
graft in the femoral position. The 
difference in the distribution of dis­
tal graft position between the two 
groups was not statistically signifi­
cant.
One ureteral injury occurred dur­
ing repair of an inflammatory aneu­
rysm. It was recognized and imme­
diately repaired and there were no 
long-term sequelae. There were no 
duodenal injuries.
The death rate for repair of intact 
aneurysms was 4% in both groups. 
There were two deaths in the in­
flammatory group during the fol­
low-up period, at 13 and 23 
months, which suggests a long­
term outcome comparable to that of 
patients with noninflammatory an­
eurysms.
Discussion
Inflammatory aneurysm of the 
abdominal aorta is a distinctive 
pathologic variant that is now well 
recognized and is within the experi­
ence of most vascular surgeons;
repair remains a challenge for even 
the most experienced. The first clin­
ical series describing inflamatory 
aneurysms was published by Walk­
er and associates in 1972.1 Subse­
quent case reports and clinical se­
ries have characterized the problem 
and documented a higher incidence 
of complications associated with re­
pair. Of all abdominal aortic aneu­
rysms 5% to 10% are reported to be 
of the inflammatory variety, which 
is more common in men than wom­
en, a feature that has not been 
emphasized in the literature. In the 
present series men outnumbered 
women 24 to 1, a rate consistent 
with that of the few other series 
that have noted the difference in 
sex distribution. Overall, women 
make up 15% to 20% of all patients 
with aneurysmal dilatation of the 
abdominal aorta. Among patients 
with inflammatory aneurysms, 
women have been reported to ac­
count for less than 4%,2-4 which is 
consistent with the present series. 
Unlike the noninflammatory variety, 
the majority of patients with inflam­
matory aneurysms have symptoms 
clearly referable to the aneurysm. 
The 52% frequency of symptoms in 
our series is consistent with rates 
reported previously. Abdominal and 
back pain and a recent history of 
substantial weight loss are the most 
constant features. The severity of 
symptoms often leads to the diag­
nosis of an expanding or ruptured 
aneurysm. Rupture among these 
patients, however, appears to be
less frequent than among patients 
with noninflammatory aneurysms. 
Symptoms of ureteral obstruction 
are found in 25% of patients with 
inflammatory aneurysms and were 
often the presenting symptom in 
the sporadic case reports prior to 
Walker’s description.5
Despite the increased awareness 
of this entity and availability of 
accurate imaging techniques for 
structures in the retroperitoneum, 
the diagnosis of inflammatory aneu­
rysm is usually made intraoperative- 
ly. Computed tomography (CT) is 
currently the most accurate test for 
identifying an inflammatory aneu­
rysm and has a reported sensitivity 
of 70% to 80%.4-6-8 Our experience 
with CT in diagnosing inflammatory 
aneurysms is similar to that report­
ed from other centres where the 
radiologic diagnosis was frequently 
made only in retrospect. Careful 
inspection of the transmural thick­
ness on the computed tomogram 
should improve the ability to make 
the correct diagnosis preoperative- 
ly. Excretory urography and ul­
trasonography may assist in the 
preoperative diagnosis although the 
sensitivity of these tests is less than 
that of CT.
An elevated erythrocyte sedimen­
tation rate has often been described 
as a reliable marker for inflammato­
ry aortic aneurysm. Pennell and 
colleagues4 found such an elevation 
in nearly three-quarters of patients 
with inflammatory aneurysms, but 
also in one-third of patients with
Tab le  1. C o m p a riso n  o f P a tien ts  W ith  In f la m m a to ry  and N o n in f la m m a to ry  A b d o m in a l A o r tic
A n e u ry sm s
In flam m ato ry  
(n  =  2 5 )
N o n in fla m m a to ry  
(n  =  4 1 4 ) p va lue
M ean age, y r 66 68 NS
M a le /fe m a le 2 4 /1 3 4 4 /7 0 0 .0 6 7
P resence o f s y m p to m s 1 3 (5 2 % ) 9 5 (1 7 % ) < 0 .0 1
R upture 1 (4% ) 7 5  (1 8 % ) 0 .0 7
C lam p  t im e , m in 97 85 NS
B lood  re p la c e m e n t, m l 3 9 6 5 3 0 0 4 < 0 . 0 2
O pera tive  d e a th s 2 (8% ) 3 6  (9 % )
R uptured 1 23
In tac t 1 13
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the noninflammatory type. The pos­
itive predictive value of this test 
would then appear to be less than 
10% and therefore of no value in 
the diagnosis. The pathognomonic 
features of inflammatory aneurysms 
are easily recognized when the re- 
troperitoneum is exposed at surgery 
or autopsy. Figure 1 illustrates the 
classic porcelain appearance with 
the anterior wall of the aneurysm 
covered by a shiny, white, pearly 
tissue. The surrounding viscera, 
particularly the duodenum, are ede­
matous and densely adherent. The 
normal anatomical planes of loose 
areolar tissue that usually allow 
separation of the periaortic struc­
tures are obliterated, and the mes­
entery of the small bowel around 
the aneurysm is often thickened 
and shortened. In addition to the 
duodenum, the ureters, vena cava, 
renal vein and sigmoid colon are 
often fixed to the inflammatory 
process surrounding the aneurysm. 
The desmoplastic reaction about 
the aneurysm involves only the an­
terior and lateral walls. The wall of 
the aneurysm in these areas is usu­
ally three to four times its normal 
thickness and may have a transmu­
ral diameter as great as 4 cm.4’7 The
posterior wall is thinned and is the 
point of disruption when rupture is 
encountered. Histologic examina­
tion reveals that the majority of the 
aneurysm wall is a thickened adven­
titia characterized by a chronic in­
flammatory process with lympho­
cyte and plasma cell infiltration. 
There is an associated endarteritis 
of the adventitial vessels and neuro­
nal entrapment.
The gross and microscopic fea­
tures of inflammatory aneurysms 
have generated various theories 
about the etiology of this process. 
The belief that the periaortic fibro­
sis is a reaction to chronic extrava­
sation of blood has been discounted 
principally because it is rare to find 
evidence of hemorrhage or hemo­
siderin-laden macrophages in the 
surrounding fibrotic reaction.3 4 The 
possibility that this process is a 
variant of Takayashu’s disease also 
appears unlikely. Takayashu’s dis­
ease affects young or middle-aged 
women and usually involves the 
branches of the aortic arch, while 
inflammatory aneurysms are seen 
almost exclusively in elderly men 
whose disease is usually concentrat­
ed in the abdominal aorta and prox­
imal iliac arteries. Inflammatory an­
eurysms have been grouped in the 
pathology literature with idiopathic 
retroperitoneal fibrosis and chronic 
periarteritis under the heading of 
chronic periaortitis.9 Although 
there are similarities among these 
disease processes, there are distinct 
differences. Inflammatory aneu­
rysms exhibit a true aneurysmal 
dilatation of the aorta associated 
with a marked thickening of the 
anterior and lateral aortic wall and 
desmoplastic reaction of the pe­
riaortic retroperitoneum. Patients 
with idiopathic retroperitoneal fi­
brosis do not usually have an aneu­
rysmal aorta and the fibrotic reac­
tion completely encases the aorta 
and vena cava without sparing the 
posterior aortic wall. Tissue planes 
between the inflammatory process 
and the great vessels, preserved in 
idiopathic fibrosis, are obliterated in 
patients with inflammatory aneu­
rysms, and this accounts for the 
great technical difficulty encoun­
tered during repair, borne out in 
this and other series by prolonged 
aortic clamp times and greater oper­
ative blood loss. The basic princi­
ples of safe repair of inflammatory 
aneurysms are described in the re­
cent vascular surgical litera­
ture. 1’2-4-5’8 The crucial component 
of safe repair is the prevention of 
injury to adherent structures by 
avoiding the duodenum entirely and 
achieving control of the aorta above 
the involved area. Special tech­
niques for obtaining proximal and 
distal aortic control such as sub- or 
supradiaphramatic cross-clamping 
and distal occlusion using a balloon 
catheter have also been described. 
These techniques are usually not 
necessary but may be of help when 
the inflammatory process extends 
beyond the infrarenal aorta. If the 
diagnosis is made preoperatively, 
ureteral catheterization is suggest­
ed, particularly if there is evidence 
of obstruction. The value of this 
approach is confirmed by the re-
FIG. 1. Inflammatory aneurysm showing typical shiny white appearance and 
inflammatory reaction involving periaortic structures (duodenum — single arrow­
head, megacolon — double arrowheads).
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duced morbidity and mortality of 
recent reports and in the present 
series. Our results indicate that 
there was no increased morbidity or 
mortality for patients with inflam­
matory compared with noninflam­
matory abdominal aortic aneurysm.
It has been suggested that rup­
ture of inflammatory aneurysms is 
an infrequent event and that the 
indications for elective repair may 
be modified in such patients with­
out serious consequences. The 
point is controversial, however, and 
there are several reports that show 
no significant difference in rupture 
rates between the two types.61011 
Steroid therapy has been suggested 
to reduce the inflammatory compo­
nent, and perhaps reduce the poten­
tial hazard of surgical repair, but 
this too, remains controversial.12 It 
appears that a modified surgical 
technique to deal with the inflam­
matory aneurysm results in no 
greater hazard to the patient than 
occurs during repair of a noninflam­
matory aneurysm. It seems appro­
priate, therefore, to recommend 
surgical repair of aneurysms with­
out regard for the presence of an 
inflammatory type.
Summary
Inflammatory aneurysms are an 
important form of abdominal aortic 
aneurysms that demand respect and 
a modified surgical approach if re­
pair is to be effected without major 
complication. Patients with this 
process are more often symptomatic 
than are patients with the nonin­
flammatory counterpart, and they 
occur almost exclusively in males. 
Although the presentation may 
mimic rupture, disruption of the 
aortic wall occurs less commonly 
than among patients with nonin­
flammatory aneurysms. The wide­
spread use of CT scans for diagno­
sis may lead to increased recogni­
tion of the variation preoperatively. 
Surgical repair is alone difficult but 
can proceed with the same morbidi­
ty and mortality as that associated 
with repair of noninflammatory an­
eurysms.
We thank Dr. James L. Wellington, 
Ottawa General Hospital for allowing us 
to use Fig. 1.
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Factors Affecting Survival After Rupture 
of Abdominal Aortic Aneurysm: Effect of 
Size on Management and Outcome
John Lawlor Murphy, MD, FRCSC;* George Graeme Barber, MD, FRCSC;f 
Neil Virden McPhail, MD, FRCSC;$ Thomas Keith Scobie, MD, FRCSC§
Between 1970 and 1985,172 consecutive patients (146 men, 26 women) underwent 
repair of ruptured abdominal aortic aneurysms. The mean age was 69.8 years. The 
overall death rate was 49.4%. The most significant predictors of death were an 
intraoperative urine output under 100 ml, systolic blood pressure less than 90 mm 
Hg on admission or in the operating room, cardiac arrest and a history of collapse. 
Discriminant analysis correctly classified 90% of the survivors and 84% of the 
nonsurvivors.
Aneurysm size was documented in 133 cases; the average diameter was 8.78 cm, 
and 13 (10%) of the aneurysms were smaller than 6.0 cm. A correct diagnosis was 
made preoperatively in 46% of these 13 cases compared with 77% overall (p < 0.05), 
and the time from arrival to transfer to the operating room was 6.71 versus 2.37 
hours (p < 0.05). The death rate for patients who had the small aneurysms was 77% 
versus 45% for those with larger aneurysms (p < 0.06).
This study confirms the continuing poor results after repair of ruptured 
abdominal aortic aneurysms. A subset of patients having small aneurysms (less than 
6.0 cm) require an aggressive approach to diagnosis and treatment.
Rupture of abdominal aortic an­eurysms accounts for less than 
1% of deaths annually.1 The inci­
dence increases with age, to 
1 .36 /1000  for those older than 90 
years.1 Reported death rates for 
patients reaching hospital range be­
tween 15% and 68%,23 averaging 
50%. Overall death rates are likely 
higher, because a considerable pro­
portion of patients may die at home, 
as suggested by Ingoldby and col­
leagues.4
De 1970 a 1985, 172 patients consecutifs (146 hommes et 26 femmes) ont subi la 
reparation d’une rupture d’un anevrisme de I’aorte abdominale. Leur age moyen 
etait de 69.8 annees. La mortality globale a ete de 49.4%. Les facteurs previsionnels 
de deces les plus importants furent: un debit urinaire peroperatoire inferieur a 100 
ml, une hypotension (a moins de 90 mm Hg) lors de l’admission ou dans le bloc 
operatoire, un arret cardiaque ou des antecedents de collapsus. Une analyse 
discriminante a permis de classifier correctement 90% des survivants et 84% des non 
survivants.
La taille de l’anevrisme a ete determine dans 133 cas; 13(10% ) etaient inferieurs a 
6.0 cm et la taille moyenne etait de 8.78 cm. Les 13 petits anevrismes ont ete 
correctement diagnostiques dans 46% des cas comparativement a 77% pour 
l’ensemble (p < 0.05), alors que le delai entre l’admission et l’operation a ete de 
6.71 heures comparativement a 2.37 heures (p < 0.05). La mortality chez les 
patients porteurs de petits anevrisme a ete de 77%, alors qu’elle etait de 45% pour 
ceux qui avaient de gros anevrismes (p < 0.06).
Cette etude confirme que les resultats de la reparation des ruptures d’anevrismes 
de l’aorte abdominale sont encore mauvais. II existe un sous-groupe de patients 
porteurs de petits anevrismes qui necessite que Ton approche le diagnostic et le 
traitement de fa?on agressive.
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The in-hospital death rate has 
not changed significantly in the 
past decade. The principal determi­
nants of outcome reflect general 
health and degree of shock. We 
attempted to prognosticate in such 
a group of patients in the hope of 
developing formulas that would reli­
ably predict outcome and therefore 
be useful in selected cases to guide 
intervention.
Aneurysm size, measured by ul­
trasonography or computed tomog­
raphy, is a major determinant of 
therapy for asymptomatic abdomi­
nal aortic aneurysms. The effect of 
size documented intraoperatively on 
management and outcome was as­
sessed.
Patients and Observations
An abdominal aortic aneurysm 
was considered ruptured when 
blood was present outside the aortic 
adventitia in the retroperitoneum or 
peritoneal cavity. All patients with 
ruptured aneurysms were taken to 
the operating room promptly for 
surgical exploration. Investigations 
were usually limited to a complete 
blood count, determination of the 
prothrombin and partial thrombo­
plastin times, the platelet count and 
the electrolyte levels, cross-match­
ing of the blood and electrocardiog­
raphy. Further investigations were 
seldom required, as this was a clini­
cal diagnosis. Therapeutic measures 
included establishment of adequate 
intravenous access, administration 
of fluids and antibiotics intrave­
nously and insertion of a urinary 
catheter. The patient was prepared 
for surgery while the team 
scrubbed, then anesthesia was in­
duced and prompt laparotomy with 
aortic control carried out. Monitor­
ing devices such as an arterial line 
and a Swan-Ganz catheter were 
usually then inserted. During the 
study period the surgery was car­
ried out by one of three full-time 
vascular surgeons practising in a 
vascular surgery unit.
Between 1970 and 1985, 172 
consecutive patients (146 men 
[85%] and 26 women [15%]) under­
went an operation for a ruptured 
abdominal aortic aneurysm. The av­
erage age was 69.8 years. The pain 
had persisted an average of 16.6 
hours, and the principal location 
was the abdomen in 43%, the back 
in 31%, the lower quadrants of the 
abdomen in 20% and other areas in 
6%. There was a history of fainting 
or collapse in 98 (57%). Cardiac 
arrest had occurred preoperatively 
(including at a referring hospital 
before transfer) in 34 (20%). Associ­
ated diseases, according to informa­
tion available at the time of arrival 
in the emergency department, in­
cluded coronary artery disease (in 
38%), hypertension (in 21%), chron­
ic obstructive pulmonary disease (in 
15%) and diabetes mellitus (in 6%). 
In all but five patients the vascular 
consultant had noted a pulsatile 
mass that had not necessarily been 
detected by the triage examination. 
The systolic blood pressure at the 
time of arrival averaged 88.4 mm 
Hg.
The correct diagnosis by the 
emergency department physician 
was considered to have been made 
when the patient was promptly re­
ferred to a vascular surgeon as the 
first consultant; this occurred in 
77% of cases. The patients were 
transferred to the operating room 
an average of 2.37 hours after 
arrival, 65 (40%) of them in less 
than 30 minutes. The average sys­
tolic blood pressure at the time of 
induction of anesthesia was 97.8 
mm Hg.
In 47 cases (27%) free in- 
traperitoneal blood was found; the 
quantity did not necessarily reflect 
frank anterior rupture of the aorta. 
The diameter of the aneurysm, doc­
umented in all but 39 cases, aver­
aged 8.78 cm. The most common 
associated vascular abnormalities 
were common iliac aneurysms (pres­
ent in 63 [37%] of the 172 cases). 
In three cases transthoracic control 
of the aorta was obtained. Although 
the operative procedure was most 
commonly bi-iliac grafting, the fre­
quency of tube grafting has in­
creased in recent years; aortic bifur­
cation grafting was done in 134 
cases, aortic tube grafting in 14, 
axillobifemoral grafting in 5 and 
other procedures in 4. In 15 cases 
only laparotomy was performed; su­
prarenal aneurysms were present in 
8 of these cases. On average 6.0 L 
of blood was lost, 8.4 L of fluid 
replaced, 11.3 units of blood re­
placed and 636.9 ml of urine 
passed.
The complication rate was sub­
stantial. Of the 59 patients with 
cardiac complications 38 had myo­
cardial infarction and 19 had ar­
rhythmias requiring therapy. 
Among the 53 patients with acute 
renal insufficiency and the 2 with 
nephrotic syndrome 21 underwent 
hemodialysis; 5 survived. The 53 
patients with pulmonary complica­
tions had, by definition, at least one 
of atelectasis, pneumonia, effusions 
and prolonged intubation. The 15 
patients with coagulopathies had 
undergone massive transfusion; 
only 2 survived. The 11 patients 
with sepsis had multiple organ fail­
ure.
Outcome
The rate of survival to hospital 
discharge was 51%. Of the 85 
deaths 20 occurred in the operating 
room and 8 more than 30 days after 
surgery.
The mortality data were analysed 
for prognostic significance of the 
independent variables with use of 
the x2 test and Yates’ correction. 
The results are shown in Table I in
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descending order of statistical sig­
nificance.
With the use of Wilkes’ A and 
the F statistic, variables were select­
ed for use in canonial discriminant 
function to construct formulas for 
prognostication (Table II). The first 
formula was based on information 
available in the emergency depart­
ment. Although it was correct in 
predicting whether the patient
would survive in 69% of the cases, 
the false-positive and false-negative 
rates were high; 25% of the patients 
predicted not to survive did survive 
and 38% of the patients predicted to 
survive actually died. The second 
formula, with additional variables 
obtained intraoperatively, was cor­
rect in 87% of its predictions; how­
ever, its false-positive rate (10%) 
and false-negative rate (16%) ren­
dered it quite imprecise for clinical 
application.
Of the 133 aneurysms whose size 
was documented 13 were less than 
6.0 cm in diameter. The 13 patients 
were more likely to die and less 
likely to receive a correct diagnosis; 
consequently, their time between 
arrival in the emergency department 
and transfer to the operating room 
was longer, and more of them had a 
low urine output in the operating 
room (Table III).
Discussion
The factors influencing outcome 
after rupture of an abdominal aortic 
aneurysm have been evaluated ex­
tensively and can be grouped into 
three categories: physiologic status 
(e.g., age and associated diseases) 
before rupture, degree of hypovo­
lemic shock (e.g., fainting or col­
lapse, systolic blood pressure in the 
emergency department and urine 
output in the operating room), and 
promptness of diagnosis and treat­
ment. A study like ours, based on 
emergency department histories, 
lacks the sophisticated preoperative 
data available to other vascular sur­
geons predicting outcome.5
Although we found age to be 
independently significant the issue 
is contentious in the literature. Au­
thors such as Mannick and associ­
ates6 have suggested that age is not 
a major factor; others2-7 have dis­
agreed. Selection may also be in­
volved: Ingoldby and colleagues4 
noted that only 5 of 70 patients 
older than 75 years survived to 
reach hospital. The influence of age 
in our discriminant analysis for­
mulas was limited. Therefore, age 
alone should not be a deterrent to 
surgery.
The prevalence of associated dis­
eases is likely understated for our 
group of patients as compared with 
similar groups.7' 10 A history of cor-
T a b le  1. Independent Variables for Patients With Ruptured Abdominal Aortic Aneurysms in 
Descending Order of Prognostic Significance
V a r ia b le
No. of s u r­
vivors (n =  8 7 )
No. of nonsur­
vivors (n  =  85 ) p v a lu e *
Intraop urine 4 32 <  0.0001
output, <  100 ml 
Intraop systolic blood pressure, 
mm Hg
Highest < 100 0 18 < 0.0001
Lowest < 60 24 50 < 0.0001
Preop cardiac arrest 7 27 < 0.0002
Postop renal failure 15 38 <  0.0002
Preop collapse 38 60 <  0.0005
Previous diagnosis; 4 21 <  0.0005
surgery not done
Systolic blood pressure 38 57 <  0.005
<  90 mm Hg on arrival 
Age, yr
<  65 34 14
6 5 - 7 5 32 42 <  0.005
>  75 21 29
>  20 units blood replaced 2 14 <0.01
Blood loss <  8 L 8 20 <0.05
*ln x z testing with Yates’ correction.
T a b le  II. Correlation Coefficients in Descending Order of Contribution to Discriminant Analysis
Formulas*
F o rm u la  1: em erg en cy F o rm u la  2: fo rm u la  1 +
d e p a rtm e n t data o p e ra tiv e  d a ta
Cardiac arrest (0.76) Cardiac arrest (0.45)
Collapse (0.70) Acute renal failure (0.42)
Pulse rate (0.54) Lowest systolic blood pressure in -(0 .36 )
Age (0.50) operating room
Systolic blood pressure Pulse rate (0.34)
In emergency dept (0.48) Urine output in operating room -(0 .34 )
Difference between emergency (0.28) Collapse (0.34)
dept and operating room Systolic blood pressure in -(0 .34 )
emergency dept
Highest systolic blood pressure in -(0 .33 )
operating room
Free intraperitoneal blood (0.29)
Age (0.24)
Systolic blood pressure at -(0 .24 )
induction of anesthesia
Units blood transfused (0.16)
Correct diagnosis (0.12)
Blood loss (0.11)
Vascular abnormalities (0.04)
'Variables were selected with the use of Wilkes' X and the F statistic.
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onary artery disease, hypertension, 
chronic obstructive pulmonary dis­
ease or diabetes mellitus did not 
affect the likelihood of survival 
among our patients. Variables dem­
onstrating the degree of shock, 
however, were highly significant 
predictors and were the major con­
tributors to the prognostic for­
mulas. Similar observations have 
been made by Donaldson and as­
sociates7 and by Wakefield and col­
laborators.11
The correct diagnosis was made 
promptly by 77% of the emergency 
department physicians, an improve­
ment from the 68% documented 
earlier.8 Although misdiagnosis has 
been found by others to affect out­
come adversely12 it was not a statis­
tically significant factor in our 
group of patients. The average time 
from arrival to transfer to the oper­
ating room, 2.37 hours, compares 
well with figures in other reports711 
and was also not a significant fac­
tor.
Although the type of operation 
was not significant the finding of 
free intraperitoneal blood was a
major contributor to the prognostic 
formulas. The importance of exces­
sive blood loss and degree of blood 
and crystalloid resuscitation has 
previously been noted.3811 Howev­
er, 28% of the patients in our study 
who lost more than 8 L of blood 
survived, and the contribution of 
the degree of blood loss to the 
prognostic formulas was limited.
Donaldson and colleagues7 found 
an accuracy of 70% in predicting 
outcome on the basis of age, hema­
tocrit and blood pressure at the 
time of admission. They also noted 
that the outcome was very poor if 
the systolic blood pressure fell 
below 100 mm Hg.
Shackleton and colleagues13 con­
structed a formula from the data for 
106 unselected patients using step­
wise logistic regression and were 
able retrospectively to classify the 
patients into one of four risk 
groups. The most significant varia­
bles were level of consciousness 
before transfer to the operating 
room, history of congestive heart 
failure and unmeasured anion gap. 
The death rates for the four groups
were 100%, 75%, 28% and 12%; 
with the two high-risk and the two 
low-risk groups combined the rates 
were 78% and 20%. The authors 
cautioned against clinical applica­
tion of this information. For the 
group at highest risk the death rate 
of 100% suggests that intervention 
is futile; however, only 5 of the 106 
patients were so classified.
With discriminant analysis we 
constructed two predictive for­
mulas. Medical information avail­
able in the emergency department, 
such as a history of congestive 
heart failure, was unhelpful in the 
statistical analysis. Since their false­
positive rates proved to be very 
high, the formulas have limited 
practicality and would likely per­
form less well prospectively.
The classification developed by 
Fitzgerald, Stillman and Powers3 
could not be applied retrospectively.
Thus, we cannot predict outcome 
reliably and can only advocate ag­
gressive management, namely 
transfer to the operating room.
The average diameter of the 133 
abdominal aortic aneurysms in our 
series for which the size was docu­
mented was 8.78 cm, similar to the 
average in previous reports.27911 
The 13 aneurysms less than 6.0 cm 
in diameter represented 10% of the 
total, a figure similar to that in the 
autopsy study by Darling.14 The 
death rate was 77% for our 13 
patients and 75% for the 12 pa­
tients studied by Cronenwett and 
associates15 who had small aneu­
rysms that became acutely tender or 
ruptured during conventional fol­
low-up. Emond and associates16 
suggested that there is an average 
of 8.2 mm of undersizing in 66% of 
preoperative ultrasonograms and 
computed tomograms compared 
with intraoperative measurements. 
The only factors that we identified 
as contributing to the high death 
rate in the patients with small ab­
dominal aortic aneurysms were in-
Tab le  II I .  E ffe c ts  o f A n e u ry s m  S ize  on  P re sen ta tion  and O u tcom e
A neurysm  d iam ete r, cm *
V a r ia b le <  6 .0  (n  =  13) >  6 .0  (n =  120) p v a lu e t
A ge  >  7 5  y r 3 0 .8 2 6 .7 NS
A s s o c ia te d  co ronary a rte ry  d isease 3 0 .8 4 1 .9 NS
C o lla p s e 7 6 .9 5 7 .3 NS
P re o p  c a rd ia c  arrest 1 5 .4 19 .0 NS
S y s to l ic  b lo o d  p ressu re  <  9 0  m m  Hg in 6 1 .5 5 4 .2 NS
e m e rg e n c y  dept
D e te c ta b le  mass 9 2 .3 9 7 .3 NS
S y s to l ic  b lo o d  p ressu re  <  9 0  m m  Hg in 3 8 .5 4 0 .0 NS
o p e ra t in g  room
F ree  in tra p e rito n e a l b lo o d 23.1 3 1 .4 NS
B lo o d  lo s s  >  7 L 2 5 .0 2 7 .6 NS
A s s o c ia te d  vascu la r a b n o rm a lit ie s 23.1 5 1 .4 <  0 .1 2
T u b e  g ra ft in g 23 .1 5 .9 <  0 .1 5
U r in e  o u tp u t <  100  m l in o p e ra tin g 3 8 .5 1 8 .4 <  0 .0 5
ro o m
C o r re c t  d iagnosis 4 6 .2 7 6 .7 <  0 .0 5
D e a th  ra te 7 6 .9 4 5 .0 <  0 .0 6
M a le / fe m a le  ratio 1 0 /3 1 0 4 /1 6 NS
T im e  be tw een  a rr iva l in e m e rg e n c y  d e p t 6.71 2 .3 4 < 0 . 0 5
a n d  tra n s fe r to  o p e ra tin g  ro o m , h
*%  o f  pa tien ts .
t  In  x 2 te s ting  w ith  Y a te s ’ c o rre c tio n ; NS =  n o t s ig n if ic a n t.
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correct diagnosis and consequent 
delay in transfer to the operating 
room and low intraoperative urine 
output. Hiatt and collaborators12 
noted that misdiagnosis and delay 
adversely affected outcome in their 
29 patients with small abdominal 
aortic aneurysms, 9 of whom died.
Conclusions
Abdominal aortic aneurysms con­
tinue to carry a high death rate 
after rupture; in our series the 
figure was 51%. The major contrib­
uting factors remain the degree of 
shock and subsequent renal insuffi­
ciency. Our ability to predict out­
come is very limited, and aggressive 
surgical treatment remains the pre­
ferred approach.
Small abdominal aortic aneu­
rysms do rupture and seem to carry 
a high death rate that is related to 
delays in diagnosis and treatment. 
This small subset may benefit from 
an ultrasonographic diagnostic 
screening program.
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P R E S C R IB IN G  IN F O R M A T IO N  
Action
In vitro studies indicate that the bacterial action of Claforan (cefotaxime sodium) a semi synthetic cephalosporin 
antibiotic, results from inhibition of cell wall synthesis.
Indications and Clinical Uses
Treatm ent: Claforan (cefotaxime sodium) may be indicated for the treatment of infections caused by susceptible 
strains of the designated micro organisms in the diseases listed below.
Lower respiratory tract infections : pneumonia and lung abscess caused by Streptococcus pneumoniae 
(formerly Diplococcus pneumoniae), other streptococci (excluding enterocci, eg. S. faecalis), Straphylococcus 
aureus (penicillinase and non penicillinase producing), Escherichia coli, Hemophilus influenzae, (including 
ampicillin resistant strains) and unspecified Klebsiella species.
Urinary tract in fec tions : caused by Escherichia coli, unspecified Klebsiella species (including K. pneumoniae), 
Proteus mirabilis, indole positive Proteus, Serratia marcescens and Staphylococcus epidermidis. Also, uncomplicated 
gonorrhea caused by N. gonorrhoeae including penicillin resistant strains.
B acte rem ia /S e p ticem ia : caused by Escherichia coli, unspecified Klebsiella strains and Serratia marcescens 
Skin in fe c tio n s : caused by Staphylococcus aureus (penicillinase and non penicillinase producing, S. epidermidis, 
Group A streptococci, Escherichia coli, Proteus mirabilis and indole positive Proteus.
Intra-abdom inal in fec tions: caused by Escherichia coli, and unspecified Klebsiella species.
Gynecological in fec tions : including pelvic inflammatory disease, endometritis and pelvic cellulitis caused by 
E. coli, Group A streptococci and Staphylococcus epidermidis; anaerobic bacteria including unspecified Peptococcus 
and Peptostreptococcus strains and some strains of Bacteroides fragilis. In several cases, although clinical cures 
were achieved, bacteriological follow-up was not available.
Central nervous system in fec tions : meningitis and ventriculitis caused by Haemophilus influenzae, Neisseria 
meningitidis, Streptococcus pneumoniae, Klebsiella pneumoniae and Escherichia coli. Claforan is not active 
against Listeria monocytogenes.
Clinical experience with Claforan in anaerobic infections is limited. Claforan has been used with some success in 
wound and intra-abdominal infections against some strains of unidentified Bacteroides and anaerobic cocci. 
Claforan has been shown to be active against some strains of Pseudomonas.
In the treatment of infections encountered in immunosuppressed and granulocytopenic patients, results of therapy 
with Claforan have not been impressive.
Claforan should not be considered in the treatment of enterococcal infections, i.e. Streptococcus laecalis. 
Specimens for bacteriologic culture should be obtained prior to therapy in order to isolate and identify the causative 
organisms and to determine their susceptibilities to Claforan. Therapy may be instituted before results of susceptibility 
studies are known; antibiotic treatment should be re evaluated once these results become available.
Prophylactic U s e : The administration of Claforan perioperatively (preoperatively, intraoperatively and postoperatively) 
may reduce the incidence of certain infections in patients undergoing elective surgical procedures (e g. abdominal 
or vaginal hysterectomy, gastrointestinal and genitourinary tract surgery) that may be classified as contaminated or 
potentially contaminated.
In patients undergoing caesarian section who are considered to be at increased risk of infection, intraoperative 
(after clamping the umbilical cord) and postoperative use of Claforan may also reduce the incidence of certain 
postoperative infections.
Effective use for elective surgery depends on the time of administration (see Dosage and Administration).
For patients undergoing gastrointestinal surgery, preoperative bowel preparation by mechanical cleansing as well as 
with a non-absorbable antibiotic (e.g. neomycin) is recommended.
If there are signs of infection, specimens for culture should be obtained for identification of the causative organism 
so that appropriate therapy may be instituted.
Contraindications
Claforan is contraindicated in patients who have shown hypersensitivity to cefotaxime sodium, the cephalosporin 
or the penicillin groups of antibiotics.
Warnings
Before therapy with Claforan is instituted, it must be carefully determined whether the patient has had previous 
hypersensitivity reactions to cefotaxime, cephalosporins, penicillins or other drugs. Claforan should be given with 
caution to patients with Type 1 hypersensitivity reactions to penicillin. Antibiotics, including Claforan should be 
administered with caution to any patient who has demonstrated some form of allergy, particularly to drugs. If an 
allergic reaction to Claforan occurs, the drug should be discontinued and the patient treated with the usual agents 
(e.g. epinephrine, antihistamine, pressor-amines or corticosteroids).
Pseudomembranous colitis has been reported w ith  the use o f cephalosporins (and other broad spectrum  
antib io tics); therefore, it is im portant to consider its diagnosis in patients who develop diarrhea during 
the adm inistration o f Claforan. This colitis  can range from  m ild to life-threatening in severity.
Treatment with broad spectrum antibiotics, such as Claforan, alters the normal flora of the colon and may permit 
overgrowth of Clostridium difficile or other Clostridia, it has been established that a toxin produced by Clostridium 
difficile is one primary cause of antibiotic-associated colitis.
Mild cases of colitis may respond to discontinuation of Claforan and replacement with a suitable specific antibiotic. 
Moderate to severe cases should be managed with fluid, electrolyte and protein supplemntation as indicated.
When the colitis is not relieved by discontinuance of Claforan administration or when it is severe, an antibiotic 
specifically effective in antibiotic-associated pseudomembranous colitis (e.g. vancomycin) or other suitable therapy 
may be indicated. Other possible causes of colitis should also be considered (see Adverse Reactions). 
Precautions
Claforan (cefotaxime sodium) should be prescribed with cauton in individuals with a history of lower gastro­
intestinal disease, particularly colitis.
The safety of Claforan in pregnancy has not been established. Consequently, use of the drug in pregnant women 
requires that the likely benefit from the drug be weighed against the possible risk to tne mother and fetus.
Use of Claforan in women of child-bearing potential requires that the anticipated benefits be weighed against the 
possible risks.
Cefotaxime is excreted in human milk in low concentrations. Caution should be exercised when the drug is 
administered to nursing mothers.
Prolonged use of Claforan may result in the overgrowth of nonsusceptible organisms. Constant evaluation of the 
patient's condition is essential. If super-infection occurs, therapy should be discontinued and appropriate measures 
taken.
Although Claforan rarely produces alterations in kidney function, evaluation of renal status is recommended, 
especially in severely ill patients receiving high doses.
Patients with markedly impaired renal function should be placed on the special dosage schedule recommended 
under Dosage and Administration, because normal dosage in these individuals is likely to produce excessive and 
prolonged serum antibiotic concentrations.
Positive direct Coomb’s test is known to develop in individuals during treatment with the cephalosporin group of 
antibiotics, including cefotaxime sodium
In laboratory tests a falso positive reaction to glucose may occur with reducing substances but not with the use 
of specific glucose oxidase methods.
Adverse Reactions
The most frequent adverse reactions with their frequency of occurrence are:
H ypersensitivity (1.8%); Rash, pruritus, fever. Local (5%): Injection site inflammation with intravenous 
administration Pam, induration and tenderness after intramuscular injection. Gastrointestinal (1.7%); Colitis, 
diarrhea, nausea and vomiting. Symptoms of pseudomembranous colitis can appear during or after Claforan 
treatment. Hemic and Lymphatic System (< 1 % ). Mild, reversible leukopenia, granulocytopenia and thrombo­
cytopenia have been reported. Some patients developed positive direct Coomb's test during treatment with 
Claforan G enitourinary System ( <  1%): Moniliasis, vaginitis. Liver ( <  1%); Transient elevations in SGOT, SGPT,
serum LDH and serum alkaline phsphatase levels have been reported. Kidney ( <  1%). Increased serum creatinine 
and BUN have occasionally been observed. Central Nervous System (0.2%): Headache.
Symptoms and Treatment of Overdosage
Since no case of overdosage has been reported to date with Claforan, no specific information on symptoms or 
treatment is available. Treatment of overdosage should be symptomatic.
Dosage and Administration
Claforan (cefotaxime sodium) may be administered intramuscularly or intravenously after reconstitution (see Table 
with recommended mode of reconstitution according to route of administration)
Adults
The dosage of Claforan should be determined by susceptibility of the causative organisms, severity of the infection 
and condition of the patient.
Guidelines for Dosage of Claforan (cefotaxime sodium)
Type of Infection
Daily Dose
(g) Frequency and Route
Uncomplicated Gonorrhea 1 1 g IM (single dose)
Uncomplicated infections 2 1 g every 12 hours IM or IV
Moderately severe to severe infections 3-6 12g every 8 hours IM or IV
Very severe infections (e.g. septicemia, CNS) 6-8 2g every 6-8 hours IV
Life-threatening infections up to 12 2g every 4 hours IV
To prevent postoperative infection in contaminated or potentially contaminated surgery, recommended doses are 
as follows.
(a) 1 g IM or IV administered 1/2 to 1-1/2 hours prior to the initial surgical incision to ensure that adequate 
antibiotic levels are present in the serum and tissues at the start of surgery
(b) 1 g IM or IV administered 1-1/2 to 2 hours following the first dose; for lengthy operative procedures, additional 
intraoperative doses may be administered, if necessary, at appropriate intervals (1-1/2 to 2 hours) during surgery
(c) 1 g IM or IV administered within 2 hours following completion of surgery 
The total cumulative prophylactic dose should not exceed 6g in a 12 hour period 
Caesarian Section Patients
The first dose of 1 g is administered IV as soon as the umbilical cord is clamped. The second and third doses 
should be given as 1 g IM or IV at 6 and 12 hours after the first dose.
Neonates, Infants, and Children
The following dosage schedule is recommended:
Neonates: 0-1 week of age 50 mg / kg IV q 12 h
1-4 weeks of age 50 mg / kg IV q 8 h
Infants and children (1 month to 12 years): For body weights less than 50 kg, the recommended daily dose is 
50 to 100 mg / kg IM or IV of body weight divided into 4 to 6 equal doses, or up to 180 mg / kg/day for severe 
infections (including central nervous system infections).
For body weights 50 kg or more, the usual adult dosage should be used.
The maximum daily dosage should not exceed 12 grams.
Administration of Claforan should be continued for a minimum of 48 to 72 hours after the patient defervesces or 
after evidence of bacterial eradication has been obtained; a minimum of 10 days of treatment is recommended for 
infections caused by Group A beta-hemolytic streptococci in order to guard against the risk of rheumatic fever or 
glomerulonephritis; frequent bacteriologic and clinical appraisal is necessary during therapy of chronic urinary 
tract infections and may be required for several months after therapy has been completed; persistent infections may 
require prolonged treatment. Doses less than those recommended should not be employed.
Dosage for Patients with Impaired Renal Function
In patients with estimated creatinine clearance of less than 20 mL / min / 1.73m? the dose of Claforan should be 
halved (see Precautions).
If serum creatinine values alone are available, the following formula (based on sex, weight, and age of the patient) 
may be used to convert these values into creatinine clearance.
Males; Weight (kg) x  (140 -  age)
72 x  serum creatinine 
Females; 0.85 x  above value
Administration
In tram uscu la r: Claforan should be injected well within the body of a relatively large muscle such as the upper 
outer quadrant of the buttock (i.e. gluteus maximus); aspiration is necessary to avoid inadvertent injection into a 
blood vessel
In travenous: The intravenous route is preferable for patients with bacteremia, bacterial spticemia, or other severe 
or life-threatening infections, or for patients who may be poor risks because of lowered resistance resulting from 
such debilitating conditions as malnutrition, trauma, surgery, diabetes, heart failure, or malignancy, particularly if 
shock is present or impending.
For bolus administration a solution containing 1 or 2 g of Claforan can be injected over a period of 3 to 5 minutes. 
Using an infusion system, it may also be given over a longer period of time through the tubing system by which 
the patient may be receiving other intravenous solutions. Butterfly* or scalp vein type needles are preferred for this 
type of infusion. However, during infusion of the solution containing Claforan, it is advisable to discontinue 
temporarily the administration of other solutions at the same site.
ADD-Vantage* Vial
When administering Claforan using the ADD-Vantage* Drug Delivery system, Claforan powder is added directly to a 
single-dose flexible plastic ADD-Vantage* diluent container. Claforan 1 g or 2 g may be reconstituted in 50 mL or 
100 mL of 5% Dextrose Injection USP or 0.9% Sodium Chloride Injection USP 
Stability
Solutions of Claforan reconstituted in 5% Dextrose Injection USP or 0.9% Sodium Chloride Injection USP in the 
ADD-Vantage* flexible containers maintain satisfactory potency for 12 hours at room temperature.
Availability
Claforan (cefotaxime sodium) is supplied as a sterile, white to pale yellow powder, in vials containing 500 mg,
1.0 and 2.0 g of cefotaxime sodium and in ADD-Vantage* vials containing 1.0 and 2.0 g of cefotaxime sodium 
(expressed as acid on a dry basis).
S to ra ge : Claforan in the dry state should be stored at room temperature protected from light and heat.
Product monograph available on request.
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The American Journal of Surgery, 1987; 153 341-346.
’ Reg’d TM of Abbott Laboratories.
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Heparin-Associated Thrombocytopenia 
and Thrombosis: Optimal Therapy With 
Ancrod
C.Wm. Cole, MD, FRCSC;* Lise M. Fournier, BScN, RVT;* Janis Bormanis, MD, FRCPCt
Heparin-associated thrombocytopenia and thrombosis (HATT) is an infrequent 
occurrence but may have disastrous consequences. Continued therapy with heparin 
must be avoided and anticoagulation achieved by alternative means. Among the few 
alternatives to heparin in critically ill patients, the best is ancrod. Depletion of 
fibrinogen with ancrod results in anticoagulation comparable to therapy with 
heparin within 12 hours. In a small series, nine patients with HATT were treated 
with ancrod; one underwent angiographic assessment, angioplasty and subsequent 
vascular reconstruction. Ancrod therapy was not associated with bleeding 
complications. It appears to provide optimal therapy for patients suspected of 
having HATT.
La thrombocytopenie et la thrombose provoquees par l’heparine (TTPH) sont des 
evenements rares, mais qui peuvent avoir des consequences desastreuses. La 
poursuite du traitement a l’heparine doit etre evitee et l’anticoagulation obtenue par 
d’autres moyens. Parmi le peu d’alternatives qui existent a l’heparine pour les 
patients gravement malades, la meilleure est l’ancrod. La depletion du fibrinogene a 
l’aide d’ancrod offre une anticoagulation comparable a celle de l’heparine en moins 
de 12 heures. Un petit groupe de neuf patients souffrant de TTPH ont re?u un 
traitement a l’ancrod; un d’entre-eux fut soumis a une angiographie et a une 
angioplastie, et il subit par la suite une reconstruction vasculaire. II n’y eut aucune 
complication hemorragique reliee a l’ancrod. Celui-ci semble offrir la meilleure 
therapie pour les patients soup^onnes de souffrir de TTPH.
H eparin-associated thrombocyto­penia and thrombosis (HATT) 
is a rare complication of heparin 
therapy, but one with dire conse­
quences. In a recent review1 of 
published cases the death rate was 
estimated to be 29%, and the rate of
Accepted fo r publication Sept. 29, 1989
major morbidity, such as lower ex­
tremity amputation, to be 21%. 
These figures probably underesti­
mate the incidence and risk. Be­
cause of the life-threatening nature 
of this complication, patients who 
have thrombocytopenia while being
treated with heparin must be con­
sidered to be at risk for HATT and 
be treated accordingly. All heparin 
must be discontinued in such pa­
tients, since exposure to even small 
amounts is sufficient to perpetuate 
the process. Unfortunately, there 
are few alternatives to heparin in 
the emergency situation. Coumadin 
cannot be used in most critically ill 
patients because it must be adminis­
tered orally, and because its action 
is delayed by 2 or 3 days in any 
case. Antiplatelet agents, such as 
acetylsalicylic acid (ASA) or dex- 
tran, have little to recommend them 
as anticoagulants. The purpose of 
this report is to describe the ratio­
nale for treatment of patients with 
HATT, using ancrod to deplete fi­
brinogen, and to report the results 
of treatment in nine such patients.
Mechanism of HATT
That thrombosis occurs in a pa­
tient being treated with heparin is 
paradoxical; it is coagulation in­
stead of anticoagulation. If it is 
going to develop, thrombocytopenia 
is usually observed after several 
days of heparin therapy, or upon 
re-exposure after a brief interval. 
Laboratory data support the prevail­
ing theory that HATT is mediated 
by a heparin-dependent immuno- 
globulin-G (IgG) or immuno- 
globulin-M (IgM) antibody that acts 
against the heparin-platelet com-
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plex, resulting in platelet activation 
and aggregation.27 These observa­
tions are consistent with an immune 
mechanism, although some features 
of the phenomenon are not clear. 
For example, thrombosis occurs in 
only a few patients with heparin- 
associated thrombocytopenia, and 
does not always develop when the 
patient is rechallenged. A possible 
explanation may be that of a short­
lived immune reaction.
Still, many of the elements that 
make up the clinical picture of 
HATT are well established. There is 
a central role for platelets, which 
aggregate abnormally and make up 
the bulk of the resulting thrombus.8 
Platelet-associated IgG can be mea­
sured in most patients in whom 
heparin-associated thrombocyto­
penia is suspected, but because it is 
also present in a variety of other 
conditions that are characterized by 
thrombocytopenia, it is not a useful 
diagnostic test for HATT. The 
mechanism of HATT appears to 
involve an immune-mediated activa­
tion of platelets, either directly, by 
the appearance of an antibody 
against the platelet-heparin com­
plex, or indirectly, by a mechanism 
causing endothelial injury.2 Ratio­
nal therapy for patients with HATT 
is directed towards inhibition of 
pathologic platelet aggregation. For 
example, Iloprost (ZK36374), a sta­
ble analogue of prostacyclin,1011 
has been used as a potent inhibitor 
of platelet aggregation in patients 
with HATT.12 Inhibition of platelet 
aggregation by such agents does 
not establish anticoagulation equal 
to heparin, however, and they are at 
best only a partial solution.
Rationale for Using Ancrod
Fibrinogen is indispensable in 
platelet aggregation1314 and may be 
a key element in adherence.15 The 
initial binding of fibrinogen to
platelets requires exposure of the 
platelet membrane GPIIb—Ilia com­
plex,16 which occurs in response to 
adenosine diphosphate or to throm­
bin, to which fibrinogen molecules 
bind with high affinity.1718 Platelets 
lacking these glycoproteins fail to 
bind fibrinogen or aggregate.2 In 
HATT, where pathologic platelet 
aggregation and adherence are the 
putative mechanisms, depletion of 
fibrinogen would reduce the matrix 
that links platelets during aggrega­
tion or binds them to injured endo­
thelial surfaces. Fibrinogen can be 
safely depleted with ancrod. This 
purified venom of the Malayan pit 
viper (Agkistrodon rhodostoma) 
acts enzymatically on the fibrinogen 
molecule and cleaves off the fi- 
brinopeptide A but not fibrinopep- 
tide B, and it fragments the a-chain 
of the fibrinogen-fibrin monomer.19 
The result is a weak fibrin matrix 
without cross-links that is rapidly 
cleared by the native fibrinolytic 
and reticuloendothelial systems. An­
crod has no effect on other blood 
coagulation factors20 and its clinical 
use is not associated with a bleed­
ing tendency. Indeed, surgical pro­
cedures have been carried out suc­
cessfully using ancrod.21
Patients and Methods
Nine patients suspected of having 
HATT were treated with ancrod. 
The diagnosis was made on the 
basis of significant thrombocyto­
penia and progressive thrombosis 
while they were undergoing treat­
ment with heparin. Heparin was 
completely eliminated and, when 
necessary, the patency of intra­
arterial catheters was maintained by 
infusing sodium citrate in saline, 
instead of heparinized solutions. 
Ancrod was administered intrave­
nously in all cases, with an initial 
infusion of 70 units over 12 hours, 
followed by a maintenance dose of 3
to 4 units/h. This therapy was 
monitored by regular determina­
tions of the serum fibrinogen level 
and prothrombin time. An attempt 
was made to keep the fibrinogen 
level between 0.2 and 0.4 g /L  by 
adjusting the ancrod dose. When 
the fibrinogen level fell below 0.2 
g/L , the prolonged prothrombin 
time was used in making adjust­
ments to the infusion rate.
Results
The relevant features of the nine 
cases are outlined in Table I. Effec­
tive anticoagulation was achieved 
within 12 hours in all cases and no 
bleeding complications were ob­
served. In eight patients the throm­
botic process was controlled with 
ancrod, which was subsequently re­
placed with Coumadin. One patient 
died of causes unrelated to therapy 
with ancrod. No patient required an 
amputation.
In one case (no. 3, Table I) HATT 
had been diagnosed when throm­
bocytopenia and progressive throm­
bosis developed while the patient 
was being treated with heparin for 
deep vein thrombosis, which had 
occurred after coronary artery by­
pass surgery. Symptoms of aor- 
toiliac occlusive disease developed 
while he was receiving long-term 
Coumadin therapy. The Coumadin 
was discontinued and ancrod substi­
tuted. The patient underwent un­
complicated transfemoral angiogra­
phy and subsequent common iliac 
balloon dilatation and femorofemor- 
al bypass surgery, during which the 
fibrinogen level was maintained at 
less than 0.2 g/L. Coumadin was 
restarted in the postoperative peri­
od.
Discussion
When any patient being treated
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with heparin is found to have 
thrombocytopenia and progressive 
or new arterial or venous thrombo­
sis, HATT should be suspected. At 
present, the diagnosis of HATT is 
based on clinical observation and 
exclusion of other causes of throm­
bocytopenia. Due to the high inci­
dence of major morbidity, some 
immediate therapeutic action is 
necessary. Thrombolytic therapy 
has been used successfully but this 
should be followed by some alterna­
tive form of anticoagulation. Other 
therapies recommended for patients 
who have HATT have included 
agents that inhibit platelet cyclo­
oxygenase, such as ASA, that in­
crease cyclic AMP, like dipyrida­
mole, or that are prostacyclin ana­
logues, like Iloprost; but these 
agents have had limited clinical ap­
plications.1022
The specific advantages of ancrod 
in patients with HATT lie in its 
mechanism of action, which is com­
pletely different from heparin. An­
ticoagulation with ancrod is 
achieved by fibrinogen depletion. 
The drug does not degrade pre­
formed thrombin or fibrin or the 
coagulation factors. Fibrinogen is
removed from the pathologic proc­
ess involved in HATT. Reducing 
fibrinogen to low levels also reduces 
blood viscosity, which may be of 
added benefit in situations in which 
intra-arterial thrombosis has caused 
significant ischemia.23
Clinical experience with ancrod 
worldwide is substantial, but be­
cause it is not yet approved for use 
in the United States, most physi­
cians and surgeons in North Ameri­
ca are unaware of its benefits. It is 
available in Canada, however, and 
has been used successfully in some 
centres. Ancrod is an excellent sub­
stitute for heparin because it pro­
vides effective anticoagulation with 
a low risk of bleeding or other 
significant complication.24
Ancrod was obtained from Knoll Phar­
maceuticals, Whippany, NJ.
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T a b le  1. Relevant Features in Nine Patients Who Had Heparin-Associated Thrombocytopenia and Thrombosis (HATT)
P atien t
no. D iagnosis
U se of heparin  
p re -H A T T
Lowest
p la te le t count, x  1 0 9/L C om m ent
1 Lung carcinoma; recurrent deep vein T 63.0 Streptokinase for 50 h followed by ancrod for 7 d
2
thrombosis
Recurrent deep vein thrombosis; T 87.0
then Coumadin. Discharged 
Ancrod for 17 d then Coumadin. Discharged
3
planned thoracotomy to investigate 
presumed malignant lesion 
Known HATT (previous excision of N/A N/A Iliac angioplasty; femorofemoral bypass. Ancrod for
4
left ventricular aneurysm)
Postop total knee surgery; deep vein SC 17.0
3 d pre- and intraoperatively and beginning 
Coumadin again postoperatively. Discharged 
Ancrod for 11 d then Coumadin. Discharged
5
thrombosis
Myocardial infarction; endometrial T 56.0 Ancrod for 6 d then Coumadin. Died
6
carcinoma; deep vein thrombosis 
Postop total knee surgery; deep vein SC 39.0 Ancrod for 9 d then Coumadin. Discharged
7
thrombosis
Acute arterial occlusion (thrombosis) T 54.0 Ancrod for 7 d then Coumadin. Discharged
8 Congestive heart failure; massive SC 101.0 Ancrod for 20 d then Coumadin. Discharged
9
pulmonary embolus 
Fractured hip; deep vein thrombosis SC 35.0 Ancrod for 5 d then Coumadin. Discharged
T =  heparin given intravenously in therapeutic dose; SC =  heparin given subcutaneously in prophylactic dose.
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BOOK REVIEWS
continued from page 188
Each topic is introduced by reprint­
ing an article previously published by 
prominent workers in the field; the 
article is then discussed by one or more 
groups with recognized expertise on 
the topic and the section is completed 
with an overview and annotated bibliog­
raphy done by surgeons well known for 
their understanding of the topic.
Although the book does not pretend 
to be comprehensive, it covers a broad 
spectrum of surgical urology. The chap­
ters range from transplantation to va­
sectomy and vas reversal. Most topics 
are dealt with in a well-balanced and 
thorough manner. The areas of conti­
nent urinary diversion and the surgical 
management of female urinary inconti­
nence are particularly well discussed 
and provide an excellent overview of 
current techniques. The reading is easy 
and creates a situation similar to being 
in a journal club in which relevant 
articles are discussed by knowledgeable 
guests. The editorial comments and 
“discussions” are sensible, focused and 
informative. The choice of topics and 
the leading articles introducing them is 
generally appropriate.
Some weaknesses are evident: the 
leading articles are 5 or more years old; 
although this is compensated for by 
updated commentaries and references, 
some of the techniques have changed 
substantially. This problem, fortunately,
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occurs infrequently. 1 felt that an inor­
dinate amount of space was devoted to 
some surgical techniques that would be 
irrelevant to the expert and neophyte 
alike: to the former because of a lack of 
new developments and to the latter 
because of too-sketchy information.
The strengths of this book, however, 
overwhelm its weaknesses. It is a 
worthwhile addition to a surgical library 
and of major interest to senior trainees 
and practising urologists.
A. Morales, MD, FRCSC
Department o f Urology,
Queen's University,
Kingston, Ont.
INFECTION IN THE ORTHOPAEDIC 
PATIENT. Edited by Richard Coombs 
and Robert H. Fitzgerald, Jr. 347 pp. 
Illust. Butterworths, London. 1989. 
$185 (US). ISBN 0-407-01316-4
This volume, under combined British 
and American editorship, includes con­
tributions from 75 different authors, 9 
of whom are American; the others are 
chiefly from the United Kingdom. The 
book is divided into 12 parts and 58 
sections, covering bacteriology, diagno­
sis and assessment, prophylaxis, surgi­
et al (eds): Hemostasis and Thrombosis. 
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Experience of extensive vascular sur­
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tients. Thromb Res 1973; 3: 161-172
22. Makhoul RG, Greenberg CS, McCann 
RL: Heparin-associated thrombocyto­
penia and thrombosis: a serious clinical 
problem and potential solution. J Vase 
Surg 1986; 4: 5 22-528
24. Dormandy JA, Reid HL: Controlled defi­
brination in the treatment of peripheral 
vascular disease. Angiology 1978; 29: 
80-88
25. Cole CW, Bormanis J: Ancrod: a practi­
cal alternative to heparin. J Vase Surg 
1988; 8: 5 9 -6 3
cal technique, antibiotics, specific infec­
tions and psychological aspects of or­
thopedic infections.
The text is well and copiously illus­
trated, easy to read and well indexed. 
As far as I can judge, it is up to date 
(publication date of 1989 and receipt 
for review in September 1989) and 
some experimental work is included 
(e.g., antibiotic-impregnated fibrin). I 
found no difficulty in using the index to 
locate references to antibiotic impreg­
nated bone cement, Brodie's abscess or 
Madura foot. Each section has its own 
bibliography.
In the past, there have been many 
criticisms of multiauthored texts be­
cause of variations in style. In my 
opinion this criticism is no longer im­
portant because we have been inundat­
ed with such texts, and medical writing 
has become so standardized by the 
professional wordsmith that individual 
style is no longer a factor. I found no 
difficulty in shifting from one section to 
another in this text.
In contrast, this British-flavoured 
and published text is refreshing in that 
it contains two early sections, one on 
musculoskeletal sepsis — the black 
hole of orthopedics — and another 
titled “Is infection still a problem?”, and
continued on page 242
210 CJS, VOL. 33, NO. 3, JUNE 1990
From Ayerst, 
the company 
that practically 
wrote the book 
on antibiotic 
therapy1
A practical new 
parenteral 
treatment for 
infections 
caused by 
susceptible 
gram-negative 
and anaerobic 
bacteria...
Introducing
CEFOTAN^,
(Sterile Cefotetan Disodium U.S.P.)
A highly effective cost efficient choice 
for parenteral cephalosporin therapy
Highly effective
Intra-abdominal
• against E. coli
• against gram-negative anaerobic bacteria
• marked beta-lactamase stability
Gynecologic
• against susceptible strains of certain gram-negative bacteria
• against anaerobic bacteria such as Bacteroides species 
(excluding B. distasonis, B. ovatus and B. thetaiotaomicron)
• marked beta-lactamase stability
Impressive pharmacokinetics
• longer half-life than most traditional cephalosporins to provide high 
therapeutic blood levels over a 12-hour period.
CEFOTAN
1 s t  3.5 ± 0.5 hrs
cefoxitin
0.8 ± 0.0 hrs
Cost efficient
• q12h dosing saves time in preparation and administration; 
reduces drug-related cost.
• less medication needed for full treatment than cefoxitin, so total cost 
therapy is comparatively low.
Full product 
monograph
Pocket
monograph
Dosage
charts
Reprints from 
the literature
Coming events 
calendar
CEFOTAN
MSSSSSS
^  *
kA
g y n e c o l o g ic
* ___________ in f e c t io n s
IM/IV
therapy
► ►
-^>4
FREE! ►
The CEFOTAN Compendium will be of practical interest to 
hospital pharmacists, infectious disease specialists, 
i, microbiologists, surgeons, obstetricians, and
gynecologists. To get your free copy of this valuable 
guide, simply complete and return the coupon on the 
reverse side or contact your Ayerst representative.
A praci 
for cer
□tan IW/'V
INTRA
in f e c -
^ B O O M IN A L
i fr io N S
CEF
the literaturefromr ntsRep
FOR CEPHALOSPORIN ADVOCATES
THE CEFOTAN 
l COMPENDIUM
A practical guide to 
highly effective 
cost efficient parenteral 
cephalosporin therapy
M
EETIN
G
S
I M / I VONEWCEFOTAN(Sterile Cefotetan Disodium U.S.P.)
A highly effective cost efficient 
choice for parenteral 
cephalosporin therapy
Available in 
1 g and 2 g vials 
in cartons of 10.
Ayerst AYERST LABORATORIESDivision of Ayerst, McKenna & Harrison, Inc
Montreal, Canada Product Monograph for this and other Ayerst products are available on request., s
T Packaged by Ayerst under licence from Yamanouchi Pharmaceutical Co. Ltd., owners of the trademark.
AYERST... at the forefront of antibiotic therapy.
AYERST LABORATORIES
Division of Ayerst, McKenna & Harrison, Inc 
Marketing Medical Division 
1025 Laurentien Boulevard 
Saint Laurent, Quebec 
H4R 9Z9
Yes, I would like a complimentary copy of the 
CEFOTAIM+ COMPENDIUM.
Name:
(please print)
Address: 
City: ___
~ \
Province:
Postal Code:
Signature:.
1
MD
COMPLETE 
AND MAIL 
THIS 
COUPON 
FOR YOUR 
FREE COPY 
OF THE 
CEFOTAN+ , 
COMPENDIUM
1. Ayerst acknowledges the research 
and development contributions of a 
number of pharmaceutical 
companies that have participated in 
licencing arrangements for 
many years.
*Reg’d TM 290
pa a b ]  I PMAC ]
290
►  >
\
CEFOTAN 1 IM /IV
(Sterile Cefotetan Disodium U.S.P.)
A highly effective cost efficient 
choice for parenteral 
cephalosporin therapy
THERAPEUTIC CLASSIFICATION
Antibiotic
ACTION
Cefotetan Disodium is a semisynthetic, beta-lactamase resistant (refer to 
STABILITY TO BETA-LACTAMASES), cephalosporin (cephamycin) antibiotic. 
In vitro studies indicate that the bactericidal action of cefotetan results from 
an interference of bacterial cell wall synthesis by inhibiting the cross-linking 
of peptidoglycan. Studies with 14C-labelled cefotetan have shown that on 
reaching the target penicillin-binding proteins (PBPs) in the inner membrane, 
the radiolabelled antibiotic binds principally to PBP 3 followed by PBP 1A 
and 1B. Cefotetan, like other cephamycins, does not bind to PBP 2.
The plasma elimination half-life of cefotetan is 3 to 4.6 hours after either 
intravenous or intramuscular administration. In normal patients, from 51 % to 
81% of the administered dose is excreted unchanged by the kidney in 24 
hours. The biliary tract is the other major route of elimination.
INDICATIONS AND CLINICAL USE
CEFOTAN (Cefotetan Disodium) is indicated for the treatment of the following 
infections when caused by susceptible strains of the designated organisms:
Urinary tract infections caused by E. coli and Klebsiella species (including 
K. pneumoniae), Proteus mirabilis and indole-positive Proteus.
Lower respiratory tract infections caused by Streptococcus pneumoniae 
(formerly D. pneumoniae), Staphylococcus aureus (penicillinase and non- 
penicillinase-producing), Haemophilus influenzae (including ampicillin- 
resistant strains), Klebsiella species (including K. pneumoniae) and E. coli.
Skin and skin structure infections caused by Staphylococcus aureus (penicil­
linase and non-penicillinase-producing), Staphylococcus epidermidis, Strep­
tococcus pyogenes, Streptococcus species (excluding Enterococci) and 
E. coli.
Treatment with broad-spectrum antibiotics may alter normal flora of the colon 
and may permit overgrowth of Clostridia. Studies indicate a toxin produced 
by Clostridium difficile is one primary cause of antibiotic-associated colitis.
Mild cases of colitis may respond to drug discontinuance alone.
Moderate to severe cases should be managed with fluid, electrolyte and 
protein supplementation as indicated. When the colitis is not relieved by drug 
discontinuance or when it is severe, consideration should be given to the 
administration of oral vancomycin for antibiotic-associated pseudomembranous 
colitis produced by C. difficile. Other causes should also be considered.
PRECAUTIONS
General: Prolonged use of CEFOTAN (Cefotetan Disodium) may result in 
overgrowth of non-susceptible organisms and organisms initially sensitive to 
the drug. Careful observation of the patients is essential. If superinfection 
does occur during therapy, appropriate measures should be taken.
CEFOTAN may be associated with a fall in prothrombin activity. Those at risk 
include patients with renal or hepatic impairment, poor nutritional state, the 
elderly, and patients with cancer. Prothrombin times should be monitored in 
patients at risk and exogenous Vitamin K administered as indicated.
CEFOTAN should be used with caution in individuals with a history of gastro­
intestinal disease, particularly colitis.
A disulfiram-like reaction characterized by flushing, sweating, headache and 
tachycardia may occur when alcohol (beer, wine, etc.) is ingested within 72 
hours after CEFOTAN administration. Patients should be cautioned about the 
ingestion of alcoholic beverages following the administration of CEFOTAN.
Patients with impaired renal function; ie, creatinine clearance of 30 ml/min or 
less, should be placed on a special dosage schedule for CEFOTAN recom­
mended under DOSAGE AND ADMINISTRATION.
Drug Interactions
Renal function should be carefully monitored, especially if high dosages of 
the aminoglycosides are to be administered or if therapy is prolonged, because 
of the potential nephrotoxicity and ototoxicity of aminoglycosidic antibiotics. 
Although, to date, this has not been noted when CEFOTAN was given alone, 
increased nephrotoxicity has been reported following concomitant adminis­
tration of cephalosporins and aminoglycoside antibiotics. However, at the 
recommended doses, enhancement of nephrotoxicity is unlikely to be a 
problem with CEFOTAN.
Drug/Laboratory Test Interactions
A false positive reaction for glucose in urine may occur with Benedict’s or 
Fehling’s solution.
. *,
Gynecologic infections caused by Staphylococcus aureus (penicillinase and 
non-penicillinase-producing), Staphylococcus epidermidis, Streptococcus 
species (excluding Enterococci), E. coli, Proteus mirabilis, Neisseria gonor- 
rhoeae, anaerobic gram-positive cocci and gram-negative bacilli, Bacteroides
> species (excluding B. distasonis, B. ovatus and B. thetaiotaomicron).
^  Intra-abdominal infections caused by£. coli, anaerobic gram-negative bacilli, 
Bacteroides species (excluding B. distasonis, B. ovatus and B. thetaiotao- 
micron).
Bone and joint infections caused by Staphylococcus aureus.
A
Specimens for bacteriological examination should be obtained prior to therapy 
in order to isolate and identify causative organisms and to determine their 
susceptibilities to CEFOTAN. Therapy may be instituted before results of 
susceptibility studies are known. However, once these results become avail- 
> able, the antibiotic treatment should be adjusted accordingly.
*- H  CONTRAINDICATION
CEFOTAN (Cefotetan Disodium) is contraindicated in patients with Type 1
► i  hypersensitivity reactions (ie, hives, angioedema, bronchospasm or ana­
phylactic shock) to the cephalosporin group of antibiotics.
WARNINGS
BEFORE THERAPY WITH CEFOTAN (Cefotetan Disodium) IS INSTITUTED, 
F-x- CAREFUL INQUIRY SHOULD BE MADE TO DETERMINE WHETHER THE 
PATIENT HAS HAD PREVIOUS HYPERSENSITIVITY REACTIONS TO 
t C E F O T E T A N  DISODIUM, CEPHALOSPORINS, PENICILLINS OR OTHER 
DRUGS. CEFOTAN SHOULD BE GIVEN CAUTIOUSLY TO PENICILLIN- 
. SENSITIVE PATIENTS. ANTIBIOTICS, INCLUDING CEFOTAN, SHOULD BE
ADMINISTERED WITH CAUTION TO ANY PATIENT WHO HAS DEMON­
STRATED SOME FORM OF ALLERGY, PARTICULARLY TO DRUGS. IF AN 
ALLERGIC REACTION TO CEFOTAN OCCURS, ADMINISTRATION OF 
CEFOTAN SHOULD BE DISCONTINUED. SERIOUS ACUTE HYPERSEN­
SITIVITY REACTIONS MAY REQUIRE EPINEPHRINE AND OTHER 
EMERGENCY MEASURES.
PSEUDOMEMBRANOUS COLITIS HAS BEEN REPORTED WITH THE USE 
OF CEPHALOSPORINS, INCLUDING CEFOTAN, (AND OTHER BROAD- 
SPECTRUM ANTIBIOTICS); THEREFORE, IT IS IMPORTANT TO CONSIDER 
THIS DIAGNOSIS IN PATIENTS WHO DEVELOP DIARRHEA IN ASSOCIATION 
WITH ANTIBIOTIC USE.
High concentrations of cefotetan may interfere with measurement of serum 
and urine creatinine levels by Jaffe reaction and produce false increases in 
the levels of creatinine reported.
Use in Pregnancy
The safety of CEFOTAN in the treatment of infection during pregnancy has 
not been established. The use of CEFOTAN in pregnant women requires that 
the likely benefit from the drug be weighed against the possible risks to the 
mother and fetus. Reproduction studies have been performed in rats and 
monkeys at doses up to 20 times the human dose and have revealed no 
evidence of impaired fertility or harm to the fetus due to cefotetan. There are, 
however, no adequate and well-controlled studies in pregnant women. Because 
animal reproductive studies are not always predictive of human response, 
CEFOTAN should be used during pregnancy only if clearly needed.
Use in Nursing Mothers
Cefotetan is excreted in human milk in very low concentrations. Caution 
should be exercised when CEFOTAN is administered to a nursing woman.
Pediatric Use
Safety and effectiveness in children have not been established.
ADVERSE REACTIONS
In clinical studies, the following adverse effects were considered related to 
CEFOTAN (Cefotetan Disodium) therapy.
Gastrointestinal: Gastrointestinal symptoms occurred in 1.5% of patients, 
the most frequent were diarrhea (1 in 80) and nausea (1 in 700).
Hematologic: Hematologic laboratory abnormalities occurred in 1.4% of 
patients and included eosinophilia (1 in 200), positive direct Coombs’ test 
(1 in 250) and thrombocytosis (1 in 300). Transient thrombocytopenia and 
leucopenia have been reported.
Hepatic: Hepatic enzyme elevations occurred in 1.2% of patients and in­
cluded a rise in SGPT (1 in 150), SGOT (1 in 300), alkaline phosphatase 
(1 in 700) and LDH (1 in 700).
Hypersensitivity: Hypersensitivity reactions were reported in 1.2% of 
patients and included rash (1 in 150) and itching (1 in 700). During post­
marketing experience with CEFOTAN, anaphylactic reactions have been 
reported.
Local Effects: Local effects were reported in less than 1% of patients 
and included phlebitis at the site of injection (1 in 300) and discomfort 
(1 in 500).
SYMPTOMS AND TREATMENT OF OVERDOSAGE
To date, there have been no documented cases of overdosage with 
CEFOTAN (Cefotetan Disodium). If overdosage should occur, it should be 
treated symptomatically. CEFOTAN may be removed by dialysis.
DOSAGE AND ADMINISTRATION
DOSAGE: Adults: The usual adult dosage is 1 or 2 g of CEFOTAN (Cefotetan 
Disodium) administered intravenously or intramuscularly every 12 hours for 
5 to 10 days. Proper dosage and route of administration should be determined 
by the condition of the patient, severity of the infection and susceptibility of the 
causative organism. Therapy may be started while awaiting the results of 
susceptibility testing.
The intravenous route is preferable for patients with bacteremia, bacterial 
septicemia, or other severe or life-threatening infections, or for patients who 
may be at risk particularly if shock is present or impending.
GENERAL GUIDELINES FOR CEFOTAN DOSAGE
Type of Infection Daily Dose Frequency and Route
Urinary Tract 1 - 4 g 500 mg every 12 hours IV or IM 
1 or 2 g every 24 hours IV or IM 
1 or 2 g every 12 hours IV or IM
Other Sites 2 - 4 g 1 or 2 g every 12 hours IV or IM
Severe 4 g 2 g every 12 hours IV
Life Threatening 6 g tt 3 g every 12 hours IV
t t  Maximum daily dosage should not exceed 6 g.
IMPAIRED RENAL FUNCTION
When renal function is impaired, a reduced dosage schedule must be employed. 
The following dosage guidelines may be used.
DOSAGE GUIDELINES FOR PATIENTS WITH IMPAIRED RENAL
FUNCTION
Creatinine Clearance
ml/min Dose Frequency
> 30 Usual Recommended Dose** Every 12 hours
1 0 -3 0  Usual Recommended Dose** Every 24 hours
< 1 0  Usual Recommended Dose** Every 48 hours
** Dose determined by the type and severity of infection, and susceptibility of 
the causative organism.
Alternatively, the dosing interval may remain constant at 12-hour intervals, 
but the dose reduced to one-half the usual recommended dose for patients 
with a creatinine clearance of 10 - 30 ml/min and one-quarter the usual recom­
mended dose for patients with a creatinine clearance of less than 10 ml/min.
When only serum creatinine levels are available, creatinine clearance (ml/min) 
may be calculated from the following formulae. The serum creatinine level 
should represent a steady state of renal function.
Creatinine Clearance (ml/min):
Traditional Units S.l. Units
Males: Weight (kg) x (140 - age) Weight (kg) x (140 - age)
72 x serum creatinine 0.8 x serum creatinine
(mg/100 ml) (/tmol/L)
Females: 0.9 x male value
Cefotetan is dialyzable and it is recommended that for patients undergoing 
intermittant hemodialysis, one-quarter of the usual recommended dose be
given every 24 hours on days between dialysis and one-half the usual recom­
mended dosage on the day of dialysis.
Children
The safety and effectiveness in children has not been established.
ADMINISTRATION
Intravenous
For intermittent intravenous administration, a solution containing 1 g or 2 g of 
CEFOTAN in Sterile Water for Injection can be injected over a period of three 
to five minutes. Using an infusion system, it may also be given over a longer 
period of time through the tubing system by which the patient may be 
receiving other IV solutions.
Butterfly or scalp vein-type needles are preferred for this type of infusion. 
However, during infusion of the solution containing CEFOTAN, it is advisable to 
discontinue temporarily the administration of other solutions at the same site.
NOTE: Solutions of CEFOTAN must not be admixed with solutions containing 
aminoglycosides. If CEFOTAN and aminoglycosides are to be administered 
to the same patient, they must be administered separately and not as a mixed 
injection.
Intramuscular
CEFOTAN should be injected well within the body of a relatively large muscle 
such as the upper outer quadrant of the buttock (ie, gluteus maximus); aspiration 
is necessary to avoid inadvertent injection into a blood vessel.
PHARMACEUTICAL INFORMATION 
Chemistry
Trade Name: CEFOTAN +
Proper Name: Sterile Cefotetan Disodium U.S.P.
Chemical Name: CEFOTAN is the disodium salt of [6R*(6<v, 7u)j-7-[[[4-
(2-amino-1 -carboxy-2-oxoethylidene)-1,3-dithietan-2- 
yljcarbonyl] amino]-7-methoxy-3-[[(1 -methyl-1 H- 
tetrazol-5-yl)thio]methyl]-8-oxo-5-thia-1-azabicyclo 
[4.2.0joct-2-ene-2-carboxylic acid.
Molecular Formula: Ci7Hi5N7Na208S4 
Molecular Weight: 619.56
Description
A white to pale yellow powder which is very soluble in water. The solution 
varies from colorless to yellow depending on the concentration and contains 
approximately 80 mg (3.5 mEq) of sodium per gram of cefotetan activity. The 
pH of freshly reconstituted solutions is usually between 4.5 to 6.5.
RECONSTITUTION 
For Intramuscular Use
Reconstitute with Sterile Water for Injection; Normal Saline, USP; 0.5% 
Lidocaine HCL; or 1.0% Lidocaine HCL. Shake to dissolve and let stand until 
clear.
Vial Size
Amount of 
Diluent To 
Be Added 
(ml)
Approximate 
Withdrawable 
Vol (ml)
Approximate
Average
Concentration
(mg/ml)
1 9 2 2.5 400
2 g 3 4.0 500
For Intravenous Use
Reconstitute with Sterile Water for Injection, 0.9% Sodium Chloride Injection 
or 5% Dextrose Injection. Shake to dissolve and let stand until clear.
Vial Size
Amount of 
Diluent To 
Be Added 
(ml)
Approximate 
Withdrawable 
Vol (ml)
Approximate
Average
Concentration
(mg/ml)
1 9 10 10.5 95
2 g 10 - 20 11 - 21 182 - 95
A solution prepared with Sterile Water for Injection may be further diluted to 
the desired volume with any of the “Solutions for I.V. Infusion” listed below.
Solutions for I.V. Infusion
0.9% Sodium Chloride for Injection
5% Dextrose Injection
10% Dextrose Injection
Ringers Injection
Lactated Ringers Injection
5% Dextrose and 0.9% Sodium Chloride Injection
5% Dextrose and 0.225% Sodium Chloride Injection
5% Dextrose and Ringers Injection
5% Dextrose and Lactated Ringers Injection
10% Invert Sugar Injection
5% Sodium Bicarbonate Injection
Sodium Lactate Injection, 1/6 Molar
Isolyte-S Injection
Compatibility and Stability
CEFOTAN reconstituted as described above (Reconstitution) maintains 
satisfactory potency for 24 hours at room temperature (25°C), or 72 hours 
under refrigeration (5°C).
Any unused portions of the reconstituted solutions should be discarded. 
CEFOTAN should not be physically mixed with other antimicrobial agents.
NOTE: Parenteral drug products should be inspected visually for particulate 
matter and discoloration prior to administration, whenever solution and 
container permit.
DOSAGE FORM 
Availability
CEFOTAN (Cefotetan Disodium) is a dry, white to pale yellow powder supplied 
in vials containing cefotetan disodium equivalent to 1 g and 2 g cefotetan 
activity for intravenous and intramuscular administration. The 1 g dose 
(No. 961) is available in 10 ml vials, and the 2 g dose (No. 962) is available in 
20 ml vials. The vials should not be stored in excess of 25°C and should be 
protected from light.
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CANADIAN SOCIETY FOR VASCULAR SURGERY
Laser-Assisted Transluminal Angioplasty 
of the Superficial Femoral and Popliteal 
Arteries
A.J. Salvian, MD, FRCSC;* D.C. Morris, MD, FRCPC;t D.G. Connell, MD, FRCPCt
During an initial 1-year experience with percutaneous laser-assisted balloon 
angioplasty at the Vancouver General Hospital, 9 of 61 patients considered suitable 
for intervention because of arterial occlusive disease were selected for laser 
treatment. The neodymium-YAG laser with a contact sapphire tip was chosen 
because the probes and tips are reusable, thereby reducing the cost per patient. The 
patients had either severe limiting claudication or pain at rest, involving the 
superficial femoral or popliteal artery. One of the patients had lesions in both legs, 
making a total of 10 lesions.
In 8 of the 10 lesions, treatment initially was successful. In the other two 
instances, the laser perforated the arterial wall, but the patients suffered no ill 
effects; repair by bypass surgery was uncomplicated. Another patient had distal 
thrombosis at the time of angioplasty of the popliteal artery; this responded to 
fibrinolytic therapy and subsequent balloon angioplasty of the peroneal artery.
The initial 80% success rate was reasonable, considering that all these patients 
would otherwise have undergone bypass surgery. One patient had recurrent stenosis 
5 months after the procedure. The other seven had good results with relief of 
symptoms. However, follow-up has been short (mean 4.9 months), the longest being 
only 11 months.
Au cours de la premiere annee d’utilisation de l’angioplastie percutanee par 
ballonnet et laser a l’Hopital General de Vancouver, 9 des 61 patients admissibles a 
une intervention pour arteriopathie obliterante ont ete choisis pour etre soumis au 
laser. Le laser YAG au neodymium, qui utilise un embout de saphire, fut choisi pour 
ses sondes et embouts reutilisables qui permettent de reduire les couts par patient. 
Les patients souffraient soit d’une claudication grave limitante, soit de douleur au 
repos, avec atteinte de 1’artere femorale superficielle ou de la poplitee. Un des 
patients avait des lesions aux deux jambes, portant le total des lesions a 10.
Pour 8 des 10 lesions, le traitement initial fut reussi. Dans les deux autres cas, il 
y eut perforation de la paroi arterielle par le laser mais les patients n’en subirent 
aucune consequence facheuse, le pontage chirurgical s’averant sans complication.
Un autre patient subit une thrombose distale au moment de l’angioplastie de l’artere 
poplitee; cette thrombose ceda a un traitement par fibrinolyse et a une angioplastie 
subsequente par ballonnet de l’artere peroniere.
Ce taux de reussite initial de 80% est acceptable, compte tenu du fait que tous ces 
patients auraient subi, autrement, un pontage chirurgical. Subsequemment, un 
patient a souffert, apres 5 mois, d’une restenose. Les sept autres patients jouissent 
de bons resultats avec soulagement des symptomes. Toutefois, la surveillance des 
suites therapeutiques est courte (moyenne de 4.9 mois), le suivi le plus long etant 
de 11 mois.
L aser recanalization o f arterial occlusion has become more 
prominent in the surgical and radi­
ologic literature over the past 2 
years. There is hope that total oc­
clusions not amenable to percutane­
ous balloon angioplasty can be 
treated either primarily by laser or 
recanalized by laser and subse­
quently dilated using a conventional 
Gruntzig-type balloon technique. 
However, recent papers12 suggest 
that results are not acceptable or 
the recanalization is not durable, 
except in certain areas and in cer­
tain patients.
Is it worth supporting laser pro­
grams, which involve a major capi­
tal outlay for the purchase o f a 
dedicated laser, plus the heavy on­
going costs? We felt that a careful 
study was needed to determine the 
place o f this technique in its present 
form for vascular surgery within
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the cost-sensitive Canadian system.
Patients with long occlusions of 
the superficial femoral artery do not 
do well with laser-assisted balloon 
angioplasty, but those with short 
occlusions and stenosis can usually 
be treated by balloon angioplasty 
alone.1' 5 To determine the efficacy 
and practicability of laser-assisted 
balloon angioplasty, therefore, we 
studied a group of patients whose 
symptoms were severe enough to 
warrant bypass surgery, but who 
were probably not candidates for 
standard transluminal balloon dila­
tation alone.
Patients and Methods
We considered for this study all 
patients admitted to our hospital 
between September 1988 and Sep­
tember 1989 for possible surgical 
intervention for occlusive arterial 
disease. They had to have either 
severe claudication with failure of 
conservative therapy (a treadmill 
walking distance of less than 100 
m), or symptoms at rest or loss of 
tissue. We looked for occlusions 
that were less than 15 cm long in 
the superficial femoral or popliteal 
segment, which would be accessible 
percutaneously, but we excluded 
patients in whom balloon dilatation 
alone would be possible. We also 
excluded all patients with iliac and 
tibial lesions, and all lesions involv­
ing the origin of the superficial 
femoral artery.
Nine of 61 patients met our as­
sessment criteria, having, we 
thought, a reasonable chance of 
success over the long term. Six 
patients had a total of seven occlu­
sions of the superficial femoral ar­
tery, and three had popliteal occlu­
sions. Their average age was 66.6 
years (range from 55 to 72 years). 
One patient was diabetic and eight 
were former smokers. The average 
length of occlusion was 7.7 cm.
Patients were evaluated with ref­
erence to treadmill testing, ankle- 
brachial pressures, and aortic and 
peripheral arteriography. All cases 
were reviewed by the principal in­
vestigators, a vascular surgeon and 
two vascular radiologists.
All patients were given an expla­
nation of the experimental nature of 
this procedure before they gave 
their informed consent.
We used an SLT 60 W Nd:YAG 
laser with a 2.2 mm fiberoptic light 
guide and a 2.2 mm synthetic sap­
phire probe (Surgical Laser Tech­
nology, Surgimedic Products Inc., 
Downsview, Ont.). Power settings 
for the laser were always started at 
10 W for a 1 second burst. The 
average energy required in treating 
any one patient was about 300 J.
The first two patients were treat­
ed in the operating room under spi­
nal anesthesia and the other seven 
in the radiology suite under local 
anesthesia, with sedation adminis­
tered intravenously. We found the 
patients’ sensation of discomfort 
when the arterial adventitia was 
accidentally heated to be a useful 
warning sign of impending perfora­
tion and therefore preferred to use 
local anesthesia.
All patients had percutaneous 
catheterization of the superficial 
femoral arteries, and an attempt 
was made to cross the lesions with 
a guide wire; in only one patient 
was this possible.
Preoperatively (between 2 and 10 
hours) patients were given 325 mg 
of acetylsalicylic acid and 50 mg of 
dipyridamole; intraoperatively an­
ticoagulation was achieved with 
3000 units of heparin; for 3 months 
postoperatively the patients were 
maintained on acetylsalicylic acid 
and dipyridamole. In only one case 
was postoperative anticoagulation 
therapy necessary because of distal 
emboli; a urokinase infusion was 
given for 12 hours and heparin 
continued for 48 hours.
Angiography was done where 
possible, and noninvasive testing 
was carried out postoperatively in 
all patients, as well as duplex scan­
ning of the arteries where possible.
No statistical analysis was possi­
ble because of the small numbers, 
and we present only our initial 
experience with this technique.
Results
In two of the three patients with 
popliteal lesions the vessels were 
successfully recanalized using the 
laser; in one a soft thrombus embol- 
ized distally and was dissolved with 
urokinase. Six of the seven superfi­
cial femoral artery lesions were suc­
cessfully recanalized by the laser 
and were dilated with initially excel­
lent results, as evidenced by the 
return of pulses and relief of symp­
toms. One of these patients re­
turned 5 months after the proce­
dure with reocclusion of the super­
ficial femoral artery below the level 
of the laser angioplasty. Subse­
quently, in-situ femoropopliteal by­
pass grafting was done.
There were two cases in which 
the laser perforated the arterial 
wall. In one case the superficial 
femoral artery was perforated distal 
to the occlusion, after the artery 
had been successfully recanalized. 
In the other, perforation of the 
popliteal artery occurred because 
the occlusion was calcified. At the 
time of perforation, the power of 
the laser had been increased to 18 
W at 2 second pulses from the 
usual 10 W, 1 second settings. 
Although there was a hematoma in 
the popliteal fossa when bypass 
surgery was carried out in both 
cases, there were no other unto­
ward side effects.
In one other patient distal emboli 
formed after we crossed a popliteal 
lesion with first a wire and then a 
catheter. This thrombus was suc-
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cessfully lysed with urokinase.
In our series, the longest follow­
up after successful angioplasty was 
11 months (mean 4.9 months). All 
patients in whom the treatment was 
successful had an increase of at 
least 0.2 in the ankle-brachial pres­
sure index. Their average hospital 
stay was 2 days. In the two unsuc­
cessful cases, bypass surgery was 
done, so their stays were increased 
by 3 to 5 days.
Discussion
We found successful recanaliza­
tion to be relatively easy in straight 
occlusions without calcification. 
The risk of perforation was higher 
if there was a relatively tight bend 
in the artery or if it was calcified. 
All patients whose arteries were 
successfully recanalized by laser 
and then dilated were clinically and 
objectively improved, as seen by 
noninvasive testing.
The initial success of the proce­
dure in 8 of 10 lesions in selected 
patients is reasonable, considering 
that all of these patients would 
otherwise have had to undergo by­
pass surgery. One of those in whom 
the technique was initially success­
ful had recurrent stenosis 5 months 
later, but the others had good re­
sults, with relief of symptoms. How­
ever, follow-up is short (mean 4.9 
months), the longest being only 11 
months.
Although there were two perfora­
tions of the arterial wall, neither 
patient suffered ill effects from this, 
and both later underwent uncompli­
cated bypass surgery. Another pa­
tient had distal thrombosis or embo­
li, but the complication responded 
well to fibrinolytic therapy and sub­
sequent balloon angioplasty of the
peroneal artery. This patient was 
subsequently asymptomatic, with 
and increase of 0.4 in the ankle- 
brachial pressure ratio.
Our patients suffered mainly 
from severe (less than one block) 
claudication or mild pain at rest. 
They generally had single-level, 
moderate-length occlusions, a con­
dition for which laser treatment 
tends to be successful. We believe 
there is no reason to broaden our 
present guidelines for intervention 
to include patients we otherwise 
would treat conservatively.
Tibial and distal popliteal occlu­
sions may well be treatable by this 
technique as experience accumu­
lates.1 The technique may thus be­
come applicable in the limb-salvage 
situation. As larger laser probes and 
“over the wire” tips become avail­
able, it may be possible to improve 
the results of percutaneous balloon 
angioplasty in the superficial femo­
ral and popliteal segments, or even 
to treat lesions primarily without 
balloon dilatation.
There are three broad catagories 
of laser systems presently available.
•  Excimer technology, is promis­
ing, but is not yet a functional tool. 
It requires a sophisticated optics 
and delivery system. A dedicated 
system costs about $250 000, plus 
operating expenses.
•The Hot-tip system, with a 
heated tungsten probe, has been 
used successfully, but there can be 
problems directing the device and 
controlling temperature to prevent 
perforation of the vessel. Also, the 
tips are disposable, so operating 
costs are high.
•  Contact surgery using an 
Nd:YAG laser directed down a fibe­
roptic cable and focused through a 
synthetic sapphire crystal is the 
third system. Although the tip itself
stays cool, just 1 mm beyond it the 
temperature can be as high as 
400 °C, hot enough to vaporize 
plaque. Each tip can be reused 5 to 
10 times. The YAG laser is portable 
and it can be used in other services. 
These features reduce the expense 
on a per patient basis.
Given the lower costs and greater 
versatility of this system, we chose 
it for our study, because we 
thought it was more applicable to 
the practice of vascular surgery in 
Canada.
Although the number of our pa­
tients is small, we feel we have 
shown that recanalization by laser 
is safe and relatively successful in 
broadening the application of 
Gruntzig balloon angioplasty. How­
ever, this is still an experimental 
procedure and not enough data are 
available to compare either the 
short- or long-term results with 
those of conventional balloon dila­
tation or of femoropopliteal bypass 
surgery. This will be the yardstick 
by which laser angioplasty will be 
measured to find its place in the 
treatment of vascular disease.
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Comparison of In-situ and Reversed 
Saphenous Vein Grafts for Infrageniculate 
Bypass
Michael A. Ricci, MD; Alan M. Graham, MD, FRCSC; James F. Symes, MD, FRCSC
Current controversy surrounding in-situ and reversed saphenous vein grafts 
prompted a review of 161 procedures performed between 1982 and 1987. Analysis 
was based on objective criteria recommended by the Society for Vascular 
Surgery/International Society for Cardiovascular Surgery (SVS/ISCVS) Committee 
on Reporting Standards.
There were 92 in-situ bypasses, 42 to the popliteal artery below the knee, and 50 
to tibial vessels; of 69 reversed vein grafts, the comparable figures were 51 and 18. 
Sixty-seven in-situ and 43 reversed grafts were done for foot salvage.
The overall primary patency rate for in-situ grafts was 81.1% at 30 days, 77.0% at 
1 year, 74.7% at 3 years and 59.8% at 5 years; corresponding reversed vein patency 
rates were 85.2%, 76.8%, 67.0% and 42.3%. Patency rates for foot salvage for in-situ 
grafts were 81.7% at 1 month, 75.9% at 1 year and 72.6% at 3 years, and for 
reversed vein grafts 78.6%, 70.3% and 66.5%. Secondary patency rates were 72.8% at 
3 years for in-situ vein and 67.2% for reversed vein; the foot-salvage rate at 3 years 
was 91.0% with in-situ vein and 78.9% with reversed vein.
The study demonstrated no statistically significant difference between in-situ and 
reversed saphenous vein bypass for infrageniculate reconstruction, regardless of the 
distal anastomotic site or severity of disease. Although a trend favouring the in-situ 
technique was noted, particularly at the tibial level, longer follow-up and a 
prospective randomized trial is needed to evaluate this.
La controverse actuelle qui entoure les techniques de greffe de la saphene (in situ 
ou inversee), est l’origine de cette etude portant sur 161 interventions pratiquees 
entre 1982 et 1987. L’analyse s’est appuyee sur les criteres objectifs recommandes 
par le Comite des normes devaluation SVS/ISCVS.
II y eut 92 pontages in situ, 42 de l’artere poplitee, sous le genou, et 50 des 
vaisseaux tibiaux. Sur 69 greffes inversees, les chiffres equivalents etaient de 51 et 
18. Soixant-sept greffes in situ et 43 greffes inversees avaient ete pratiquees pour 
sauvegarder le pied.
Les taux de permeabilite primaires pour les greffes in situ ont ete de 81,1% a 30 
jours, de 77,0% a 1 an, de 74,7% a 3 ans et 59,8% a 5 ans; pour les greffes inversees, 
les taux de permeabilite correspondants furent de 85,2%, 76,8%, 67,0% et 42,3%. 
Dans les cas de greffe in situ pour sauvegarder le pied, les taux de permeabilite 
furent de 81,7% a 1 mois, 75,9% a 1 an et 72,6% a 3 ans; pour les greffes inversees 
les taux sont de 78,6%, 70,3% et 66,5%. Le taux de permeabilite secondaire a ete de 
72,8% a 3 ans pour la greffe in situ et de 67,2% pour la greffe inversee; le taux de 
sauvegarde du pied a 3 ans a ete de 91,0% pour la greffe in situ et de 78,9% pour la 
greffe inversee.
Cette etude n’a montre aucune difference significative entre les techniques de 
greffe in situ ou inversee de la veine saphene pour une reconstruction sous le 
genou, quels que soient le lieu d’anastomose ou la gravite de l’arteropathie. Bien 
qu’il existe une tendance favorisant la technique in situ, particulierement au niveau 
tibial, une surveillance plus longue des resultats et une etude prospective 
randomisee sont requises pour confirmer cette observation.
T he in-situ saphenous vein by­pass, popularized recently by 
Leather and colleagues,1'3 has pro­
duced excellent long-term patency 
and foot-salvage rates. Recently, 
Taylor and associates45 have report­
ed achieving equivalent results with 
the reversed vein technique using 
current technical innovations and 
paying meticulous attention to de­
tail. In light of controversy over 
which method is best, we reviewed 
our experience at the Royal Victoria 
Hospital with both techniques over 
a recent 5-year period.
Patients and Methods
The records of 161 patients who 
had undergone infrageniculate by­
pass with autogenous saphenous 
vein grafts between 1982 and 1987, 
for whom complete follow-up was 
available, were reviewed retrospec­
tively. The in-situ bypass was first 
used in 1984, while reversed vein 
bypasses were used throughout the 
period. The technique for in-situ
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bypass was virtually identical to 
that described by Leather and asso­
ciates,3 and that for reversed vein 
bypasses was similar to the one 
described by Taylor and associates.5 
Demographic data, the presence of 
diabetes, the site of distal anasto­
mosis and operative death rate were 
documented. Each patient was clas­
sified retrospectively according to 
the objective criteria recently rec­
ommended by the Society for Vas­
cular Surgery/International Society 
for Cardiovascular Surgery (SVS/ 
ISCVS) Ad Hoc Committee on Re­
porting Standards.6 Categories 1, 2 
and 3 represent patients generally 
considered to have claudication; 
categories 4 and 5 represent foot- 
salvage situations.
Data recorded noninvasively in 
the laboratory during regular fol­
low-up visits at 3- to 6-month inter­
vals were used to determine patency 
and foot-salvage rates. Grafts were 
considered patent if the segmental 
pressure ankle-arm index was with­
in 0.10 of the index immediately 
preoperatively, if plethysmographic 
tracings were substantially im­
proved, if pulses were present in the 
graft or at the pedal level on physi­
cal examination, or they were seen 
to be patent at reoperation, as rec­
ommended.6
Primary patency was considered 
to be uninterrupted patency from 
the time of surgery (except for 
arteriovenous fistula ligation after 
in-situ saphenous vein grafting). If 
patency was maintained or restored 
by reoperation, this was considered 
secondary patency.
Foot salvage was considered suc­
cessful if, at most, transmetatarsal 
amputation or other minor amputa­
tions had to be performed.
Failures were reviewed retrospec­
tively and, if possible, a reason for 
failure determined for both types of 
graft.
Life-table analysis was performed 
according to the recommendations 
of the Ad Hoc Committee on Re­
porting Standards,6 as described by 
Peto and colleagues.7-8 Only those 
points at which the standard error7-8 
is less than or equal to 10% are 
reported (or are represented in the 
life tables by heavy dashes.6 Com­
parisons of life-table patency rates 
were done by the log-rank test of 
significance.6-8 Other statistical 
comparisons between groups were 
done by Fisher’s exact test. All 
life-table and statistical calculations 
were done on a personal computer 
with the aid of commercially avail­
able software (Lotus 1-2-3 (R), Sy- 
stat/Survival (R), Epistat).
Results
Both groups were equally 
matched with regard to age, sex, 
presence of diabetes, incidence of 
prior ipsilateral reconstruction and 
SVS/ISCVS classification, al­
though a significantly greater per­
centage of in-situ bypasses were to 
tibial vessels (Table I). There were 
no deaths perioperatively in the 
patients undergoing reversed saphe­
nous vein bypass, but one patient 
(1.1%) died after in-situ saphenous 
vein grafting; the overall death rate 
for the entire group of 161 patients 
was 0.6%.
Overall primary patency of the 
in-situ and reversed vein bypasses 
was not significantly different (Fig. 
1). At 30 days, the in-situ patency 
rate was 81.1%, at 1 year 77.0%, at 
3 years 74.7% and, at 5 years 
59.8%. Patency rates of the re­
versed vein at the corresponding 
times were 85.2%, 76.8%, 67.0% 
and 42.3%.
When anastomosis was to the 
popliteal artery below the knee, no 
significant difference was noted be­
tween the two groups (Fig. 2, left); 
at 3 years, in-situ patency was 
82.1% and reversed vein patency 
was 70.4%. Likewise, neither proce­
dure was significantly better at the 
tibial level (Fig. 2, right), although 
the trend favoured the in-situ by­
pass. At 1 year, in-situ patency to 
tibial vessels was 72.3%, and at 
both 3 and 5 years was 67.8%; the 
reversed vein patency rates in this 
group were 59.1% at each of these 
times (although the standard error 
at these points was 12%).
When patency was considered in 
relation to the SVS/ISCVS class- 
ificiation (Fig. 3), the trend again 
favoured the in-situ bypass, but no 
significant difference was found 
with either group (claudication or 
foot salvage). Likewise, age, sex 
and the presence of diabetes did not 
affect patency rates.
Table I. Patient Characteristics for Those Receiving In-situ Versus Reversed Saphenous Vein
Grafts
Saphenous vein grafts
Characteristic
In-situ 
(n =  92)
Reversed 
(n =  69)
Age (± SD), yr 67 ± 9.6 64.8 ±  10.2
Sex, no.
Male 64 53
Female 28 16
Diabetes present, no. 32 21
Previous bypass, no. 9 11
SVS/ISCVS classification, no.
Class 2-3 24 25
Class 4-5 67 42
Distal anastomosis site, no.
Popliteal artery, below knee 42 51
Tibial artery* 50 18
'The only significant difference between the two groups was that of the tibial artery being the site 
of distal anastomosis, p =  0.003.
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The secondary patency rate of 
the in-situ bypasses was 72.8% at 3 
years, not significantly different 
from the 67.2% rate for reversed 
vein after the same period (Fig. 4). 
The reason for early graft failures 
was attributable to technical errors 
in 8 of 12 in-situ bypasses: vein 
injury (3), veins that were too small 
(2), retained valves (2) and problems
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FIG. 1. Life-table showing overall pri­
mary patency rates of in-situ (circles) 
and reversed (squares) saphenous vein 
bypass grafts. Heavy dashed line indi­
cates standard error > 10%.
at the distal anastomosis (1). The 
use of poor veins was the cause of 
failure of two reversed vein grafts, 
but the reason could not be deter­
mined in the remaining 12 cases.
Foot-salvage rates were also not 
significantly different for the two 
techniques: at 3 years they were 
91% (in situ) and 78.9% (reversed) 
(Fig. 5).
Discussion
Controversy continues as to the 
superiority of the in-situ bypass 
over the reversed vein technique for 
infrainguinal reconstruction in the 
ischemic limb. It has been suggest­
ed that the in-situ procedure has 
superior hemodynamic characterist­
ics,910 preserves endothelium11 and 
avoids fibrosis at valve sites,12 re­
sulting in better long-term patency 
and foot salvage.13 Others4513-15
have questioned these claims, sug­
gesting that the in-situ technique is 
not innately superior to reversed 
vein bypasses but simply reflects 
current technical improvements and 
innovations. Furthermore, the re­
versed vein technique has the added 
advantage of allowing reconstruc­
tion when the ipsilateral saphenous 
vein is absent or inadequate.14-16
In early reports of in-situ graft­
ing, 3-year patency rates in excess 
of 80% were compared with those 
of previously published series of 
reversed vein bypasses, in which the 
patency rate was generally 50% or 
less.1-2 More recently, Leather and 
colleagues3 have summarized their 
13-year experience with 1038 in- 
situ bypasses. Operative mortality 
was 6.7%. The primary patency rate 
at 5 years was 59% and the second­
ary patency rate was 76%. Graft 
failures were usually the result of 
technical problems, such as the use
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FIG. 2. Primary patency rates of in-situ (circles) and reversed (squares) saphenous 
vein bypass grafts to (left) popliteal artery, below knee, and (right) tibial artery. 
Heavy dashed line indicates standard error > 10%.
FIG. 4. Overall secondary patency 
rates of in-situ (circles) and reversed 
(squares) saphenous vein bypass 
grafts.
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FIG. 3. Primary patency rates of in-situ (circles) and reversed (squares) saphenous 
vein bypass grafts in patients classified as SV/ISCVS classes 2 and 3 (left) and 4 
and 5 (right). Heavy dashed line indicates standard error > 10%.
FIG. 5. Foot-salvage rates with use of 
in-situ (circles) and reversed (squares) 
saphenous vein bypass grafts.
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of a vein of insufficient size, vein 
injury or retained valves. Others 
have reported comparable re­
sults;1718 the results of this study, 
regarding primary patency, are also 
comparable.
Leather’s group3 used a follow­
up program similar to the one we 
used, with the later addition of 
duplex sonography. They reported 
that secondary patency rates gener­
ally improved by 10% to 20% over 
primary rates. The reasons for fail­
ure in that series are similar to 
ours. However, in our series, sec­
ondary patency rates were not sig­
nificantly improved. In general, we 
experienced a significant early fail­
ure rate because of technical prob­
lems, followed by a relatively slower 
decline in patency in subsequent 
years, a pattern observed by oth­
ers.19 It is quite possible that our 
surveillance protocol was not suffi­
ciently sensitive to detect impending 
late graft failures. Duplex scanning 
allows hemodynamic assessment of 
the failing graft and may be superi­
or to the use of segmental pres­
sures and waveforms.18 This is cur­
rently being evaluated in our labo­
ratory.
In contrast, the reversed saphe­
nous vein bypass displayed a gradu­
al decline in patency rates with 
time, as has also been described 
previously.19 This is in contrast to 
the findings of Taylor’s group5 who 
demonstrated excellent results with 
reversed saphenous vein: at 1 year 
their primary patency rate was 90%, 
at 3 and 5 years, it was 85%. The 
limb salvage rate was 93% at 5 
years. Our results are more in line 
with those of others, who have 
reported 3-year patency rates in the 
range of 60% to 70%.19-21
Several studies have attempted to 
compare the two techniques retro­
spectively, but no difference has 
been noted.14-2022 Similarly, our re­
sults showed no significant differ­
ence between in-situ and reversed
vein bypasses, whether considering 
primary and secondary patency or 
foot-salvage rates.
Likewise, in two prospective tri­
als23-24 no difference was found be­
tween the two techniques. In addi­
tion, in our review there was no 
significant difference between tech­
niques when analysed according to 
the SVS/ISCVS classification or 
the site of distal anastomosis. The 
trend at the tibial level, however, 
clearly favoured the in-situ tech­
nique. It is possible that this differ­
ence did not attain significance be­
cause of the smaller number of 
bypasses to the tibial level with 
reversed saphenous vein. Thus the 
possibility of a type II error must be 
acknowledged. This bias clearly rep­
resented surgeon preference due to 
a greater confidence in the in-situ 
bypass at the tibial level during this 
period.
In summary, from this retrospec­
tive review of our recent experience 
with 161 infrageniculate recon­
structions, there appears to be no 
significant difference between in- 
situ and reversed saphenous vein 
bypasses with regard to primary 
patency, secondary patency or limb- 
salvage rates. Although a trend 
favoured the in-situ bypass at the 
tibial level, further study, including 
longer follow-up and perhaps a pro­
spective randomized evaluation, is 
necessary to confirm this. Improved 
protocols for surveillance, using 
currently available duplex scanning 
techniques to detect the failing 
graft, may increase secondary pat­
ency rates.
We have found the SVS/ISCVS 
classification system based upon ob­
jective criteria useful for standard­
ized comparisons of infrainguinal 
reconstructions in the ischemic 
limb.
We thank Dr. Jack Williams for assis­
tance in the statistical analysis, Ms. 
Diane Major and Ms. France Singher
for assistance in data collection and 
Mrs. Maria Grant for preparing the 
manuscript.
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Histamine H2 Receptor Antagonist
ACTIONS AND 
CLINICAL PHARMACOLOGY
PEPCID® (famotidine) is a competitive inhibitor of 
histamine H2-receptors. The primary clin ically 
important pharmacologic activity of PEPCID® is 
inhibition of gastric juice secretion. PEPCID® 
reduces the acid and pepsin content, as well as the 
volume, of basal, nocturnal, and stimulated gastric 
secretion.
INDICATIONS AND CLINICAL USE
PEPCID® (famotidine) is indicated in the treatment 
of the following conditions where a controlled 
reduction of gastric secretion is required for ulcer 
healing:
1. Treatment of acute duodenal ulcer;
2. Prophylactic use in duodenal ulcer;
3. Treatment of acute benign gastric ulcer;
4. Treatment of pathological hypersecretory 
conditions (e.g., Zollinger-Ellison syndrome).
PEPCID® I.V. is indicated in some hospitalized 
patients with pathological hypersecretory con­
ditions or intractable ulcers, or as an alternative to 
the oral dosage forms for short-term use in patients 
who are unable to take oral medication.
CONTRAINDICATIONS
H ypersens itiv ity  to any com ponent o f th is  
medication.
PRECAUTIONS
Patients with Severe Renal Insufficiency
Dosing intervals may need to be prolonged in 
pa tients w ith advanced renal insu ffic ie ncy  
(creatinine clearance<10 mL/min.) to adjust for the 
longer elimination half-life of famotidine. (See 
CLINICAL PHARMACOLOGY and DOSAGE AND 
ADMINISTRATION.)
Drug Interactions
Studies with famotidine in man, in animal models, 
and in vitro have shown no significant interference 
with the disposition of compounds metabolized by 
the hepatic microsomal enzymes, e.g., cytochrome 
P450 system. Compounds tested in man have 
inc luded w arfarin, theophy lline , phenyto in , 
diazepam, am inopyrine and antipyrine. Indo­
cyanine green as an index of hepatic blood flow 
and/or hepatic drug extraction has been tested and 
no significant effects have been found.
Use in Gastric Ulcer
Gastric malignancy should be excluded prior to 
initiation of therapy of gastric ulcer with PEPCID®. 
Symptomatic response of gastric ulcer to PEPCID® 
therapy does not preclude the presence of gastric 
malignancy.
Use In Pregnancy
Reproductive studies have been performed in rats 
and rabbits at oral doses of up to  2000 and 
500 mg/kg/day, respectively (approximately 2500 
and 625 times the maximum recommended human 
dose, respectively), and have revealed no evidence 
of impaired fertility or harm to the fetus due to 
PEPCID®. There are, however, no adequate or well- 
controlled studies in pregnant women.
Since the safe use of PEPCID® in pregnant women 
has not been established, the benefits of treatment 
with PEPCID® should be weighed against potential 
risks.
Nursing Mothers
Studies performed in lactating rats have shown that 
PEPCID® is secreted in breast milk. It is not known 
whether this drug is secreted in human milk. 
Nursing mothers should either stop this drug or 
should stop nursing.
Pediatric Use
Safety and effectiveness in children have not been 
established.
Use in Elderly Patients
No dosage adjustment is required based on age (see 
HUMAN PHARMACOLOGY, Pharmacokinetics).
ADVERSE REACTIONS
PEPCID® (famotidine) is usually well tolerated; 
most adverse reactions have been mild and 
transient. The adverse reactions listed below have 
been reported during clinical trials in 2333 patients. 
In those controlled clinical trials in which PEPCID® 
was compared to placebo, the overall incidence of 
adverse experiences in the group which received 
PEPCID®, 40 mg at bedtime, was similar to the 
placebo group. No antiandrogenic or other adverse 
hormonal effects have been observed.
The following adverse reactions have been reported 
at a rate of greater than 1% in patients on therapy 
with PEPCID® in controlled clinical trials, and may 
be causally related to the drug: headache (4.6%), 
dizziness (1.2%), constipation (1.2%) and diarrhea 
( 1.6% ) .
Other reactions have been reported in clinical trials 
but occurred under circumstances where a causal 
relationship could not be established. However, in 
these rarely reported events, that possibility cannot 
be excluded. Therefore, these observations are 
listed to serve as alerting information to physicians.
Gastrointestinal 8.0%
Nausea 1.6%
Vomiting 0.9%
Anorexia 0.5%
Abdominal discomfort 0.3%
Dry mouth 0.2%
Nervous System/Psychlatrlc 7.3%
Insomnia 0.6%
Somnolence 0.4%
Anxiety 0.3%
Paresthesia 0.3%
Depression 0.2%
Libido decreased 0.1%
Respiratory 4.4%
Bronchospasm <0.1%
Body as a Whole 3.0%
Fatigue 0.6%
Asthenia 0.3%
Fever 0.2%
Musculoskeletal 1.7%
Musculoskeletal pain 0.1%
Arthralgia 0.1%
Skin 1.7%
Pruritus 0.4%
Rash 0.3%
Alopecia 0.2%
Flushing 0.2%
Acne 0.1%
Dry skin 0.1%
Cardiovascular 1.0%
Palpitations 0.2%
Special Senses 0.9%
Taste disorder 0.1%
Tinnitus 0.1%
Orbital Edema <0.1%
Urogenital 0.9%
The adverse reactions reported for PEPCID® 
Tablets may also occur with PEPCID® I.V. In 
addition, transient irritation at the injection site has 
been observed with PEPCID® I.V.
Laboratory Abnormalities
Laboratory parameters may be affected during 
treatment with PEPCID®, but the changes are 
usually not considered serious. Among the 
laboratory changes that were reported during 
clinical trials were increases in AST, ALT, BUN, and 
serum creatinine. These changes were rarely of 
clinical significance.
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Only three patients had to be discontinued from 
therapy because of laboratory adverse experiences, 
however laboratory abnormalities were present at 
baseline.
SYMPTOMS AND TREATMENT 
OF OVERDOSAGE
There is no experience to date with deliberate 
overdosage. Doses of up to 640 mg/day have been 
employed in patients with pathological hyper­
secretory conditions with no serious adverse 
effects. In the event of overdosage, treatment 
should be symptomatic and supportive. Un­
absorbed material should be removed from the 
gastrointestinal tract, the patient should be 
monitored, and supportive therapy should be 
employed.
The oral LDm of famotidine in male and female rats 
and mice was >5000 mg/kg.
DOSAGE AND ADMINISTRATION 
DUODENAL ULCER 
Acute Therapy
The recommended adult oral dosage of PEPCID® 
(famotidine) for acute duodenal ulcer is 40 mg once 
a day at bedtime. Treatment should be given for 
4-8 weeks, but the duration of treatment may be 
shortened if healing can be documented. Healing 
occurs within 4 weeks in most cases of duodenal 
ulcer.
Maintenance Therapy
For the prevention of recurrence of duodenal ulcer, 
it is recommended that therapy with PEPCID® be 
continued with a dose of 20 mg once a day at 
bedtime, for a duration of up to  6-12 months 
depending on the severity of the condition.
BENIGN GASTRIC ULCER 
Acute Therapy
The recommended adult oral dosage for acute 
benign gastric ulcer is 40 mg once a day at bedtime. 
Treatment should be given for 4 to 8 weeks, but the 
duration of treatment may be shortened if healing 
can be documented.
PATH O LO G IC A L HYPERSECRETO RY C O N ­
D IT IO N S  (SU CH  AS Z O LL IN G E R -E L L IS O N  
SYNDROME)
The dosage o f PEPCID® in pa tien ts  w ith  
pathological hypersecretory conditions varies with 
the individual patient. The recommended adult oral 
starting dose fo r pathological hypersecretory 
conditions is 20 mg q6h. In some patients, a higher 
starting dose may be required.
Doses should be adjusted to individual patient 
needs and should continue as long as clinically 
indicated. Doses up to 160 mg q6h have been 
adm inistered to  some pa tients w ith  severe 
Zollinger-Ellison syndrome.
Intravenous Administration
In some hospitalized patients with pathological 
hypersecretory conditions or intractable ulcers, or 
in patients who are unable to take oral medication, 
PEPCID® I V. may be administered. The recom­
mended dosage is 20 mg every 12 hours.
Intravenous injection therapy should be changed to 
oral treatment as soon as the acute situation is 
under control.
Concomitant Use with Antacids
Antacids may be given concomitantly if needed.
Dosage Adjustment for Patients with Severe Renal 
Insufficiency
In patients with advanced renal insufficiency, i.e., 
with a creatinine clearance less than 10 mL/min., 
the elimination half-life of PEPCID® may exceed 
12 hours reaching approximately 24 hours in anuric 
patients.
To avoid excess accumulation of the drug, the 
dosing interval of PEPCID® may be prolonged to 
36-48 hours as indicated by the patient's clinical 
response.
PHARMACEUTICAL INFORMATION
COMPOSITION
Tablets
Each tablet for oral administration contains either 
20 mg or 40 mg of famotidine.
Injection
Each mL of the solution for intravenous injection 
contains 10 mg of famotidine and the following 
inactive ingred ients: L -aspartic  acid 4 mg, 
mannitol 20 mg, and Water for Injection, q.s., 1 mL. 
The multidose injection also contains benzyl 
alcohol 0.9% added as preservative.
RECONSTITUTION  
Parenteral Products
Dilution of PEPCID® I.V. 
for Infusion
P E P C ID *  I.V . 
Solution
V o l . . . .a o f  
Com patible 
I.V . Solution
Final
Volum e
Final
Concentration
R ate o f 
In fu s io n
2 mL 3mL 5m L 4 mg/mL Not less than 
2 minutes
2 mL 8 mL 10 mL 2mg/mL Not less than 
2 minutes
2 mL 100 mL 102 mL 0.196 mg/mL 15-30 minutes
PEPCID® I.V. Solutions are compatible with:
Water for Injection
0.9% Sodium Chloride Injection 
5% Dextrose Injection 
10% Dextrose Injection 
Lactated Ringer’s Injection 
Sodium Bicarbonate Injection 5%
STABILITY AND STORAGE 
RECOMMENDATIONS
PEPCID® I.V. Solution
Store at 2 - 8°C. Protect from light. If solution 
freezes, bring the solution to room temperature; 
a llow  s u ff ic ie n t tim e  to  s o lu b iliz e  a ll the 
components.
Diluted PEPCID® I.V. Solutions should be used 
within 24 hours due to the possibility of microbial 
contamination during preparation.
NOTE: Parenteral drug p roducts shou ld  be 
i nspected visually for particulate matter and 
d isco loura tion p rio r to  adm inistra tion 
whenever solution and container permit.
DOSAGE FORMS AND AVAILABILITY
Tab le ts  PEPCID® (fa m o tid in e  ta b le ts ) are 
D-shaped, film-coated tablets supplied as follows:
No. Ca 8102 - 20 mg be ige c o lo u re d , 
coded 963. Available in bottles of 100 tablets. 
No. Ca 8103 - 40 mg light brownish orange, 
coded 964. Available in bottles of 100 tablets. 
No. Ca 3539 - PEPCID® I.V., 10 mg per 1 mL, is a 
clear, colourless solution and is available as a non- 
preserved unit dose containing 2 mL of injectable 
solution. Available in 10 x 2 mL vials.
No. Ca3541 - PEPCID® I.V., 10 mg per 1 mL, is a 
clear, colourless solution and is available as a 
preserved m ultip le dose conta in ing 4 mL of 
injectable solution. Available in 4 mL vials.
HUMAN PHARMACOLOGY
In both normal volunteers and hypersecretors, 
PEPCID® inhibited basal nocturnal and daytime 
gastric secretion, as well as secretion stimulated by 
a variety of stimuli, such as pentagastrin and food. 
After oral administration, the onset of the anti- 
secretory effect occurred within one hour; the 
maximum effect was dose-dependent, occurring 
within one to three hours. Duration of inhibition of 
secretion was 10 to 12 hours. After intravenous 
administration, the maximum effect was achieved 
within 30 minutes. Single intravenous doses of 10 
and 20 mg inhibited basal nocturnal secretion for a 
period o f 10-12 hours. The 20 mg dose was 
associated with the longest duration of action in 
most subjects. Single oral doses of 20 and 40 mg 
inhibited basal nocturnal acid secretion in all 
subjects; mean gastric acid secretion was inhibited 
by 86% and 94%, respectively, for a period of at least 
10 hours. S imilar doses given in the morning 
suppressed food-stimulated acid secretion in all 
subjects, with mean suppression of 76% and 84%, 
respectively, 3 to 5 hours after drug, and of 25% and 
30%, respectively, 8 to  10 hours a fte r drug; 
however, in some subjects who received the 20 mg 
dose, the antisecretory effect was dissipated earlier, 
within 6-8 hours. There was no cumulative effect 
with repeated doses. The basal nocturnal intra- 
gastric pH was raised by evening doses of 20 and 
40 mg of PEPCID® to mean values of 5.0 and 6.4, 
respectively. When PEPCID® was given in the 
morning, the basal daytime interdigestive pH at 3 
and 8 hours after 20 or 40 mg of PEPCID® was 
raised to about 5.0.
Fasting and postprandial serum gastrin levels may 
be s ligh tly  elevated du ring  periods of drug 
antisecretory effect, and with chronic therapy an 
increase in gastric bacterial flora may occur. Gastric
emptying and exocrine pancreatic function are not 
affected by PEPCID®
Other effects
Systemic pharmacologic effects of PEPCID® in the 
CNS, cardiovascular, respiratory or endocrine 
systems have not been found to date. Serum 
prolactin levels do not rise after intravenous bolus 
doses of 20 mg PEPCID® and no antiandrogenic 
effects have been detected.
Pharmacokinetics
PEPCID® is incompletely absorbed. The bioavaila­
bility of oral doses is 40-45%. Bioavailability may be 
slightly increased by food, or slightly decreased by 
acntacids; however, these effects are of no clinical 
consequence. PEPCID® undergoes minimal first- 
pass metabolism. After oral doses, peak plasma 
levels occur in 1-3 hours. Plasma levels after 
multiple doses are similar to those after single 
doses. Fifteen to 20% of PEPCID® in plasma is 
protein bound. PEPCID® has an elimination half-life 
of 2 5-3.5 hours. PEPCID® is eliminated by renal 
(65-70%) and metabolic (30-35%) routes. Renal 
clearance is 250-450 mL/min., indicating some 
tubular excretion.
Twenty-five to 30% of an oral dose and 65-70% of an 
intravenous dose are recovered in the urine as 
unchanged com pound. The on ly  m etabo lite  
identified in man is the S-oxide. There is a close 
relationship between creatinine clearance values 
and the elimination half-life of PEPCID®. In patients 
with severe renal insufficiency, i.e., creatinine 
clearance less than 10 mL/min., PEPCID® elimi­
n a tio n  h a lf - l ife  may exceed 20 ho u rs  and 
adjustment of dosing intervals may be necessary 
(see PRECAUTIONS, DOSAGE AND ADMINIS­
TRATION). In e lderly patients, there are no 
clinically significant age-related changes in the 
pharmacokinetics of PEPCID®
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CANADIAN SOCIETY FOR VASCULAR SURGERY
Management of Venous Stasis Ulcer: 
Long-Term Follow-up
W.G. Jamieson, MD, FRCS, FRCSC, FACS; G. DeRose, MD, FRCSC, FACS; K.A. Harris, MD, FRCSC
In this study 112 patients (122 lower limbs) who had chronic venous stasis 
ulceration refractory to conservative management were treated surgically. Subfascial 
ligation was performed on 118 limbs and the long saphenous vein was removed in 4. 
Complications consisted of postoperative thromboplebitis (2%), wound infection (2%) 
and wound infection with ulcer necrosis (1.5%). These all responded to conservative 
management. Follow-up (mean 7.9 years, median 11 years) showed a good or 
excellent result in 82% of cases, with healing of the ulcer and no ulcer recurrence 
despite significant noncompliance with support stockings.
This paper is a long-term follow-up study of a surgical procedure for chronic 
venous stasis ulcers. The authors believe that the 82% good and excellent results 
may indicate that surgical intervention for refractory venous ulcers is a worthwhile 
procedure, providing potentially satisfactory long-term results.
Dans cette etude, 112 patients souffrant d’ulceres d’insuffisance veineuse chronique 
(affectant 122 membres inferieurs), resistants au traitement conservateur, ont ete 
traites par chirurgie. Une ligature sous-aponevrotique fut pratiquee sur 118 jambes 
et un stripping de la saphene longue, sur les 4 autres. Les complications observees 
comprennent des thrombophlebites postoperatoires (2%), des infections de plaies 
(2%) et des infections de plaies avec necrose ulcereuse (1.5%). Toutes cederent a un 
traitement conservateur. La surveillance des suites therapeutiques (d’une duree 
moyenne de 7.9 ans et mediane de 11 ans) revele des resultats bons ou excellents 
dans 82% des cas, avec cicatrisation de l’ulcere et absence de recidive malgre un 
manque de fidelite notoire au port de bas de soutien.
Cet article fait le bilan a long terme de l’etude d’une intervention chirurgicale 
pour les ulceres d’insuffisance veineuse chronique. Les auteurs croient qu’avec 82% 
de bons ou d’excellents resultats une intervention chirurgicale dans les cas d’ulceres 
veineux tenaces represente une approche interessante qui offre la possibilite de 
resultats satisfaisants a long terme.
V enous ulcers are common, de­bilitating and costly to both the 
patient and the health-care system. 
Long-term management is difficult 
and recurrence is frequent. The 
cause of venous ulcers is venous 
hypertension in the subcutaneous 
space due either to incompetent 
perforating veins or to incompetent 
valves in the long saphenous vein.
Management includes compression 
therapy, sclerotherapy and surgery. 
No study of refractory ulcers treat­
ed by surgery with a follow-up of 
more than 10 years has yet been 
published.1 In this paper we discuss 
the management and follow-up of 
112 patients (122 lower limbs) with 
refractory venous ulcers operated 
on between 1966 and 1986. The
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mean follow-up was 7.9 years (me­
dian 11 years).
Patients and Methods
The diagnosis of incompetent 
perforating veins was made by his­
tory, physical examination and as­
cending phlebography (96 limbs).
All limbs were subjected to a 
subfascial ligation of incompetent 
perforators (88), long saphenous 
vein stripping and tributary removal 
(4), or combination of the two (30). 
The type of incision depended on 
the site of the ulcer; posteromedial 
and posterolateral incisions were 
used originally, but these were re­
placed by the posterior seam ap­
proach. All perforators were ligated 
and divided between sutures. 
Wounds were closed in one layer 
with nonabsorbable sutures. Post- 
operatively the patient had complete 
bed rest for 3 days with the limb 
well elevated and was instructed to 
move the foot in plantar and dorsi- 
flexion.
After operation the 112 patients 
were followed up by chart review 
and telephone interview by a labora­
tory assistant. Information on 31 
limbs was unavailable because the 
patients were lost to follow-up 
(death — 13 limbs, inability to 
locate — 15 or lost charts — 3). 
The follow-up therefore was of 91 
limbs, 75% of those operated on.
The factors considered were as 
follows: recurrence of the ulcer, 
relief of symptoms and compliance 
in wearing support stockings post- 
operatively. The criterion for a good 
result was no recurrent ulcer.
Results
Five limbs required reoperation 
for recurrent venous ulcer. In all at
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least one recurrent or missed in­
competent perforating vein was 
found and ligated between non­
absorbable sutures. There was no 
further recurrence; however, these 
limbs were followed up for a maxi­
mum of only 2 years.
In 71 limbs (82%) there was a 
good result; the patients had no 
recurrence, and had marked allevia­
tion of symptoms of heaviness, 
bursting and swelling of the calf. In 
the other 16 (18%) limbs the result 
was poor, because of recurrent re­
fractory ulcers.
Compliance in wearing support 
stockings in the postoperative 
phase was poor and probably no 
more than 20% to 25%.
Discussion
Venous stasis ulcer is a demand­
ing, persistent problem for the pa­
tient and physician because of its 
chronicity due to underlying venous 
hypertension. The cause of the ve­
nous hypertension is well docu­
mented.2 Incompetent perforating 
veins release the hypertension in 
the deep venous system into the 
subcutaneous tissue. Incompetence 
of the long saphenous valve in the 
superficial system of veins, trans­
mitting a high venous pressure to 
the gaiter area is also implicated, 
although this is a rare cause. We 
have adopted the attitude that if the 
subcutaneous venous hypertension 
can be alleviated the ulcer has a 
good chance of healing.
Patients are treated conservative­
ly at first with attention to good 
hygiene. Antibiotics are given if the 
ulcer is infected, the limb is kept 
elevated whenever possible and sup­
port stockings, ranging from sup­
port hose to elastic stockings to 
pressure gradient stockings to vi­
scopaste boot are prescribed. No 
patient in this series was operated 
on without at least 1 year of this 
type of conservative therapy aimed
at healing a long-standing ulcer.
We believe that the diagnosis of 
venous ulcer secondary to incompe­
tent valves in the long saphenous 
vein is not difficult since these 
ulcers are always associated with 
greatly dilated veins, and incompe­
tent valves can be demonstrated on 
clinical examination.
Our operative approach has been 
to ligate and divide the incompetent 
perforating veins and when neces­
sary remove coexisting varicose 
veins. In only four limbs was the 
long saphenous alone removed and 
in these cases there was a huge 
dilatation of the long saphenous 
vein and no incompetent perforators 
as shown on venography. This con­
dition seems to be very rare and 
some authors suggest it does not 
exist,3 but in these four cases there 
was no ulcer recurrence.
We used aggressive subfascial li­
gation. Originally we used post­
eromedial and posterolateral inci­
sions, but recently we have been 
using the seam approach from pop­
liteal fossa to the ankle joint. We 
stress a bold approach, making the 
incisions at right angles to the skin 
to prevent undermining, and quick­
ly entering the subfascial space. 
The short saphenous vein is re­
moved if it is varicose, taking care 
to protect the sural nerve. The 
subfascial exposure is developed 
medially as far as the tibia, being 
very sure, by blunt and sharp dis­
section, not to overlook any perfo­
rating veins. If there is pigmenta­
tion laterally the lateral side is done 
at the same time, taking the dissec­
tion to the fibula.
The surgeon must be aggressive 
in the region of the fascial insertion 
into the tibia and fibula, because we 
believe that if any incompetent per­
forating veins are left intact, the 
problem is not solved. In this paper, 
we have reported a long-term fol­
low-up and have shown an 82% rate 
of freedom from ulcer recurrence.
We believe these figures are signifi­
cant and accurate. Others4 have 
reported a similar ulcer-free rate 
(80%) but a shorter follow-up.
In some areas of the country 
conservative therapy is the pre­
ferred method of managing this 
problem. With aggressive weight 
reduction, exercise, leg elevation 
and appropriate support stockings 
including the Unna paste boot this 
can be done. However, we think 
that the effort expended, the long­
term morbidity with the various 
stockings and the repeat visits indi­
cate another approach.
Sclerotherapy has been used in 
many centres with excellent results 
but it is our feeling that the ability 
to inject these perforating veins is 
very difficult. The legs are often 
brawny, thick and ulcerated, and it 
is extremely difficult to ascertain 
the exact location of the perforating 
veins.
Conclusion
Ninety-one limbs were operated 
on for refractory venous ulcers with 
a good result in 82%, the criterion 
for a good result being no recurrent 
ulcer. The median follow-up was 11 
years. We believe that this result 
suggests that an aggressive surgi­
cal approach is a satisfactory alter­
native in the management of refrac­
tory venous ulcers.
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Comparison of Left Ventricular Function 
and Myocardial Perfusion for Evaluating 
Perioperative Cardiac Risk of Abdominal 
Aortic Surgery
N.V. McPhail, MD, FRCSC;* T.D. Ruddy, MD, FRCPC;t J.E. Calvin, MD, FRCPC;t G.G. Barber, MD, 
FRCSC;* C.Wm. Cole, MD, FRCSC;* R.A. Davies, MD, FRCPC;t K.Y. Gulenchyn, MD, FRCPC*
The measurement of left ventricular function by gated blood pool scanning and of 
myocardial perfusion by dipyridamole thallium imaging were compared in a 
prospective study of patients who had abdominal aortic aneurysm or aortoiliac 
occlusive disease to determine which measurement was the better predictor of 
postoperative cardiac complications. Sixty-six men and 19 women (mean age 67 
years) underwent both tests before admission for surgery. Fifty-six had repair of an 
abdominal aortic aneurysm, and 29 had reconstruction for aortoiliac occlusive 
disease. In 17 patients the left ventricular ejection fraction was less than 50%.
Dipyridamole thallium imaging was positive, showing redistribution, in 45 
patients. Postoperative cardiac complications occurred in 33 patients.
The sensitivity of dipyridamole thallium imaging (91%) was significantly (p < 
0.01) greater than that observed with gated blood pool scanning (27%). However, 
the specificity of gated blood pool scanning (85%) was similar to that of 
dipyridamole thallium imaging (71%). Diagnostic accuracy was greatest with 
dipyridamole thallium imaging (79% versus 62% [p < 0.02]).
Dipyridamole thallium imaging is superior to gated blood pool scanning for 
perioperative evaluation of vascular surgical patients.
L’evaluation de la fonction ventriculaire gauche par scintigraphie controlee de la 
masse sanguine et celle de la perfusion du myocarde par scintigraphie au 
thallium-dipyridamole ont ete comparees dans une etude prospective chez des 
patients souffrant d’un anevrisme de l’aorte abdominale ou d’une arteriopathie 
aorto-iliaque, dans le but d’etablir quelle methode etait la meilleure pour predire les 
complications cardiaques postoperatoires. Soixante-six hommes et 19 femmes (dont 
l’age moyen etait de 67 ans) furent soumis aux deux examens avant la chirurgie. 
Cinquante-six subirent la reparation d’un anevrisme de l’aorte abdominale et 29 
eurent une reconstruction pour stenose aorto-iliaque. Chez 17 de ces patients, la 
fraction d’ejection ventriculaire gauche etait inferieure a 50%.
La scintigraphie au thallium-dipyridamole fut positive, montrant une redistribu­
tion chez 45 patients. Des complications cardiaques postoperatoires survinrent chez 
33 patients.
La sensibilite de la scintigraphie au thallium-dipyridamole (91%) a ete significati- 
vement plus grande (p < 0.01) que celle observee avec la scintigraphie controlee de 
la masse sanguine (27%). Neanmoins, la specificite de cette derniere (85%) a ete 
similaire a celle de la scintigraphie au thallium-dipyridamole (71%). La precision 
diagnostique fut meilleure avec la scintigraphie au thallium-dipyridamole (79% 
contre 62% [p < 0.02]).
La scintigraphie au thallium-dipyridamole est superieure a la scintigraphie 
controlee de la masse sanguine pour l’evaluation peroperatoire des patients qui 
subissent une chirurgie vasculaire.
Careful preoperative cardiac as­sessment is most important in 
patients who must undergo vascu­
lar surgery, since cardiac complica­
tions account for half of all the 
postoperative deaths.1 The methods 
used for this assessment include 
clinical evaluation, electrocardio­
graphic exercise stress testing, 
gated blood pool scanning, dipyri­
damole thallium imaging and coro­
nary arteriography. Although coro­
nary arteriography may be the most 
definitive examination, its routine 
use as a preoperative screening test2 
has not been widely accepted, be­
cause it is invasive and expensive 
and provides anatomical rather than 
functional information. Initially the 
use of noninvasive tests may be 
preferable to identify those patients
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who are at cardiac risk. Coronary 
arteriography can then be carried 
out selectively to plan preliminary 
coronary artery repair when indicat­
ed.
Indices of clinical risk, though 
important, may be unreliable.3 The 
use of exercise electrocardiographic 
testing is severely limited by the 
inability of many patients with vas­
cular disease to perform at a level 
sufficient to produce symptoms or 
electrocardiographic changes.4-5 
Dipyridamole thallium imaging is a 
valuable preoperative screening test 
in this group of patients because of 
its high sensitivity.6' 8 The measure­
ment of left ventricular ejection 
fraction by gated blood pool scan­
ning has proven helpful in deter­
mining which patients are at high 
risk for perioperative myocardial in­
farction9 after aortic aneurysm re­
pair.
The present study was undertak­
en to compare the ability of dipyri­
damole thallium imaging and gated 
blood pool scanning to predict peri­
operative cardiac complications in a 
group of patients requiring abdomi­
nal aortic surgery.
Method
Patients, seen by members of the 
Division of Vascular Surgery at the 
Ottawa Civic Hospital, who required 
abdominal aortic aneurysm repair or 
aortoiliac reconstruction for occlu­
sive disease were enrolled in a pro­
spective study protocol. Informed 
consent was obtained. Each patient 
was then seen by one of two cardi­
ologists (J.E.C. or T.D.R.) for care­
ful evaluation of their clinical status 
and electrocardiographic findings. 
Patients who had had an acute 
myocardial infarction within 3 
months, who had unstable angina 
or valvular disease were excluded 
from the study. The remaining pa­
tients underwent dipyridamole thal­
lium imaging and gated blood pool 
scanning for measurement of left 
ventricular ejection fraction prior to 
admission for surgery. Patients who 
had more than one area of delayed 
reperfusion on dipyridamole thalli­
um imaging or a left ventricular 
ejection fraction of 20% or less 
were also excluded.
Dipyridamole thallium imaging 
was carried out as described previ­
ously.8 Dipyridamole was infused 
intravenously at a rate of 0.14 
m g/kg-m in'1 for 5 minutes and 
was followed 2 minutes later by 2 
mCi of thallium-201. Myocardial 
imaging was performed 5 and 180 
minutes after thallium injection. Se­
quential planar images were ob­
tained on an imaging table in the 
anterior, 45° and 70° left anterior 
oblique positions for a pre-set time 
of 7 minutes each. Electrocardio­
graphic tracings and blood pressure 
were monitored throughout the 
test. The thallium images were re­
viewed on a computer display and 
interpreted by two independent ob­
servers.
Gated blood pool scanning was 
carried out as previously described9 
The red blood cell pool of each 
patient was labelled using the in 
vivo method and 25 mCi of tech- 
netium-99m. Images were obtained 
at rest in multiple views — anterior, 
45° left anterior oblique and 30° 
left posterior oblique. The left ven­
tricular ejection fraction was calcu­
lated from a background subtracted 
time-activity curve generated using 
a semiautomated threshold and sec­
ond derivative edge detection algo­
rithm.
Study patients were carefully 
monitored intraoperatively and for 
72 hours postoperatively. Cardiac 
complications recorded were cardiac 
death, acute myocardial infarction, 
acute pulmonary edema, ventricular 
tachycardia or fibrillation and se­
vere intraoperative ischemia. A di­
agnosis of acute myocardial infarc­
tion was based on electrocardio­
graphic evidence of new ST-seg- 
ment elevation or T-wave inversion 
with elevated levels of creatine ki­
nase isoenzymes-MB fraction. A di­
agnosis of acute pulmonary edema 
was based on chest x-ray films and 
clinical criteria with a mean pulmo­
nary capillary wedge pressure great­
er than 18 mm Hg.
Severe intraoperative ischemia 
was diagnosed by electrocardio­
graphic evidence of ST-segment de­
pression in association with system­
ic hypotension and an elevation of 
the mean capillary wedge pressure 
above 18 mm Hg.
Results
The final study population com­
prised 85 patients (66 men, 19 
women), and the average age was 
67 years. Fifty-six patients had re­
pair of an abdominal aortic aneu­
rysm, and 29 had reconstruction for 
aortoiliac occlusive disease.
Perioperative cardiac complica­
tions were observed in 33 patients 
(39%). These complications oc­
curred following 21 (38%) of the 56 
aortic aneurysm repairs and 12 
(41%) of the 29 aortobifemoral 
grafting procedures. There were 11 
acute myocardial infarctions, 2 car­
diac deaths, 26 episodes of acute 
pulmonary edema, 3 of ventricular 
arrhythmia and 2 of severe intraop­
erative cardiac ischemia.
Thallium redistribution, indicat­
ing an area of ischemic myocardi­
um, was found in 45 (53%) patients. 
Cardiac complications occurred in 
30 (67%) of them. Only 3 (8%) of 
the 40 patients without thallium 
redistribution suffered cardiac com­
plications. The sensitivity of dipyri­
damole thallium scanning, defined 
as the proportion of patients with 
complications who had a positive 
test, was 91%. The specificity, de­
fined as the proportion of patients
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without complications who had a 
negative test, was 71%.
The left ventricular ejection frac­
tion was less than 50% in 17 (20%) 
of the patients in the study; cardiac 
complications occurred in 9 (53%) 
of these. Only 24 (35%) of the 68 
patients with no ventricular dys­
function suffered perioperative car­
diac complications. The sensitivity 
of the left ventricular ejection frac­
tion was 27% and the specificity 
85%.
The sensitivity of dipyridamole 
thallium scanning was significantly 
(p < 0.01, Student’s t-test) greater 
than that of left ventricular ejection 
fraction (Fig. 1). However, the spec­
ificity of the two tests was not 
significantly different.
Diagnostic accuracy combines 
sensitivity and specificity and is cal­
culated as true-positive results plus 
true-negative results divided by the 
total number of patients. The diag­
nostic accuracy of thallium imaging 
(79%) was significantly greater (p < 
0.02) than that of gated blood pool 
scanning (62%) (Fig. 1).
Discussion
The importance of perioperative 
cardiac complications as a cause of 
death and major morbidity after 
arterial repair was noted by Hertz- 
er,1 who followed up 273 patients 
for as long as 11 years after lower 
limb revascularization. He found 
that acute myocardial infarction 
was responsible for 52% of the early 
and 55% of the late postoperative 
deaths. He also reported2 an inci­
dence of severe coronary artery dis­
ease in 25% of 1000 patients who 
presented with peripheral vascular 
disease and had preoperative cardi­
ac catheterization. It has been sug­
gested that cardiac risk is decreased 
by preliminary coronary artery re­
construction.1011 However, coro­
nary arteriography has been criti­
cized because of its high cost and 
invasive complications.
Risk indices have been developed 
by Goldman and colleagues12 and 
modified by others, including 
Detsky and associates.13 In our ex­
perience,14 53 (15.9%) of a series of 
353 patients requiring arterial re­
pair had postoperative cardiac com­
plications. The serious clinical risk 
factors were symptom severity 
(NYHA class III or greater), evi­
dence of previous myocardial infarc­
tion on a resting electrocardiogram, 
nonspecific ST-segment electrocar­
diographic changes and age older 
than 70 years. Similar results were 
reported by Johnston,15 who found 
that 15.1% of patients from a mul­
ticentre series of 666 nonruptured 
aneurysms had postoperative cardi­
ac problems, and that age, previous 
electrocardiograhic evidence of 
myocardial infarction and conges­
tive failure were associated with 
these events.
We have also reported the value 
of exercise testing in the evaluation 
of cardiac risk in vascular surgical
patients.48 Although the exercise 
stress test is an excellent method of 
excluding serious coronary artery 
disease (specificity 89%), its sensi­
tivity is low (23%), because up to 
50% of patients with peripheral vas­
cular disease cannot achieve a suffi­
ciently high exercise level to pro­
duce a positive test. This problem 
of inconclusive electrocardiographic 
test results has also been noted by 
Cutler and colleagues5 and by 
Leppo and associates.16 We believe 
that exercise electrocardiographic 
testing is not very helpful in preop­
erative assessment of patients with 
peripheral vascular disease.8
Dipyridamole thallium imaging is 
a noninvasive test which can be 
performed readily in most patients 
with peripheral vascular disease. Its 
value in these patients was first 
reported by Boucher and associ­
ates,6 who found that 8 of 16 
patients with thallium redistribution 
suffered postoperative cardiac com­
plications compared with none of 
32 patients without thallium redis­
tribution. Leppo and associates,16 in
FIG. 1. Comparison of sensitivity, specificity and diagnostic accuracy of gated blood 
pool scanning (stippled bars) and dipyridamole thallium-201 imaging (black bars) 
for prediction of cardiac complications after aortic surgery. * =  p < 0.02; ** = p < 
0 .01.
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a study of 89 patients, found that 
thallium scanning was superior to 
clinical risk factors and to exercise 
stress testing. The presence of thal­
lium redistribution was the most 
important predictor of serious cardi­
ac events. In a subsequent report by 
Cutler and Leppo,7 60 patients with 
normal thallium scan results had 
aortic repair without myocardial in­
farction or cardiac deaths, com­
pared with an infarction rate of 21% 
in 31 patients with one or more 
areas of thallium redistribution. We 
reported previously8 that dipyrida­
mole thallium scanning had a sensi­
tivity of 86% as a predictor of 
cardiac complications after aortic 
surgery and was clearly superior to 
exercise stress testing.
The measurement of global and 
regional ventricular function by 
gated blood pool imaging was de­
veloped by Strauss and colleagues 
in 1971.9 The test is relatively non- 
invasive, is associated with mini­
mal risk and radiation exposure, is 
reproducible and can readily be re­
peated. Like dipyridamole thallium 
imaging, gated blood pool scanning 
can be applied to almost all patients 
with vascular disease. Left ventricu­
lar ejection fraction has been shown 
to correlate with both early and late 
deaths after acute myocardial in­
farction.17' 20
Pasternack and colleagues21 stud­
ied 50 patients before they under­
went abdominal aortic aneurysm re­
pair and found that the risk of 
postoperative myocardial infarction 
and cardiac death correlated with 
the left ventricular ejection fraction. 
The cardiac death rate was zero 
when the left ventricular ejection 
fraction was greater than 55% and 
20% when the ejection fraction was 
less than 35%.
McCann and colleagues22 evaluat­
ed the influence of left ventricular 
ejection fraction on perioperative 
death in 104 patients who had 
repair of abdominal aortic aneu­
rysms. They found that the periop­
erative death rate was not signifi­
cantly different in patients who had 
an ejection fraction less than 35% 
compared with those whose ejection 
fraction was greater than 35%. 
They concluded that patients 
should not be denied aortic aneu­
rysm repair solely on the basis of a 
low left ventricular ejection frac­
tion.
Our data showed (Fig. 1) that a 
left ventricular ejection fraction less 
than 50% was not a sensitive pre­
dictor of perioperative cardiac com­
plications. The presence of thallium 
redistribution was significantly 
more sensitive (91% versus 27%, p 
< 0.01), with similar specificity. 
The diagnostic accuracy of thallium 
imaging was significantly greater 
than that of gated blood pool scan­
ning.
Postoperative cardiac complica­
tions develop after vascular surgical 
procedures because of severe coro­
nary artery stenosis or left ventricu­
lar dysfunction, or both. Dipyrida­
mole thallium imaging detects sig­
nificant coronary artery stenoses in 
contrast to gated blood pool imag­
ing which assesses left ventricular 
function. Our data suggest that the 
presence of coronary artery disease 
is a more important factor than left 
ventricular dysfunction in the devel­
opment of postoperative cardiac 
complications.
Optimal preoperative evaluation 
of patients who require aortic sur­
gery includes clinical assessment 
and dipyridamole thallium imaging. 
Patients who have a negative scan 
are at low risk and can undergo 
operation without further investiga­
tion. Those with a positive dipyrida­
mole thallium scan should undergo 
coronary arteriography with the 
goal of coronary revascularization if 
the patient has angina or if the 
perfusion defect is extensive, indi­
cating multivessel disease.
In a patient who has a perfusion
abnormality limited to one segment, 
the clinician must consider a num­
ber of factors, including the urgen­
cy of the aortic surgery, the likeli­
hood of benefit from coronary angi­
oplasty or repair over medical treat­
ment, and the additional risk of 
these procedures. Gated blood pool 
scanning is useful to further stratify 
risk in this group of patients.
Conclusions
Dipyridamole thallium imaging of 
myocardial perfusion is superior to 
gated blood pool scanning evalua­
tion of left ventricular function for 
predicting cardiac complications 
after abdominal aortic surgery. It 
should be the initial noninvasive 
test used to screen these patients 
preoperatively.
We acknowledge the technical assis­
tance of Norma Bowman and Lynn 
Vigus, RN, BScN.
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SESAP VI Critique
Item 121
Abdominal computed tomographic (CT) scans are helping to change the management of liver injuries. Small 
intraparenchymal hematomas seen on CT scan in otherwise asymptomatic patients after blunt trauma may be 
managed nonoperatively. Expanding intrahepatic hematomas are best treated by evacuation, direct ligation of 
the bleeding vessels, and adequate drainage when found at operation. Subcapsular rupture may follow an injury 
that appears to be slight, with an interval of several hours or days between the injury and the onset of 
symptoms. Hepatic artery ligation is rarely indicated. Recent evidence suggests that packing the liver wound and 
returning to the operating room three to four days later is a useful technique for an unstable patient whose 
hemorrhage is otherwise uncontrollable.
0
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Chest-Wall Tumours
Between August 1984 and October 1988, 7 women and 16 men underwent 
chest-wall resection. The 23 patients ranged in age from 17 to 79 years. Resection 
was done for benign lesions in 9 patients, for recurrent chest-wall sarcoma in 4 and 
for carcinoma involving the chest wall in 10. The number of ribs resected ranged 
from none to six.
Prosthetic material was required for reconstruction in eight patients. There were 
no operative deaths and no flail segments developed postoperatively. Three patients 
have since died of metastatic disease, one has died of unrelated causes but with no 
residual disease and the remainder were alive and well at follow-up intervals ranging 
from 11 to 60 months. Aggressive resection, including a wide margin of healthy 
tissue, provides the best chance for recurrence-free survival for patients with many 
types of chest-wall tumour. Resection can be performed with low morbidity and 
satisfactory cosmetic results.
Entre aout 1984 et octobre 1988, 7 femmes et 16 hommes ont subi une resection de 
paroi thoracique. L’age des 23 patients s’etalait de 17 a 79 ans. La resection fut 
pratiquee pour des lesions benignes dans 9 cas, pour une recidive d’un sarcome de 
la paroi thoracique dans 4 cas et pour un carcinome envahissant la paroi thoracique 
dans les 10 autres cas. Le nombre de cotes resequees a varie de zero a six.
Du materiel prosthetique a ete requis pour la reconstruction chez huit patients. 
Aucun deces peroperatoire n’a ete enregistre et aucun volet thoracique n’est apparu 
en postoperatoire. Trois patients sont decedes depuis, de metastases, un patient est 
mort de causes non reliees mais sans signe de maladie residuelle, alors que les 
autres sont toujours vivants et en bonne sante, de 11 a 60 mois apres Tintervention. 
Une resection agressive comprenant une large bordure de tissu sain offre la 
meilleure chance de survie sans recidive chez les patients souffrant de plusieurs 
types de tumeurs de la paroi thoracique. Cette resection, qui peut etre pratiquee 
avec une faible morbidity, donne des resultats esthetiques satisfaisants.
Resection and reconstruction of the chest wall is a continuing 
challenge to the thoracic surgeon. 
Indications for chest-wall resection 
include primary benign tumours 
and tumour-like lesions, primary 
chest-wall sarcomas, neoplasms 
metastatic to chest wall, direct ex­
tension to chest wall by otherwise 
operable bronchogenic carcinomas 
(stage Ilia) and loss of chest-wall
Accepted for publication Oct. 12, 1989
integrity because of congenital 
anomalies, traumatic injury, ra­
dionecrosis or chronic infection.1-10 
The two basic goals of chest-wall 
resection are to treat the underlying 
lesion adequately and to provide a 
repair that is stable enough for 
respiratory function, sturdy enough 
to protect chest contents and cos­
metically acceptable.
We present our experience with
chest-wall resection and reconstruc­
tion at the Vancouver General Hos­
pital.
Patients and Methods
Between August 1984 and Octo­
ber 1988, chest-wall tumours were 
removed from 16 men and 7 women 
who ranged in age from 17 to 79 
years. Chest-wall resection, defined 
as resection of bone and muscle, 
was performed in 21 patients. Com­
puted tomography (CT) of the chest 
and bone scanning were carried out 
preoperatively in all 23 patients. In 
nine patients involvement of the 
chest wall by bronchogenic carcino­
ma was suspected; mediastinoscopy 
and surveys for metastasis were 
carried out, but preoperative chest- 
wall biopsy was not done. Eight of 
the remaining 14 patients had pre­
operative biopsy of their chest-wall 
lesion, as described below. All CT 
scans were reviewed by one of us 
(N.L.M.) and resected specimens 
were reviewed by another (R.R.M.).
Results
Nine patients had resection for 
benign lesions (Table I). Seven of 
these were symptomatic. Two pa­
tients had fibromatosis that was not 
associated with rib destruction. Fol­
lowing wide excision and Prolene- 
mesh reconstruction, cosmetic and 
functional results were excellent. 
Five patients had radiologic evi­
dence of bone destruction; three 
were thought preoperatively to have 
malignant disease, but needle-
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aspiration biopsies were not diag­
nostic (Table I). Four had local 
excision only. One patient was 
treated with wide excision when 
intraoperative analysis of a frozen 
section suggested a necrotic tu­
mour; the interpretation was erro­
neous. The two patients with 
asymptomatic peripheral nerve 
sheath tumour had excisional biop­
sy only. No patient with a benign 
lesion has experienced recurrence.
Four patients underwent resec­
tion for recurrent chest-wall sarco­
mas (Table I). All had radiologic 
evidence of bone destruction and a 
chest-wall mass on physical exami­
nation. In two patients biopsy was 
done before wide excision to con­
firm the diagnosis. The three pa­
tients with recurrent chondrosar­
coma had undergone local excision,
4, 24 and 34 months previously. 
The fourth patient had experienced 
multiple recurrences of malignant 
fibrous histiocytoma of the shoul­
der which ultimately required en 
bloc forequarter and apical chest- 
wall resection. All patients required 
reconstruction of the chest wall 
with Prolene; all were free of recur­
rence from 17 to 26 months after 
operation.
Ten patients had carcinoma in­
volving the chest wall (Table II). 
Nine underwent pulmonary resec­
tion for bronchogenic carcinoma 
with en bloc removal of adjacent 
ribs for suspected chest-wall inva­
sion. Five lobectomies and four 
pneumonectomies were performed. 
Three patients had radiotherapy to 
the chest wall preoperatively; none 
had adjuvant therapy postoperative­
ly. Intraoperatively in each case, 
when no extrapleural plane of dis­
section was found, two to five over- 
lying ribs had to be removed. Al­
though only two of these nine pa­
tients had CT evidence of chest-wall 
invasion preoperatively, at opera­
tion tumour was found to involve 
bone or soft tissue, or both, of the 
chest wall in all but one. The tenth 
patient had an isolated rib metasta­
sis. Two of the 10 patients required 
Prolene mesh reconstruction; the 
defects in the other 8 were post- 
erosuperior and protected by the 
scapula. Three of these 10 patients 
died of tumour, the other 7 were 
alive and well at follow-up from 11 
to 60 months after operation. There 
were no operative deaths, no flail 
segments and no wound complica­
tions postoperatively.
Table 1. P atien ts  W h o  Had M e s e n ch ym a l C h est-W a ll L e s ion s
Patient
no. Sex Age, yr Symptoms Biopsy type Diagnosis
No. ribs 
resected Follow-up, mo
B en ig n
1 M 29 M ass IB D e sm o id  tu m o u r 6 17
2 F 35 M ass IB D e sm o id  tu m o u r 2 46
3 F 33 N one N one P erip h e ra l ne rve  shea th  tu m o u r 0 50
4 M 65 N one N one P erip h e ra l ne rve  shea th  tu m o u r 0 14
5 F 40 Pain FNA F ib ro us  d ys p la s ia 1 28
6 M 17 Pain None U n ic a m e ra l bone c y s t 1 21
7 F 52 Pain None E o s in o p h ilic  g ra n u lo m a 1 50
8 M 32 Pain FNA T u b e rc u lo s is 4 50
9 M 33 Pain FNA T u b e rc u lo s is 1 15
M a lig n a n t
10 M 62 M ass FNA R e cu rre n t ch o n d ro sa rc o m a 3 21
11 F 69 M ass Needle R e cu rre n t ch o n d ro sa rc o m a 3 20
12 M 67 M ass None R e cu rre n t c h o n d ro sa rc o m a 5 26
13 M 72 M ass None R e cu rre n t m a lig n a n t f ib ro u s  h is t io c y to m a 4 17
IB =  in c is io n a l b io p sy , FN A =  f in e -n e e d le  a s p ira tio n  b io p sy .
Table II. P a tie n ts  W h o  Had C a rc in o m a s  In vo lv in g  th e  C hest W a ll
Patient
no. Sex Age, yr Symptoms
Preoperative
radiotherapy Diagnosis
No. ribs 
resected Follow-up, mo
14 M 66 Pain No A d e n o ca rc in o m a , T 3N 0 4 2 *
15 M 54 Pain No S q u a m o u s  ca rc in o m a , T3N1 3 3 2 *
16 M 67 N one No S q u a m o u s  ca rc inom a , T3N1 2 38
17 F 56 Pain No A d e n o ca rc in o m a , T3N 0 2 36
18 M 40 None No L a rge  ce ll ca rc inom a , T 2N 0 5 16
19 M 46 Pain No S q u a m o u s  ca rc in o m a , T 3N 2 3 11
2 0 M 79 Pain Yes S q u a m o u s  ca rc in o m a , T 3N 0 3 11
21 M 55 Pain Yes A d e n o ca rc in o m a , T3N 0 3 2 0 *
2 2 F 44 Pain Y es A d e n o ca rc in o m a , T3N 0 4 60
2 3 M 46 M ass No M e ta s ta tic  m a lig n a n t m ixed  tu m o u r 3 16
'D ie d  o f  d isease .
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Discussion
The features of primary chest- 
wall mesenchymal lesions are de­
scribed in several series.1' 7 Overall, 
approximately half of such lesions 
are malignant. In those series, as in 
ours, clinical features such as pain 
or a palpable mass were unreliable 
for distinguishing benign from ma­
lignant processes. Relatively com­
mon benign tumours include chon­
dromas, osteochondromas and fi­
brous dysplasia.1’27 Extensive fi­
bromatosis of the chest wall is less 
common6 and tuberculomas defying 
pre-excisional diagnosis are unusu­
al.2 Except in the instance of fi­
bromatosis, local excision of benign 
tumours is generally considered to 
be adequate and is associated with a 
low risk of recurrence.1'2,6
Malignant mesenchymal chest- 
wall neoplasms are more difficult to 
manage. Fibrosarcoma of soft tissue 
and osteosarcoma and chondrosar­
coma of bone23'56 are the most 
common types in adults. The treat­
ment of choice for fibrosarcoma and 
osteosarcoma is radical excision 
with adjuvant chemotherapy.2 
These series clearly show that the 
best chance for survival in patients 
with such lesions is wide excision at 
the time of presentation. Complete 
initial excision of relatively well-dif­
ferentiated osteo-, chondro- and fi­
brosarcomas is associated with a 
long-term survival of approximately 
90%.4'6 However, late recurrence is 
associated with a high risk of death.
In contrast, there are several 
types of primary chest-wall malig­
nant disease in which primary sur­
gical resection is not indicated and 
definitive treatment starts with che­
motherapy or radiotherapy, or both. 
These include lymphoma, Ewing’s 
sarcoma, rhabdomyosarcoma and 
solitary myeloma of bone.2 8 9
The dilemma facing the thoracic 
surgeon is what approach to use in 
a patient with an unknown diagno­
sis so that the procedure is neither 
unnecessarily radical nor so inade­
quate as to risk recurrence. The 
solution to this dilemma is contro­
versial. Fine-needle aspiration 
serves mainly to confirm a specific 
diagnostic impression rather than 
to establish a firm primary diagno­
sis. Similarly, core needle biopsy 
provides insufficient material for a 
specific primary diagnosis.8 Al­
though there are advocates of wide 
excision for all lesions,7 most inves­
tigators recommend excisional biop­
sy followed by wide resection at a 
later date, depending on the histo­
logic diagnosis.1’2 6-8 For very large 
lesions in which excisional biopsy is 
not feasible, generous incisional bi­
opsy is recommended.8
Clinical, diagnostic, surgical and 
prognostic considerations for pa­
tients with bronchogenic carcinoma 
involving the chest wall differ from 
those for patients with primary 
mesenchymal chest-wall lesions. In 
our series, seven of eight patients 
who had chest-wall invasion had 
pain, but none had a palpable mass. 
This finding is in agreement with 
the experience of others.1011 We 
found that CT was insensitive for 
assessing chest-wall invasion;12 two 
series1011 reported radiologic evi­
dence of bone or chest-wall invasion 
in approximately 40% of cases in 
which resection of the overlying 
chest wall was required. Chest-wall 
biopsy is not indicated in patients 
with possible stage Ilia broncho­
genic carcinoma.
Like Patterson and colleagues11 
and unlike Grillo and asssociates10 
we have not included in this series 
cases of parietal pleural dissection 
without sacrifice of bone and mus­
cle. It is crucial that tumour not be 
left behind at the resection margins 
of pleural and chest wall in cases of 
resected T3 bronchogenic carcino­
ma. Grillo and colleagues10 in fact 
recommend chest-wall resection 
rather than extrapleural dissection
for T3 bronchogenic carcinoma be­
cause in their series it provided the 
best chance for long-term survival 
and also better palliation; our ap­
proach is less aggressive.
Intraoperatively, we decide to re­
sect overlying chest wall on the 
basis of whether or not an extra­
pleural dissection plane can readily 
be achieved. If there is any difficulty 
in establishing such a plane, wide 
excision of the adherent chest wall 
is performed. In eight of our nine 
cases of bronchogenic carcinoma, 
the surgical impression of tumour 
invasion of chest wall proved cor­
rect; the other case was fibrous 
adhesions negative for malignant 
disease. The number of ribs sacri­
ficed en bloc (two to five) in our 
series was comparable to that of 
others (one to five).11
The question of preoperative and 
postoperative radiotherapy in such 
patients is not resolved. Although 
postoperative radiotherapy is used 
by some surgeons,1011 we prefer to 
apply radiotherapy, if appropriate, 
to tissues that will later be resected 
and to avoid the potential for post­
operative radiation to damage the 
residual lung tissue filling the in­
volved hemithorax. The prognosis 
for patients with bronchogenic car­
cinoma involving the chest wall is 
by no means hopeless. In the series 
of Grillo and colleagues,10 for pa­
tients undergoing chest-wall resec­
tion, the 4-year survival rate was 
16%. In the Toronto series,11 the 
5-year survival rate was 38%. In a 
Mayo Clinic series,6 in which the 
median follow-up was 31.5 months, 
54% of patients were survivors. In 
our series, five of eight patients 
with resected T3 bronchogenic car­
cinoma were free of tumour al­
though in only three of them was 
the follow-up longer than 2 years.
Wide excision of the chest wall is 
generally defined67 as complete re­
moval of involved rib(s), portions of 
the ribs immediately above and
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below the area of involvement and 
all adherent muscle, pleura and 
lung. We strongly advise wide exci­
sion for all malignant chest-wall 
tumours. In our series, three of the 
recurrent sarcomas resulted from 
previous excisions that were inade­
quate. Resection of the entire in­
volved rib is recommended for pri­
mary rib sarcomas.
Wide excision would often be 
impossible were it not for methods 
of chest-wall reconstruction.5-613' 17 
Unless the bone defect is covered by 
the scapula, resection of four or 
more ribs usually requires bone 
reconstruction to prevent flail seg­
ments.14 Such reconstructions may 
be achieved by a variety of prosthe- 
ses. Marlex mesh is a single-stitch 
knit polypropylene material6 that 
can be used as a single layer,16 as a 
double layer11 or as a “sandwich” 
enclosing a solid layer of hardened 
methyl methacrylate.5-15 Prolene 
mesh is a double-stitch knit poly­
propylene material6 that is more 
rigid than Marlex and which we and 
others6-13-17 prefer.
In the event that extensive over- 
lying skin and subcutaneous tissue 
must be sacrificed, soft-tissue repair 
with myocutaneous or omental 
flaps provide functionally accept­
able results.14 Soft-tissue repair was 
unnecessary for the 23 patients in 
this series.
From a subjective standpoint, the 
cosmetic results following wide ex­
cision and reconstruction were sat­
isfactory in this series. The func­
tional results in terms of respiratory 
mechanics and chest-wall stability 
were also satisfactory.
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Everybody's now into activity 
and healthy eating, doggone it! 
We think you should be too!
Make your move.
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Abdominal Tuberculosis
Sabah Al-Hadeedi, MB, FRCSI; H.S. Walia, MB, MS, FRCS(Edin), FRCS;
Hilal M. Al-Sayer, MB, ChM, FRCS
Forty-two cases of abdominal tuberculosis seen between June 1984 and June 1988 at 
Amiri Hospital in Kuwait were reviewed retrospectively. The clinical diagnosis was 
correct in only 35%. Nine patients presented as an emergency, but in none was a 
diagnosis of tuberculosis considered. Abdominal pain and tenderness were the 
commonest clinical findings; “doughy abdomen” and a mass in right iliac fossa were 
uncommon. Thus, symptoms were vague, signs nonspecific and investigations 
nonpathognomonic. In spite of this, abdominal tuberculosis should be considered in 
any patient who has obscure abdominal symptoms, weight loss and lethargy. 
Laparoscopy and colonoscopy with biopsy for histologic and bacteriologic study led 
to a definitive diagnosis in 66% of cases, obviating the need for exploratory 
laparotomy in many. Histologic examination was the surest way to establish the 
diagnosis.
Quarante-deux cas de tuberculose abdominale vus entre juin 1984 et juin 1988 a 
l’hopital Amiri, au Koweit, ont fait l’objet d’une etude retrospective. Le bon 
diagnostic clinique fut pose dans seulement 35% des cas. Neuf patients etaient des 
cas d’urgence; pas une fois, le diagnostic de tuberculose fut entretenu. La sensibilite 
et la douleur abdominales etaient les signes cliniques les plus frequents; la presence 
d’une “abdomen pateux” et d’une masse dans la fosse iliaque droite etaient des 
observations frequentes. Les symptomes etaient done vagues, les signes non 
specifiques et les examens non pathognomoniques. Neanmoins, une tuberculose 
abdominale devrait etre envisagee chez les patients qui se plaignent de symptomes 
abdominaux obscurs, de perte de poids et de lethargie. Une laparoscopie et une 
colonoscopie avec biopsie pour examens histologique et bacteriologique ont permis 
d’arriver a un diagnostic definitif dans 66% des cas, ce qui a permis d’eviter, pour 
plusieurs, une laparotomie exploratrice. L’examen histologique s’est avere le moyen 
le plus fiable pour etablir le diagnostic.
At the turn of the century, Walsh1 stated that it was im­
possible to diagnose abdominal tu­
berculosis with any degree of cer­
tainty. Unfortunately, this remains 
true, even in situations in which 
abdominal tuberculosis is relatively 
common. The number of cases of 
abdominal tuberculosis has fallen
rapidly in developed countries, but 
the disease continues to be a major 
scourge in developing countries. 
The symptoms are vague, signs 
nonspecific and investigations are 
nonpathognomonic, so many pa­
tients require a diagnostic laparoto­
my, even though tuberculosis is 
rarely an emergency.2 Abdominal
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tuberculosis is often forgotten, es­
pecially when pulmonary disease is 
absent.3 Overemphasis on the pres­
ence of an abdominal mass or 
“doughy” abdomen, coupled with 
the insidious nature of the disease, 
reduces suspicion further.4 An accu­
rate diagnosis of abdominal tuber­
culosis is important because chemo­
therapy alone has been proven sat­
isfactory5 and a definitive diagnosis 
would obviate an exploratory lapa­
rotomy.
In this paper, we emphasize how 
often abdominal tuberculosis is un­
suspected, the pitfalls in diagnosis 
and the use of emerging endoscopic 
modalities.
Patients and Methods
The records of 42 patients (26 
men, 16 women) who had abdomi­
nal tuberculosis and were seen at 
Amiri Hospital in Kuwait between 
June 1984 and June 1988 were 
studied retrospectively. They repre­
sented 1.05% of all admissions to 
the surgical department. Tuberculo­
sis of the abdomen was diagnosed if 
the following were present.
•  Histologic evidence of caseat- 
ing granulomas.
•  Histologic demonstration of 
acid fast bacilli (AFB) in the lesion 
or lymph nodes.
•  Growth of AFB on culture of 
tissue or in ascitic fluid.
•  Typical macroscopic appear­
ance at operation with mesenteric 
glands showing caseating granulo­
mas or AFB.
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•  Typical picture with non- 
caseating granulomas but proven 
tuberculosis elsewhere.
•  Typical gross appearance of 
bowel with positive response to che­
motherapy without subsequent re­
currence.
Specimens were examined for 
bacteria using standard laboratory 
techniques. The tubercular skin test 
(Mantoux test, 1 in 1000) was inter­
preted as positive if 10 mm or more 
of induration was measured or if it 
was recorded positive.
All patients underwent operation 
or laparoscopy. Starting on postop­
erative day 2, they received two or 
three antitubercular drug regimens 
consisting of streptomycin, rifam- 
picin, isonicotinic acid hydrazide, 
ethambutol or pyrazinamide, and 
this was continued for 9 to 12 
months.
Findings
Of the 42 patients, 16 were Ku­
waitis, 16 were from the Indian 
subcontinent, 3 were Egyptians and 
the remaining 7 were from other 
Arab countries. The average age 
was 38.6 years (range from 22 to 
70 years).
Nine patients presented with 
acute abdominal symptoms and re­
quired emergency surgery shortly 
after admission. In none of these 
was the diagnosis of abdominal tu­
berculosis entertained (Table I). 
Nine other patients underwent diag­
nostic laparotomy and only in four 
was tuberculosis suspected. In most 
of the other cases either Crohn’s 
disease, lymphoma or other intra­
Table 1. Provisional Diagnosis in Patients 
Who Had Emergency Surgery
Diagnosis No.
Perirenal abscess 1
Intestinal obstruction 2
Acute appendicitis 3
Peritonitis 2
Subphrenic abscess 1
abdominal malignant disease was 
considered (Table II). In 12 patients 
abdominal tuberculosis was diag­
nosed unexpectedly when surgery 
was performed for another indica­
tion.
The duration of symptoms 
ranged from 6 hours to 4 years 
(mean 3.6 months). The majority of 
patients (71%) had localized abdom­
inal pain. Other common symptoms 
(Table III) were vomiting, anorexia, 
weight loss and pyrexia, followed in 
frequency by night sweats, abdomi­
nal distension and diarrhea. Tender­
ness, with or without rigidity, was 
the commonest sign, especially in 
those who had acute symptoms. 
Anemia and malnutrition were next. 
An abdominal mass was found in 
six cases; in four it occurred in the 
right iliac fossa and in the other 
two in the left hypochondrium and 
right renal area.
The erythrocyte sedimentation 
rate was elevated (more than 25 
mm/h) in all patients except the 12 
whose tuberculosis was found inci­
dentally, in whom the rate was 
normal (8 to 20 mm/h). In eight
patients the rate exceeded 100 
mm/h. The hemoglobin level was 
below 100 g /L  in 17 patients, 6 of 
whom had macrocytic anemia sec­
ondary to vitamin B12 deficiency. 
Surprisingly, all the patients who 
had acute symptoms had leukocyto­
sis (more than 11.0 X 109/L). The 
Mantoux test was positive in only 
30% of patients.
Thirty-nine of the 42 patients 
had no evidence of pulmonary dis­
ease on chest x-ray examination. 
The others had a picture compatible 
with healed lung lesions, pleural 
effusion and mediastinal lymph- 
node enlargement, respectively. A 
plain abdominal x-ray film, obtained 
in 25 cases, showed nonspecific 
changes such as small-bowel fluid 
levels, with or without ascites, dif­
fuse calcifications or localized ab­
scess. Contrast studies, carried out 
in 22 patients, included barium 
meal in 10 patients, with follow- 
through in 5, and barium enema 
examination in 7. The lesions iden­
tified were as follows: esophageal 
tuberculosis in one, duodenal stric­
ture in one, small-bowel stricture in
Table II. Preoperative Diagnosis in Patients Who Had Elective Laparotomy
Crohn’s disease or tubercular stricture of duodenum
Right iliac fossa mass: tuberculosis or Crohn’s disease of colon
Lymphoma of the abdomen
Carcinoma of the head of the pancreas
Tuberculosis or carcinoma of the colon
Chronic appendicular abscess
Ileocecal tuberculosis
Stricture in the ascending colon, malignant disease or Crohn's disease 
Cholangiocarcinoma
Table III. Presenting Clinical Features
Symptoms No. (%) Signs No. (°/»)
Upper abdominal pain 17 (40) Malnutrition 14 (33)
Lower abdominal pain 13 (31) Anemia 17 (40)
Weight loss 22 (52) Lymph nodes 2 (5)
Anorexia 19 (45) Tender abdomen 24 (57)
Fever 14 (33) “ Doughy”  abdomen 4 (10)
Diarrhea 8 (19) Visible peristalsis 3 (7)
Vomiting 24 (57) Ascites 8 (19)
Distension 10 (24) Palpable liver 5 (12)
Night sweats 10 (24) Rigidity 9 (21)
Constipation 3 (7) Mass: Right iliac fossa 4 (10)
Jaundice 3 (7) Other 2 (5)
Melena 3 (7) Pleural effusion 1 (2)
Hematemesis (hemobilia) 1 (2) Hip flexion deformity 1 (2)
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two, ileocecal deformity in five and 
proximal colonic deformities in 
four. Ultrasonography and comput­
ed tomography were done in 30 
cases but did not add to the find­
ings of conventional radiology, ex­
cept in three patients. In one, an 
abdominal mass was shown to 
“melt” under antitubercular chemo­
therapy. In the second, the two 
investigations confirmed the origin 
of a gluteal sinus from the retroper­
itoneal lymph nodes and in the 
third, they established the percuta­
neous drainage in a case of psoas 
abscess.
Twenty-four patients underwent 
various endoscopic procedures. Six 
had upper gastrointestinal endosco­
py and biopsy which gave a diagno­
sis in two (one lesion each in esoph­
agus and duodenum). Seven of 11 
colonoscopies were positive, but 
surgery was avoided in only two 
cases. Laparoscopy was the most 
successful procedure, being positive 
in all seven cases, and thus avoiding 
surgery in all.
The accuracy of clinical diagnosis 
was only 38%. In all patients, the 
diagnosis was confirmed histologi­
cally from peritoneal tubercles,
Table IV. Operative or Laparoscopic 
Findings of Tissue Involvement in 42 
Patients
Finding No.
Gastrointestinal involvement
Esophageal 1
Duodenal 1
Stomach 1
Small intestinal 5
Appendiceal 2
Ileocecal 5
Colonic/rectal 4
Perianal 3
Peritoneal or lymph-node 
involvement
Peritoneal tubercles 10
Lymphadenopathy 17
Paradochal lymph nodes 2
Adhesive 3
Subphrenic 1
Other organ involvement
Pancreatic 1
Hepatic 9
Gallbladder 1
Omental 2
lymph nodes or resected specimens, 
or by demonstration of AFB in 
tissues or smears and cultures. 
Table IV shows the tissues or or­
gans involved in the tubercular 
process.
All three patients who died had 
associated serious disease. One had 
leiomyosarcoma of the stomach 
with a single secondary tumour in 
the right lobe of the liver. Radical 
gastrectomy and right hepatectomy 
were performed. The liver was 
found to be packed with caseating 
granulomas. The patient had hemo- 
bilia from one of the tuberculomas 
after disseminated intravascular co­
agulation developed. The second 
patient was operated on for cirrho­
sis of the liver. A Sugiura proce­
dure was performed. Liver biopsy 
showed multiple caseating granulo­
mas. Antitubercular treatment was 
started, but a subphrenic abscess 
developed and the patient died 8 
weeks after operation. The third 
patient had radical gastrectomy for 
carcinoma of the stomach. The 
stomach and enlarged lymph nodes 
along the lesser curve contained 
caseating granulomas. This patient 
received antitubercular treatment in 
addition to chemotherapy for carci­
noma. She died 1.5 years later of 
metastatic disease.
Discussion
With socioeconomic progress, 
the prevalence of tuberculosis has 
declined in the West but remains a 
common disease in developing 
countries. The incidence of gas­
trointestinal tuberculosis complicat­
ing pulmonary disease has been 
reported to range from 5%, possibly 
due to antitubercular chemothera­
py,6 to 70%.7-9 In contrast, abdomi­
nal tuberculosis at our hospital is 
almost never associated with pul­
monary disease, and this has been 
confirmed by others.210
Although it is generally believed 
that abdominal tuberculosis is more 
common in women than in men, 
our ratio was 1:1.6. Kaufman and 
Donovan11 and Khoury and associ­
ates12 reported a similar predomi­
nance. The mean age of our pa­
tients (38.6 years) is similar to that 
reported by Howell and Knapton13 
and Wales and colleagues14 but is 
considerably more than that report­
ed by Addison15 and Walsh.1
Tuberculosis may infect the gas­
trointestinal tract through blood, 
lymphatics or by direct extension; 
most infection results from swal­
lowing infected sputum. But a 
change in pattern with greater pre­
dominance of nonpulmonary disease 
has been reported by Schofield.16 
The 42 cases of gastrointestinal 
tuberculosis in this series included 
few (only 5) cases of ileocecal in­
volvement in contrast to earlier re­
ports.141517 Disease higher up in the 
ileum is considered common (but 
not in our series), involvement of 
jejunum and appendix uncommon, 
and tuberculosis of colon, rectum 
or upper gastrointestinal tract is 
rare.14151819 Tubercular peritonitis 
often follows blood-borne spread 
from near or remote infection sites 
or locally from the lymph nodes, 
bowel or female reproductive or­
gans. Concomitant lesions of bowel 
and peritoneum were uncommon in 
our study and that reported by 
Gonnella and Hudson.20
The duration of symptoms of 
abdominal tuberculosis before the 
diagnosis is made range from 1 year 
or less up to 3 years.21' 24 Although 
symptoms are nonspecific, the dis­
ease should be considered in any 
patient who has obscure abdominal 
symptoms with lethargy and weight 
loss. Physical findings are also non­
specific.1921 Although an abdominal 
mass is cited historically as the 
most common finding,71419 21 it was 
noted in only six (14%) of our 
cases. Twelve of our patients had
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no complaints and the diagnosis 
was made during unrelated surgery.
Most investigations were of little 
help. The Mantoux test was positive 
in only 30% of the patients, a rate 
similar to that reported by Find­
lay.25 Like Shukla and Hughes,10 we 
observed a strong association be­
tween a markedly positive test and 
intra-abdominal tuberculosis. The 
erythrocyte sedimentation rate was 
elevated above 100 mm/h in about 
19% of the cases and more than 25 
m m /h in 70% of the patients but 
was normal in the other 30%. Allen 
and associates26 also noted a normal 
rate in 25% of cases. The leukocyte 
count was normal in all except 
emergency cases. A further 40% of 
our patients were anemic, and 33% 
had m alnutrition and hypo- 
proteinemia. Although a histologic 
diagnosis was obtained in all pa­
tients, only three had demonstrated 
AFB and five were reported to have 
positive cultures. This low yield has 
also been reported by Prakash and 
colleagues27 and Lambrianides and 
associates.2
Homan and associates3 stated 
that negative findings on the chest 
x-ray film are sufficient to exclude 
abdominal tuberculosis whereas 
Sharma and colleagues24 and Shuk­
la and Hughes,10 like us, recorded a 
very small number of patients with 
pulmonary disease. Similarly, radi­
ologic appearances on contrast 
studies of the gut are often sugges­
tive, but seldom diagnostic, of tu­
berculosis. The changes seen are 
secondary to inflammatory masses, 
thickening of bowel wall, ulceration 
or fistulization of the gut.
In our series, ultrasonography 
and computed tomography were not 
especially helpful in making the 
diagnosis of abdominal tuberculo­
sis. This finding is in contrast to 
that of Zirinsky and colleagues.28
Confirmation of the diagnosis re­
mains the main problem in the 
management of abdominal tubercu­
losis. There are no diagnostic clini­
cal features, but awareness on the 
part of the physician will lead to an 
accurate clinical diagnosis in 38% 
of cases, as in our study and that of 
Hoon and colleagues.9 Das and 
Shukla7 and others29 have quoted a 
higher figure of 50%. Histologic 
examination or culture of tissue are 
the only tests that will clearly sepa­
rate abdominal tuberculosis from 
Crohn’s disease, carcinoma of colon 
and small-bowel lymphoma.
Many authors believe that lapa­
rotomy and biopsy are necessary 
arbiters in the final diagnosis of 
abdominal tuberculosis, thus the 
rate of laparotomy in many studies 
is high.2121619 Also, up to 50% of 
patients may have acute manifesta­
tions1719 necessitating emergency 
surgery. But this course should not 
be followed lightly, as a 20% death 
rate was noted by Bhansali.19 In our 
study, emergency surgery was car­
ried out in 26% of cases, a figure 
similar to that of others,2 and there 
were no deaths in this group.
The role of endoscopy in diagnos­
ing obscure abdominal conditions 
was accepted reluctantly, but has 
been used increasingly in surgical 
practice. The importance of increas­
ing diagnostic accuracy by obtain­
ing multiple biopsies from suspect­
ed lesions lies in avoiding a diag­
nostic laparotomy. Laparoscopy and 
colonoscopy coupled with histolog­
ic and bacteriologic examinations 
have emerged as the best diagnostic 
approach. Udwadia is credited with 
a personal series of 321 laparosco­
pies, as a result of which 218 
patients had their diagnosis con­
firmed and tubercles were seen in 
206.15 Wolfe and colleagues30 re­
corded 8 positive biopsies out of 11; 
we had 7 positive biopsies out of 7 
on laparoscopy. The role of colo­
noscopy in colonic tuberculosis was 
established by Aoki and col­
leagues.31 Hoshino and associates32 
reviewed the literature and found a
50% yield for colonoscopic biopsies, 
utilizing both culture and histologic 
findings. We had positive results in 
7 of 11 colonoscopies, similar to 
Breiter and Hajjar’s33 8 positive 
results out of 12. Thus, endoscopic 
procedures were successful in 66% 
of our cases (Table V) and surgery 
was avoided in many.
The therapeutic approach to ab­
dominal tuberculosis has undergone 
much change during the last de­
cade. Laparotomy and extensive re­
section34 is being replaced by a 
more medically oriented approach. 
Our current policy is to recommend 
a triple drug therapy for 9 to 12 
months. With effective antitubercu- 
lar therapy, the death rate has 
decreased markedly.2,12
Conclusions
Abdominal tuberculosis in its di­
verse forms still affects the local 
and immigrant population in Ku­
wait. Symptoms are vague, signs 
nonspecific and investigations non- 
pathognomonic. Caseation or de­
monstration of AFB remains the 
hallmark of diagnosis. Accurate di­
agnosis is important in avoiding 
unnecessary laparotomy. Laparos­
copy and colonoscopy are the diag­
nostic modalities of choice in pa­
tients with suspected abdominal tu­
berculosis.
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Post-traumatic Microvascular 
Reconstruction: Toronto’s 500th 
Reattachment
David P. Ewart, BSc;* Ronald M. Zuker, MD, FRCSC, FACS
The authors describe a case of a severe crush injury in a 28-year-old man, whose left 
hand was caught in a punch press. Several carpal bones and all structures at the 
wrist except the extensor tendons were destroyed. The hand was totally denervated 
and devascularized. This case represents the 500th reattachment performed by the 
University of Toronto microvascular team. The authors review the operative 
technique and discuss the functional results 9 months after operation followed by a 
rigorous program of rehabilitative therapy.
Les auteurs decrivent un cas de fracture grave par ecrasement chez un homme de 28 
ans dont la main gauche fut happee par une presse a emporte-piece. Plusieurs os 
carpiens et toutes les structures du poignet, a l’exception des tendons extenseurs, 
avaient ete detruits. La main avait perdu toute innervation et etait totalement 
devascularisee. C’etait le 500eme cas de reimplantation pratiquee par l’equipe de 
microchirurgie vasculaire de l’Universite de Toronto. Les auteurs passent en revue 
la technique operatoire et commentent les resultats fonctionnels 9 mois apres 
l’operation qui fut suivie d’un rigoureux programme de readaptation.
The first reported successful re­plantation was of the arm of a 
12-year-old boy. The procedure was 
performed in 1962 by Malt and 
McKhann.1 The first reported re­
plantation in Toronto was that of a 
single digit, and was performed in 
1973 by R.T. Manktelow (personal 
communication). Since then, mi- 
crosurgical and reconstructive tech­
niques have advanced considerably, 
allowing for the salvage of a variety 
of amputated extremities. To date, 
over 500 such replantations and 
revascularizations have been per­
formed in Toronto. Toronto’s mi­
crovascular team now consists of 
Drs. Ralph Manktelow, Ronald Zuk­
er, James Mahoney, Nancy McKee, 
Vaughan Bowen and Howard 
Clarke and is cooperatively based at 
St. Michael’s Hospital, Toronto 
General Hospital and The Hospital 
for Sick Children.
Replantation of the hand remains 
one of the most important areas of 
reconstructive surgery. A poor 
functional result may be worse for 
the patient than a complete amputa­
tion. We present the case of a
devastating injury to the hand, 
which demonstrates the postopera­
tive results that can be obtained by 
current surgical techniques and 
postoperative therapy.
Case Report
A 28-year-old left-handed ma­
chinist sustained a major crush in­
jury to his left hand while working 
with a punch press. On arrival at 
the emergency department of the 
local hospital, the injury was found 
to involve the wrist and proximal 
palm. Multiple fragments of alumi­
num, which was in use on the 
press, were embedded in the palm, 
dorsum and wrist. The wound wa? 
also heavily contaminated with 
grease. The hand was totally devas­
cularized and remained attached to 
the forearm only by the remaining 
extensor tendons. He was stabi­
lized, resuscitated and transferred 
to Toronto General Hospital for 
assessment by the microvascular 
team for possible replantation.
On his arrival he was taken to 
the operating room. Any decision to 
attempt revascularization and sal­
vage was deferred until the injury 
could be properly evaluated. The 
patient was intubated and given a 
general anesthetic. A Foley catheter 
and right radial artery catheter were 
introduced. An inflatable tourniquet 
was applied to the left upper arm 
and inflated to 250 mm Hg. Exten-
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sive irrigation and debridement 
were carried out; the fragments of 
aluminum required mechanical re­
moval. Assessment of the wound 
revealed that all the carpal bones, 
excluding portions of the scaphoid 
and hamate, were destroyed. All the 
flexor tendons and the median and 
ulnar neurovascular bundles had 
been transected. The thenar muscu­
lature had been completely de­
stroyed. There was also a partial 
degloving over the dorsum of the 
hand. The few structures that re­
mained intact were the extensor 
pollicis longus and extensor com­
munis tendons, and a small dorsal 
vein in the snuff-box region. Preop­
erative x-ray films also showed frac­
tures of all four metacarpals (Fig. 
1). It was decided to attempt sal­
vage. Proximal and distal vessel, 
nerve and tendon ends were identi­
fied and labelled.
Bony fixation was achieved by 
first trimming the remaining carpal 
bones and bases of the last four 
metacarpals, to provide a surface
FIG. 1. Extensive carpal damage and 
metacarpal fractures. Multiple alumi­
num fragments are embedded in soft 
tissues.
for wrist fusion. Longitudinal K 
wires were then used to fix the first 
four metacarpals to the distal radi­
us. The first metacarpal required 
two K wires to prevent rotational 
instability. A bone graft, from the 
debrided carpal bones, was placed 
around the fusion area (Fig. 2).
Revascularization of the hand 
began with anastomosis of the 
ulnar artery, using the operating 
microscope and 10-0 nylon inter­
rupted sutures. This provided good 
circulation to the three ulnar digits 
but was insufficient to perfuse the 
thumb and index finger properly. 
The radial artery was therefore 
anastomosed to a distal arterial 
branch in the volar first web space, 
again with 10-0 nylon sutures. As 
well, the ulnar digital artery to the 
thumb was anastomosed to the ar­
terial palmar arch, originating from 
the ulnar artery, at the mid-palm. 
Adequate perfusion of all digits was 
thereby obtained.
The single remaining vein in the 
snuff-box area did not provide ade-
FIG. 2. Bony fixation has been ob­
tained. K-wires were used to secure 
first four metacarpals to radial head.
quate drainage and there was evi­
dence of venous hypertension. Vein 
stumps in the ulnar area of the 
wrist were anastomosed using a 
small vein graft from the forearm.
Tendon repairs were facilitated by 
a Mason-Alien type stitch, which 
had been placed in the tendon ends 
at the time of identification and 
labelling. The four profundus ten­
dons were connected first, followed 
by the superficialis, flexor pollicis 
longus and extensor digiti minimi.
Both motor and sensory branches 
of the median nerve in the hand 
were anastomosed primarily to the 
median nerve stump in the forearm, 
using the operating microscope, 
with 9-0 and 10-0 nylon sutures. 
Motor and sensory branches of the 
ulnar nerve were likewise anas­
tomosed to the proximal ulnar 
nerve stump.
A large skin defect in the dorsum 
of the hand was covered with a 
distally based skin flap that had 
been degloved to the level of the 
metacarpophalangeal joints, but 
there remained a skin defect over 
the wrist and forearm. An interosse­
ous muscle fasciotomy was per­
formed under the flap.
To obtain soft-tissue coverage, all 
skin edges were first debrided. 
Using 4-0 nylon interrupted su­
tures, the skin was closed primarily 
on the volar surface of the hand. 
The remaining skin defect over the 
wrist and forearm was covered with 
a split-thickness meshed skin graft, 
taken from the patient’s right 
thigh. A running horizontal mat­
tress suture of 4-0 chromic catgut 
was used to sew the graft in place.
Drains were placed in the volar 
wrist and dorsal first web space. 
Dressings, a volar supporting slab 
and a protective tulip-type plaster 
splint were applied.
The patient was transferred to 
the recovery room where 2 units of 
packed red cells were given and 
mechanical ventilation was contin-
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ued. Antibiotics were administered. 
Total tourniquet time was 125 min­
utes. Total operative time was 21.5 
hours. The patient was extubated 
the next day.
Postoperative Follow-up
Five days postoperatively, the 
tulip splint was removed and a new 
splint fashioned by the occupational 
therapists was applied. Vascularity 
of the hand remained intact. The 
skin showed good healing. There 
was no wound dehiscence or infec­
tion. Physiotherapy was initiated to 
mobilize the fingers and thumb. 
Protected exercises and range-of- 
motion exercises were also started 
and were done several times daily.
Six weeks postoperatively, the 
patient was given a bivalved wrist 
cock-up splint to support the wrist 
fusion during active finger-flexion 
exercises. At this stage, he was 
being treated by the physiothera­
pists twice a week and performing 
various exercises at home. His moti­
vation continued to be very high, 
despite some reported pain during 
the exercises.
FIG. 3. Full active flexion of fingers is 
demonstrated 9 months postoperative­
ly.
At this time all but one of the 
K wires were removed. The final 
K wire at the base of the first 
metacarpal was removed 4 weeks 
later, at which time an anti-claw 
splint, to maintain the hand in a 
functional position, and dynamic 
extension splint were applied. Ul­
trasonography was used to loosen 
some scarring around the tendons. 
Over the next few months, the 
patient continued with therapy and 
was periodically assessed by physio­
therapy, occupational therapy and 
surgical staff.
At approximately 9 months the 
patient had achieved excellent func­
tional results. Constant and moving 
touch were intact to the tips of all 
but the little finger, which was 
intact to the proximal interphalan- 
geal joint. Although sensation was 
insufficient to provide two-point dis­
crimination, localization to constant 
touch stimulus was very good. Full 
active flexion of the fingers was 
evident (Fig. 3). Thumb flexion was 
good but limited by the fusion of 
the metacarpal to the radius. De­
spite this limitation, the patient was 
able to achieve a useful modified
FIG. 4. Modified key pinch was ob­
tained and was useful in patient’s daily 
life.
key pinch (Fig. 4). We believed 
function would further improve 
with continued therapy. Grip 
strength of his left hand was ap­
proximately 20% of that of the 
right. He had virtually full active 
extension of all his fingers except 
the long finger (Fig. 5). The wrist 
was fused, stable and pain free. The 
patient reported using his hand a 
great deal in daily life to perform 
such tasks as opening doors as well 
as carrying various objects.
Discussion
Considerable progress has been 
made in the field of limb salvage 
since 1962. While it is evident that 
full recovery cannot yet be 
achieved, useful function can be 
restored. This case demonstrates 
the results that can now be ob­
tained through current surgical 
techniques. In the past, a devastat­
ing injury such as this would have 
left the patient with an amputation 
stump and prosthetic device. It is 
important to point out that even 
though the functional recovery ob-
FIG. 5. There was full active extension 
of all fingers except long finger 9 
months postoperatively.
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tained is not complete, it is infinite­
ly preferable to an amputation.
The functional outcome depends 
a great deal on the follow-up thera­
py. Perhaps more important is the 
patient’s motivation to comply with 
such therapy. Expertise from reha­
bilitative therapists constitutes an
BOOK REVIEWS
continued from page 210
concludes with a section entitled “Un­
conscious guilt in the treatment of 
infected patients”.
Finally, there remains the question of 
price. The orthopedic resident studying 
for fellowship examinations may find 
this book rather expensive and the 
practising orthopedic surgeon may pre­
fer to rely on a quick discussion with 
colleagues in bacteriology and infec­
tious diseases. But for a concise and 
current presentation of the broad field 
of orthopedic infection, this text will be 
a welcome addition to medical libraries.
Kenneth S. Morton, MD, FRCSC, FACS
Department of Orthopedics,
University o f British Columbia,
910 West 10th Avenue,
Vancouver, BC
THE PERITONEUM AND PERITO­
NEAL ACCESS. Edited by S. Beng- 
mark. 376 pp. Illust. Butterworths, 
Stoneham, Mass. 1989. $225 (US). 
ISBN 0-7236-0767-2
This authoritative work on many facets 
of the peritoneum comprises 31 chap­
ters by different authors and deals with 
scientific knowledge of the peritoneum 
as well as the role of the peritoneum in 
clinical medicine.
The first 12 chapters deal with anat­
omy, ultrastructure and cellular biolo­
gy, as well as the physiology of perito­
neal fluid movements. The chapter on 
peritoneal microbiology is really a thor­
integral component of the overall 
management of these patients.
In celebrating its 500th reattach­
ment, Toronto’s microvascular team 
can look back on a history of 
significant advancement in the field 
and look forward to further im­
provement in the years to come.
ough discussion on the bacteriology of 
various types of peritonitis. Wound re­
pair is discussed under the heading of 
healing of the peritoneum and considers 
role of peritoneal closure. The impact of 
drains and foreign bodies in the perito­
neal cavity is discussed at a basic 
science level. Lymphatic drainage, the 
role of the diaphragmatic lymphatics in 
clearing the peritoneal cavity and lym­
phatic impairment in ascites are clearly 
dealt with. The first chapters also de­
scribe the role of prostaglandins in the 
peritoneal cavity; this chapter is too 
detailed for the average abdominal sur­
geon.
The majority of the next 12 chapters 
deal with the role of the peritoneum in 
dialysis, which has no relevance for the 
average abdominal surgeon, although I 
found these chapters well written. They 
describe the rationale, various tech­
niques and complications of peritoneal 
dialysis. Of importance to the surgeon, 
particularly the urologist associated 
with a dialysis unit, are several chapters 
dealing with the techniques of peritone­
al access. These include implantable 
reservoirs and pumps as well as the 
long-term use of catheters. Insertion 
techniques and complications are dis­
cussed thoroughly with excellent dia­
grams. Within the second 12 chapters, 
there is a detailed discussion of in- 
traperitoneal insulin administration and 
its potential role in the future. The role 
of intraperitoneal chemotherapy is dis­
cussed and will interest the oncologic 
surgeon.
The final seven chapters include a
We acknowledge the contribution made 
to this case by Drs. N. Hutchinson, J. 
Semple, E. Swanson and B. Kenny.
Reference
1. M alt RA, M cKhann CF: Replantation of 
severed arms. JAMA 1964; 189: 716-722
superb chapter on peritoneovenous 
shunting. It is succinct and well written 
and covers the techniques, indications 
and complications and how to deal with 
them. There is a thorough discussion of 
diagnostic peritoneal lavage which is 
excellent. The role of therapeutic la­
vage, particularly in pancreatitis is well 
discussed. Two chapters on laparoscopy 
are included. These are quite basic but 
describe the technique and its role in 
abdominal as well as pelvic disease. 
Laparoscopic surgical techniques are 
discussed briefly.
The layout of the book is good with 
many relatively short chapters, allowing 
the reader to find a particular area of 
interest easily. Although many of the 
authors are European, the text is very 
readable. Diagrams are appropriately 
used and are clear.
Considered as a whole, this book will 
be useful to the surgeon as well as the 
nephrologist, but will be of particular 
value to the surgical intensivist who 
needs a working knowledge of dialysis. 
It would certainly be of value to a 
urologist affiliated with a dialysis unit. 
As a reference book, it belongs in the 
library of any institution that has a 
dialysis unit. Its scope, however, is 
beyond what is required by the average 
general surgeon. Its list price of $225 
US may deter many potential buyers.
Ken Saunders, MD, FRCSC
Assistant Clinical Professor,
Department o f  Surgery,
McMaster University,
Hamilton, Ont.
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Effet de la cyclosporine sur la fonction 
renale apres transplantation cardiaque: 
peut-on diminuer la toxicite?
Michel Carrier, MD, FRCSC; Guy B. Pelletier, MD, FRCPC; Yves Leclerc, MD, FRCSC;
Yves R. Castonguay, MD; B. Charles Solymoss, MD, PhD; L. Conrad Pelletier, MD, FACS, FRCSC
Entre 1983 et 1988, 50 patients ont subi une transplantation cardiaque a l’ lnstitut 
de Cardiologie de Montreal. Au cours de cette periode, quatre protocoles d’immuno- 
suppression ont ete employes, chacun incluant la cyclosporine. L’association 
cyclosporine-prednisone a ete utilisee chez les premiers 24 patients (groupe 1). Une 
therapie triple composee de cyclosporine, prednisone et azathioprine a ete donnee a 
la periode perioperatoire chez 13 patients (groupe 2). L’utilisation prophylactique 
du serum anti-lymphocytaire de lapin et l’administration tardive, au 4eme jour 
postoperatoire, de la cyclosporine pour prevenir l’insuffisance renale precoce liee a 
cette derniere, fut choisie chez 13 autres patients (groupe 3). Devant la deterioration 
importante de la fonction renale du premier groupe, la creatinine passant a 255 ±
51 mmol/L et la clearance de la creatinine a 35 ±  2 ml/min 4 ans apres la 
transplantation, 1’immunosuppression chez 15 d’entre eux a ete modifiee pour une 
therapie triple par addition d’azathioprine et diminution des niveaux seriques de 
cyclosporine (groupe 4). Douze (80%) de ces derniers patients ont presente une 
amelioration significative de la fonction renale, 3 a 18 mois apres l’introduction de 
ces changements. Aucun patient des groupes 2 et 3 n’a presente d’insuffisance 
renale tardivement et les patients du groupe 3 ont tous conserve une fonction renale 
normale meme a la periode postoperatoire immediate.
En conclusion, d’importantes modifications au protocole d’immunosuppression 
ont permis de reduire la toxicite renale precoce et tardive due a la cyclosporine, 
apres transplantation cardiaque.
Between 1983 and 1988, 50 patients underwent cardiac transplantation at the 
Institut de Cardiologie de Montreal. During this period, four immunosuppression 
protocols were used, each including cyclosporine. A combination of cyclosporine and 
prednisone was used in the first 24 patients (group 1). Triple combination 
immunosuppression (cyclosporine, prednisone and azathioprine) was given 
perioperatively in 13 patients (group 2). The prophylactic use of rabbit 
antithymocyte globulin and late administration (4 days postoperatively) of 
cyclosporine to prevent early renal failure associated with cyclosporine therapy was 
chosen in 13 other patients (group 3). Owing to serious deterioration of renal 
function in 15 of the 24 group 1 patients, the serum creatinine levels reaching 255 
±  51 mmol/L and the creatinine clearance 34 ±  2 ml/min between 6 months and 4 
years after transplantation, immunosuppression was modified to triple-combination 
therapy by the addition of azathioprine and a reduction of the serum levels of 
cyclosporine (group 4). Twelve of the 15 patients showed a substantial improvement 
in renal function from 3 to 18 months after these changes were introduced. No 
patient in groups 2 and 3 had late renal insufficiency, and in all group 3 patients 
renal function remained normal as in the immediate postoperative period.
In conclusion, important modifications in protocol permitted a reduction of early 
and late renal failure due to cyclosporine after cardiac transplantation.
L a transplantation cardiaque est devenue une approche thera- 
peutique valable dans le traitement 
des patients atteints de maladies 
cardiaques en phase terminale. Les 
recents succes de cette approche 
sont principalement lies a l’utilisa- 
tion de la cyclosporine comme 
agent immunosuppresseur.1-3 
Toutefois, cette medication est en- 
tachee d’effets secondaires impor- 
tants dont, particulierement, l’hy- 
pertension arterielle et 1’insuffisance 
renale.4 L’atteinte de la fonction 
renale se presente essentiellement 
sous forme d’une oligoanurie au 
cours de la periode postoperatoire 
ou d’une deterioration progressive 
de la fonction renale apres quelques 
mois ou quelques annees.
Dans notre milieu, l’association 
de cyclosporine et de prednisone fut 
utilisee en immunosuppression au 
cours de la phase initiale de notre 
experience clinique. Etant donne 
l’apparition d’une toxicite renale 
non negligeable chez ces patients, 
nous avons modifie notre approche. 
Les effets de ces changements de
Du departement de chirurgie, departement 
de medecine et departement de pathologie, 
Institut de Cardiologie de Montreal et Uni­
versity de Montreal, Montreal, PQ
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adressees au: Dr Michel Carrier, Ins titu t de 
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regime immunosuppresseur sur la 
fonction renale font l’objet de cette 
etude.
Materiel clinique
De 1983 a 1988, 50 patients ont 
subi une transplantation cardiaque 
a l’lnstitut de Cardiologie de Mon­
treal. Ces patients ont ete selection- 
nes selon les criteres habituels.5 
Aucun d’entre eux ne presentait 
d’atteinte renale preoperatoire im- 
portante.
Ce groupe de patients comprend 
5 femmes et 45 hommes dont l’age 
moyen est de 43 ± 1 ans. Les 
cardiomyopathies ischemiques (32), 
idiopathiques (13) et rhumatismales 
(5) furent responsables de la defail- 
lance ayant conduit a la transplan­
tation cardiaque. Le diagnostic du 
rejet fut etabli par biopsie endomyo- 
cardique selon la classification de 
Billingham.6
Quatre protocoles d’immunosup- 
pression ont ete utilises (tableau I). 
De 1983 a 1986 (groupe 1), 24 
patients ont re?u l’association cy­
closporine et prednisone. En 1987 
(groupe 2), une therapie triple com- 
posee de cyclosporine, prednisone 
et azathioprine a ete donnee a partir 
de la periode preoperatoire chez 13 
patients. En 1988 (groupe 3), l’utili- 
sation prophylactique du serum an- 
ti-lymphocytaire de lapin (RATG) a 
permis de retarder l’administration 
de la cyclosporine au 4eme jour 
postoperatoire chez 13 patients. Fi- 
nalement, un protocole de conver­
sion a la therapie triple (groupe 4) a 
ete applique a 15 patients du pre­
mier groupe, suite a une deteriora­
tion de leur fonction renale entre 6 
mois et 4 ans apres la transplanta­
tion. Ce dernier protocole implique 
l’administration, a doses progressi­
ves, d’azathioprine jusqu’a l’obten- 
tion d’une baisse du nombre des 
globules blancs entre 5000 et 8000
T a b le a u  1. P ro to c o le s  d ’ im m u n o s u p p re s s io n
No. de
G roupe patien ts P rotocole
1 24 C yc lo sp o r in e  (C S A ) e t p re d n ison e .
CSA dose  d 'a tta q u e  p re o p e ra to ire  10  m g /k g  pa r v o ie  ora le , 
d o se s  su iva n te s  se lo n  les n ive au x  se riq u e s  m a in te n u s  a u tou r de 
150  n g /m l.
P re dn iso n e  1 m g /k g  a 0 .2  m g /k g  1 m o is  a p re s  tra n s p la n ta tio n .
2 13 C y c lo sp o rin e , p re d n is o n e  et a za th io p rin s .
CSA dose  d 'a tta q u e  p re o p e ra to ire  6  m g /k g  par vo ie  ora le , d oses  
su iva n te s  se lo n  les  n iveaux s e riq u e s  m a in te n u s  a u tou r de 100  
n g /m l.
P re dn iso n e  1 m g /k g  a 0 .2  m g /k g  1 m o is  ap res  tra n sp la n ta tio n . 
A za th io p rin e  d o se  d 'a ttaq u e  p re o p e ra to ire  4  m g /k g  par vo ie  o ra le  
e t d o se s  s u iv a n te s  v isa n t a m a in te n ir  le n o m b re  des g lo b u le s  
b la n cs  e n tre s  5 0 0 0  e t 8 0 0 0 /m m .
3 13 R A T G t, c y c lo s p o r in e , p re d n ison e  e t a za th io p rin e .
CSA de b u te e  au 4 e m e  jo u r p o s to p e ra to ire .
RATG 1 2 5  m g / j  par vo ie  IV p o u r 3  j.
CSA n ive au x  se riq u e s  m a in te n u s  a u to u r de  50  a 100 n g /m l.  
P re dn iso n e  1 m g /k g  a 0 .2  m g /k g  1 m o is  a p re s  tra n sp la n ta tio n . 
A za th io p r in e  d o se  d 'a ttaq u e  p re o p e ra to ire  4  m g /k g  par vo ie  o ra le  
e t d o se s  s u iv a n te s  v isa n t a m a in te n ir  le  n o m b re  des g lo b u le s  
b la n cs  e n tre  5 0 0 0  e t 8 0 0 0 /m m .
4 1 5 * C o n ve rs io n  a la th e ra p is  tr ip le .
A za th io p rin e  2 5  m g / j e t d o se  a ju s tee  p o u r  m a in te n ir  le n o m b re  
des g lo b u le s  b la n c s  en tre  5 0 0 0  e t 8 0 0 0 /m m .
R e duc tion  p ro g re s s iv e  du n ive au  de c y c lo s p o r in e  en tre  5 0  e t 100 
n g /m l.
* A u s s i partie  du  g ro u p e  1
tS e r u m  a n ti- ly m p h o c y ta ire  de lap in .
cellules/mm, la diminution des ni- 
veaux seriques de cyclosporine 
entre 50 et 100 ng/ml et la main- 
tien de la prednisone orale a la dose 
quotidienne d’entretien de 0.2 
mg/kg.
Le dosage serique de la cyclospo­
rine a ete effectue par radio-immu- 
no dosage. Les niveaux de creatini­
ne ont ete mesures quotidiennement 
pendant l’hospitalisation a la suite 
de la transplantation et a chaque 
visite en clinique externe. Une col- 
lecte urinaire de 24 heures pour 
mesurer la clearance de la creatini­
ne a ete faite a chaque annee apres 
transplantation.
Les resultats sont exprimes en 
moyennes ± ecart-type. La differen­
ce entre deux moyennes fut evaluee 
par le test de t, alors que la differen­
ce entre plusieurs moyennes le fut 
par analyse de variance (ANOVA). 
La survie est exprimee selon la 
methode actuarielle et la difference 
entre deux courbes de survie fut 
etudiee a l’aide du test de Mantel- 
Cox. Le niveau de signification sta- 
tistique fut etabli a 95%.
FIG. 1. Fonction renale evaluee par la 
creatinine du groupe 1 (CSA et predni­
sone) (n =  24).
FIG. 2. Fonction renale evaluee par la 
clearance de la creatinine du groupe 1 
(CSA et prednisone) (n = 19).
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Resultats
Au cours de l’experience initiale, 
chez le premier groupe de 24 pa­
tients sous cyclosporine et predni­
sone, nous avons observe une 
deterioration lente et progressive de 
la fonction renale telle que re­
presentee par les niveaux de creati­
nine et de clearance de la creatinine 
(figs. 1 et 2). Les parametres de 
fonction renale se deteriorent alors 
que les niveaux seriques de cyclos­
porine sont maintenus en moyenne 
a 152 ± 10 ng/ml. Lors de la 
premiere annee, la creatinine est 
passee de 99 ± 7 mmol/L, 1 mois 
apres la transplantation, a 157 ± 7 
mmol/L apres 12 mois. Cette 
deterioration se poursuit par la 
suite de faqon progressive jusqu’a 4 
ans apres la transplantation alors 
que la creatinine atteint 255 ± 5 1
Groupe 1 Groupe 2
*  p<0.05 (CSA ♦ Prednisone) (CSA ♦ Prednisone ♦ AZA)
FIG. 3. Fonction renale evaluee par les 
niveaux de creatinine du groupe 1 
(CSA et prednisone, n =  18) et groupe 
2 (CSA, prednisone et azathioprine 
[AZA], n = 10) 1 an apres la trans­
plantation.
Groupe 1 Groupe 2
p<0.05 (CSA ♦ Prednisone) (CSA ♦ AZA ♦ Prednisone)
FIG. 4. Fonction renale evaluee par la 
clearance de la creatinine du groupe 1 
(CSA et prednisone, n =  15) et groupe 
2 (CSA, prednisone et azathioprine, n 
= 10) 1 an apres la transplantation.
CYCLOSPORINE ET FONCTION RENALE
mmol/L et la clearance de la creati­
nine 35 ± 2 ml/min.
Dans le deuxieme groupe (13 
patients), avec therapie triple en 
perioperatoire, la fonction renale 
demeure normale 1 an apres la 
transplantation, avec une creatinine 
de 120 ± 8 mmol/L et une legere 
diminution de la clearance de la 
creatinine a 79 ±  8 ml/min. L’evo- 
lution de la fonction renale differe 
du premier groupe chez qui la crea­
tinine etait de 157 ± 7 mmol/L et 
la clearance de 57 ± 6 ml/min a la 
meme periode postoperatoire (figs. 
3 et 4). Toutefois, revolution posto­
peratoire immediate fut aussi diffici­
le pour le deuxieme groupe, tous 
les patients presentant une eleva­
tion transitoire de la creatinine et 
quatre d’entre eux ayant developpe 
une oligoanurie transitoire.
Chez les patients du troisieme 
groupe (13 patients), traites par 
RATG suivi de cyclosporine au 
4eme jour, il n’y eut aucun episode 
d’oligoanurie pendant la phase pos­
toperatoire precoce, ni elevation de 
la creatinine. La creatinine etait en
FIG. 5. Effets de la conversion a la 
therapie triple sur la creatinine chez 
12 patients.
FIG. 6. Effets de la conversion a la 
therapie triple sur la clearance de la 
creatinine chez 12 patients.
moyenne de 117 ± 11 mmol/L a la 
fin de la premiere semaine et elle est 
demeuree normale, avec une 
moyenne de 97 ± 2 mmol/L, 1 an 
apres la transplantation.
Enfin, le groupe 4, constitue de 
15 des 24 premiers patients, dont le 
traitement immunosuppresseur a 
ete modifie par l’addition d’azathio- 
prine pour diminuer la cyclosporine, 
a montre une amelioration sensible 
de la fonction renale apres modifica­
tion du traitement. Les niveaux 
seriques de cyclosporine furent di- 
minues de faqon significative de 
146 ± 13 a 100 ± 12 ng/m l (p < 
0.05), la creatinine a diminue de 
199 ± 23 a 160 ± 18 mmol/L et la 
clearance est passee de 46 ±  6 a 75 
± 15 ml/min, de 3 a 18 mois apres 
le debut de la therapie triple chez 
ces malades. L’amelioration de la 
fonction renale fut observee chez 
12 (80%) de ces 15 patients, avec 
une diminution significative de la 
creatinine et une augmentation de 
la clearance de la creatinine (figs. 5 
et 6). Dans ces cas, il y avait 
correlation significative entre les ni­
veaux seriques de cyclosporine et 
ceux de la creatinine (r =  0.66). Par 
contre, trois patients n’ont pas 
demontre une amelioration de la 
fonction renale, dont Tune evolua 
vers une insuffisance renale chroni- 
que qui a necessite des hemodialy­
ses et une greffe renale.
L’azathioprine a du etre inter- 
rompue chez deux patients qui ont 
presente une anemie et une infec­
tion virale resistante au traitement. 
Parmi ces 15 patients, aucun episo­
de de rejet n’a ete detecte au cours 
de la periode de changement. Un 
patient a developpe un sarcome de 
Kaposi, dont le diagnostic a ete 
etabli 30 mois apres la transplanta­
tion alors qu’il etait sous therapie 
triple.
De plus, ces changements au pro­
tocole d’immunosuppression n’ont 
pas eu que des effets sur la fonction 
renale. En effet, la survie actuarielle
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fut de 92 ± 6% 1 an apres la 
transplantation pour le groupe rece- 
vant la therapie triple (groupes 2 et 
3) comparativement a 83 ± 7% 
pour les patients sous cyclosporine 
et prednisone (groupe 1) (fig. 7). 
Enfin, la therapie triple a aussi 
diminue de fa?on significative l’inci- 
dence des episodes de rejet sans 
augmenter celle des episodes infec- 
tieux (tableau II).
Discussion
L’insuffisance renale, l’infection 
et le rejet, represented les compli­
cations les plus frequentes apres 
transplantation cardiaque depuis 
l’utilisation de la cyclosporine 
comme un agent immunosuppress- 
eur.7’8
L’insuffisance renale progressive 
survenant quelques mois ou quel- 
ques annees apres la transplantation 
a ete attribute a une atteinte tubu- 
lo-glomerulaire, comme le demon- 
trent les lesions histologiques im- 
portantes d’atrophie tubulaire, de 
fibrose interstitielle et de glome- 
rulosclerose.9 Malgre les effets toxi- 
ques de la cyclosporine sur les 
tubules renaux et les lesions histo­
logiques, nous avons constate une 
reversibilite partielle de l’insuffisan­
ce renale avec la diminution des 
niveaux seriques de cyclosporine de 
6 mois a 4 ans apres la transplanta­
tion, diminution rendue possible par 
l’addition de l’azathioprine. De plus, 
lorsque la therapie triple est debu- 
tee d’emblee a la periode periopera- 
toire, cette triple association impli- 
quant de faibles niveaux de cyclos­
porine, permet d’eviter le risque 
d’insuffisance renale precoce et de 
maintenir une fonction renale nor- 
male 1 an apres la transplanta­
tion.10' 13
Une incidence elevee de rejet et 
une mortality non negligeable fu- 
rent rapportees a la suite de l’arret 
de la cyclosporine et de son rempla- 
cement par une immunosuppression
conventionnelle composee d’aza- 
thioprine et de prednisone seule- 
ment.14' 16 Le protocole de conver­
sion a la therapie triple tel qu’utilise 
dans l’etude presente n’a pas provo- 
que d’effet secondaire important en 
ce qui a trait au rejet et a l’infec­
tion, et il a entraine une ameliora­
tion significative de la fonction 
renale pour 80% des patients. De 
plus, ces changements au traite- 
ment immunosuppresseur ont ete 
effectues progressivement en clini- 
que externe, sans necessiter d’hos- 
pitalisation.
L’atteinte precoce de la fonction 
renale, se presentant sous forme 
d’une oligoanurie postoperatoire, 
semble reliee a un effet hemodyna- 
mique aigu de la cyclosporine qui
produit une diminution du flot san- 
guin cortical. L’administration tar­
dive, progressive et a faible dose de 
la cyclosporine au 4eme jour posto­
peratoire apres stabilisation hemo- 
dynamique a permis d’eliminer en- 
tierement ce probleme et la morbidi- 
te qui lui est associee. Ceci a ete 
rendu possible par l’utilisation pro- 
phylactique du RATG au cours des 
jours postoperatoires 1 a 3.1718 
Ce protocole, en plus de proteger 
la fonction renale precocement 
apres la chirurgie, a aussi permis le 
maintien d’une fonction renale nor- 
male tout au long de la premiere 
annee apres transplantation.19
Toutefois, en plus de la fonction 
renale, il est aussi important d’eva- 
luer attentivement l’effet des chan-
FIG. 7. Effets de l’administration de la therapie triple sur la survie actuarielle 
(groupe 1, n =  24; groupes 2 et 3, n =  26).
Tableau II. Incidence des episodes de rejet et d'infection selon les quatre protocoles
Groupe
No. de 
patients
Rejet
(no.
d’episodes/patient)
Infection
1 -  CSA -  prednisone 24 1.3 ± 1 1.7 ± 4
2 -  CSA -  prednisone -
azathioprine 13 0.8 ± 1 t 0.3 ± 1
3 -  CSA -  prednisone -
azathioprine -  RATG 13 0.3 ± 1 t 0.3 ± 1
4 -  Apres la conversion tardive 15* 0 0
*Les 15 patients font aussi partie du groupe 1. 
tp  < 0.05.
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gements de la medication sur l’en- 
semble des resultats cliniques. L’u- 
tilisation de l’azathioprine et du 
RATG ont entralne une diminution 
de l’incidence de rejet sans causer 
d’augmentation des episodes infec- 
tieux. De plus, la survie actuarielle 
s ’est trouvee legerement amelioree 
avec la therapie triple bien que les 
changements ne soient pas signifi- 
catifs.
En conclusion, l’utilisation de la 
cyclosporine a permis le developpe- 
ment de la transplantation d’organe 
comme therapeutique courante. La 
greffe cardiaque est ainsi devenue 
une procedure bien acceptee et 
mieux etablie. Notre experience 
demontre que tout en conservant 
les qualites immunosuppressives de 
la cyclosporine, les effets toxiques 
renaux peuvent etre evites par une 
modification de l’approche immuno­
suppressive visant a maintenir la 
cyclosporine a des niveaux seriques 
plus faibles, grace a l’utilisation 
d’une therapie triple composee de 
cyclosporine, azathioprine et pred­
nisone. Pour ce qui est de l’atteinte 
renale deja etablie, il semble qu’elle 
soit du moins en partie reversible 
par le changement de regime immu- 
nosuppresseur, meme plusieurs an- 
nees apres la transplantation et ce, 
sans augmentation du risque de 
rejet, si la modification therapeuti­
que est effectuee graduellement 
pour assurer le maintien constant 
d’un niveau d’immunosuppression 
adequat.
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GENERAL SURGEON
PERM ANENT AND/OR LOCUM
A general surgeon is required, either as a 
summer locum and/or permanently, to 
join a busy community practice in PEI. The 
present medical centre has twenty doc­
tors, split evenly between GPs and spe­
cialists. The practice requires three gener­
al surgeons; as of July 1, 1990 it will have 
only two. Experience in orthopedics and 
urology would be an asset, but not a 
necessity. LMCC and FRCSC required for 
licensure.
Applications to:
W.L. Walker, MD, FRCSC 
Summerside Medical Center 
Summerside, PEI
C 1N 3N 9 _s
_________Tel: (902) 436-9283 bau 14
GENERAL SURGERY PRACTICE: BC -  Lu­
crative practice in the lower mainland. Excel­
lent on-call schedule. Superb recreational area 
on doorstep. Full complement of specialists 
present. Reply in confidence to: Box 982, 
CJS. -S90-17
GENERAL SURGEON: ON -  A general sur­
geon is required for a 542-bed community 
hospital in a rapidly growing city on the 
outskirts of metropolitan Toronto. Please 
send curriculum vitae and enquiries to: Dr. T. 
Varga, Chief of Surgery, c/o Program Ad­
ministration Office, Peel Memorial Hospi­
tal, 20 Lynch St., Brampton, ON L6W 2Z8.
-S90-15
THORACIC SURGEON: AB -  Applications 
are invited for an active staff position at the 
University of Alberta Hospitals in the Division 
of Cardiovascular and Thoracic Surgery of the 
Department of Surgery. Candidates must 
have the fellowship of the Royal College of 
Physicians and Surgeons of Canada in cardio­
vascular and thoracic surgery or certification 
of special competence in thoracic surgery. 
The position will carry an appropriate clinical 
rank in the Faculty of Medicine for the Univer­
sity of Alberta and candidates must be willing 
to participate in the teaching programs of the 
faculty and support academic activity. They 
must also be eligible for registration with the 
College of Physicians and Surgeons of Alber­
ta. In accordance with Canadian immigration 
requirements, this advertisement is directed 
to Canadian citizens and permanent residents 
of Canada. Please submit a current curriculum
CHIEF OF SURGERY
Central Hospital is expanding its community services to 
keep pace with evolving needs of its exciting, culturally 
diverse, downtown community. To meet these needs the 
Hospital has appointed a new Medical Director and is 
currently seeking to recruit an imaginative, energetic, Chief 
of Surgery. As Chief of Surgery in an accredited 176-bed 
community hospital, located in the core of Downtown 
Toronto, you will provide leadership in further developing 
existing practice guidelines and quality assurance programs 
to meet the surgical needs of the community in the 1990’s, 
and to ensure the effective utilization of in-patient and day 
surgical facilities as required to fulfill the demands of the 
primary health care physicians in their new Department.
The successful applicant will head a sizeable Department 
including general surgery and the specialties of 
orthopaedics, urology, plastic surgery, ophthalmology and 
otolaryngology. Preference will be given to applicants with 
recent academic and/or administrative backgrounds.
Send Curriculum Vitae to the 
Medical Director.
yCENTRAL I
—S90-21
HOSPITALJ
333 Sherbourne Street, Toronto, Ontario M5A 2S5 
The Best Care in Any Language
vitae and the names of three referees by June 
30, 1990 to: Dr. Bryce Weir, Chairman. 
Department of Surgery, Faculty of Medi­
cine, University of Alberta, 2D2 Walter C. 
Mackenzie Health Sciences Centre, 8440  
- 112 St. Edmonton, AB T6G 2B7. The 
University of Alberta is committed to the 
principle of equity in employment.
-S90-16
CLINICAL FELLOW IN 
NEUROSURGERY
Applications are invited for the position of clinical fellow in 
neurosurgery, Memorial University of Newfoundland. The post 
becomes vacant July 1,1990 and is for a period of 1 year (renewable). 
The Provincial Neurosurgeiy Unit is based at the Health Sciences 
Centre. Previous experience  in neurosurgery is required. 
Salary — $46 488.
In accordance with Canadian immigration requirements, priority will 
be given to Canadian citizens and permanent residents.
For further information contact:
Dr. F.B. Maroun, Acting Chairman 
Discipline of Surgery 
Memorial University 
Health Sciences Centre 
St. John’s, NF
A1B 3V6 —S90-24
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HEAD, DIVISION OF GENERAL SURGERY 
ST. MICHAEL’S HOSPITAL
St. Michael’s Hospital, a 700-bed active treatment 
teaching hospital, fully affiliated with the University of 
Toronto, invites applications for the position of Head, 
Division of General Surgery.
Located in downtown Toronto, the hospital is in close 
proximity to the University of Toronto and other major 
teaching and research activities.
Essential requirements for the position include a clear 
commitment to patient care, demonstrated clinical and 
managerial expertise and proven leadership in teaching 
and research.
Applicant must have certification by the Royal College of 
Physicians and Surgeons of Canada or equivalent.
The successful candidate will be jointly appointed to the 
Department of Surgery in the Faculty of Medicine at the 
University of Toronto.
In accordance with Canadian immigration requirements, 
this advertisement is directed to Canadian citizens and 
permanent residents.
Please apply with curriculum vitae by June 30, 1990 to:
Dr. J.C. Platt, MD
Vice P resident, Medical A ffa irs
St. M ichael’s Hospital
30 B ond S tree t
T o ro n to , O ntario
M5B 1W8
Tel: (416) 864-5041 _S9o-18
TEXAS A&M UNIVERSITY 
College o f Medicine
TEMPLE CAMPUS
The Department o f Neurologic Surgery o f the Scott 
and White Institutions and Texas A&M University 
College o f Medicine is seeking applications for 
senior staff physician faculty in the Sections o f 
Pain/Stereotaxic Surgery or Neurosurgical Oncology. 
Residency or post residency experience and a 
defined interest in either subspecialty area together 
with a broad capability and interest in general 
neurosurgical disorders is desired. Basic and clinical 
research opportunities are available commensurate 
with previous experience. Medical student and 
resident teaching/daily responsibilities are required. 
The main campus is located in central Texas, north 
of Austin in the approximate center o f the Dallas/ Ft. 
Worth, San Antonio, Houston triangle and benefits 
from easy access to other surrounding universities 
(Southwestern University, Georgetown; University of 
Mary Hardin-Baylor, Belton; Baylor University, 
Waco.)
For further information, please send curriculum 
vitae and references to:
M itc h e ll S m ig ic l, M .D .
C ha irm an , N euro log ic  S u rg e ry  
Scott and W h ite , Texas A &M  U n iv e rs ity  
C ollege o f  M e d ic ine  
2401 South  31st S tree t 
T e m p le , TX 76 508
—S90-06
LEADERSHIP IN SURGICAL ONCOLOGY
The Ontario Cancer Institute incorporating 
the Princess Margaret Hospital is 
Canadas largest centre for cancer 
treatment, research and education, and 
the major tertiary care cancer centre in the 
Province of Ontario. The care, vision and 
professional collaboration of this staff 
have earned OCI/PMH an international 
reputation for excellence.
In collaboration with the Faculty 
Departments of Surgery, Otolaryngology, 
Ophthalmology and Obstetrics and 
Gynaecology of the University of Toronto, 
the OCI/PMH wishes to appoint a Head 
and create a program in Surgical 
Oncology to function in parallel with the 
Departments of Medical and Radiation 
Oncology. This program, with its 
academic base at OCI/PMH, would be 
part of a broad initiative in multidisciplinary 
cancer patient care enacted through the 
OCI/PMH and participating hospitals 
affiliated with the University of Toronto.
Responsibilities of the appointee will 
include planning and priority setting within 
the Surgical Oncology program, 
development and maintenance of a 
research program in collaboration with the 
Department of Research, supervision of 
the educational program in undergraduate 
and post-graduate Surgical Oncology, 
administrative responsibility for the 
Surgical Oncology program and liaison 
with other organizations such as 
government, universities and industry. 
The incumbent will have a major
opportunity to help shape oncology 
programs for the new Princess Margaret 
Hospital prior to and following its 
relocation in 1993 to its University Avenue 
site.
Professional qualifications and
accomplishments appropriate to this
important leadership position will 
encompass substantial achievement in 
the clinical, administrative, and
research/teaching domains. The 
appointment will be at the Associate or full 
Professor level within the appropriate 
faculty department of the University of 
Toronto.
Canadian citizens will be given priority 
consideration. Surgeons attracted by this 
important and challenging opportunity 
should submit a current curriculum vitae 
with their letter of application to Mr. W.R. 
Livingston, Chairman, Search 
Committee for Head o f Surgical 
Oncology, The Princess Margaret 
Hospital, 500 Sherbourne St., Toronto, 
Ontario, M4X 1K9 by June 31,1990.
Iscarr& w H iTE
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General Surgeon
This vital young community of 35,000 seeks a general surgeon. 
Office space available with another surgeon in a very rewarding 
and lucrative practice with excellent referral base. Enjoy state 
of the art technology, a full range of diagnostic and procedural 
services including CT scan, and six O.R. theatres offering flexi­
ble schedules and minimal waiting time. Our 300-bed hospital 
is fully accredited, with planned expansion of the 150 beds cur­
rently open. The city offers superb recreational, cultural, and 
educational facilities. Don't miss this exceptional opportunity!
Contact:
The President
Fort McMurray Regional Hospital 
7 Hospital Street
Fort McMurray, Alberta T9H 1P2 
Phone (403) 791-6161
Fort McMurray
Regional
Hospital
CLEAN AIR ENVIRONMENT
-S90-19
The Calgary 
General Hospital i *
Bow Valley Centre 
Peter Lougheed Centre
General Surgeon
The Calgary General Hospital invites 
applications for a position in General 
Surgery. The successful applicant will be 
expected to have specialized training and 
interest in thoracic or peripheral vascular 
surgery and to participate in undergraduate 
and post-graduate teaching and research. 
The candidate should be a Fellow of the 
Royal College of Physicians and Surgeons 
of Canada and be eligible for licensure by 
the College of Physicians and Surgeons of 
Alberta.
The Calgary General Hospital is a 940-bed 
teach ing hospita l a ffilia ted  with the 
University of Calgary.
In a c c o r d a n c e  w i t h  i m m i g r a t i o n  
requirements, preference will be given to 
Ca nad ia n  c i t i z en s  and p e rmane nt  
residents.
Reply, including curriculum vitae and the 
names of three referees, to:
Director, Department of Surgery
The Calgary General Hospital - Bow Valley Centre
841 Centre Avenue E. Calgary, Alberta T2E 0A1
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INTENSIVIST/GENERAL
SURGEON
NOVA SCOTIA
Dalhousie University, Department of 
Surgery Hospital invites applications 
from individuals with an FRCSC in 
gene ra l s u rg e ry  and fo rm a l 
postgraduate training in critical care 
along w ith a proven research 
background for a position prime 
based at the V ictoria General 
Hospital. Duties will include an active 
involvement in basic and/or clinical 
research and undergraduate and 
postgraduate  educa tion . The 
successful applicant will assume 
co-directorship of a surgical intensive 
care unit and will be a member of the 
hospita l based traum a team. 
Dalhousie University has a policy of 
affirmative action in hiring qualified 
women academic sta ff and in 
a c c o rd a n c e  w ith  C a n a d ia n  
immigration requirements, this 
adve rtisem en t is d ire c te d  to 
Canadian citizens and permanent 
residents. All interested persons 
should send their resume to:
Dr. A.J. Bodurtha, Head, 
D epartm ent o f  Surgery, 
V ic to ria  General H osp ita l, 
Suite 8-032 
1278 T ow e r Road 
H alifax, Nova Scotia
B3H 2Y9 — S90-23
NANAIMO REGIONAL 
GENERAL HOSPfTAL 
Requires An
Orthopaedic
Surgeon
The Nanaimo Regional General 
Hospital is searching for an 
orthopaedic surgeon to join four 
others on the medical staff. Our 436 
bed regional referral hospital 
provides community hospital 
services for an immediate 
population of 85,000 and secondary 
referral services for a population of 
250,000.
Nanaimo is a scenic harbour city 
with exceptional recreational 
opportunities on the east coast of 
Vancouver Island. We are looking 
for a surgeon who is interested in 
establishing a busy, general 
orthopaedic practice in this very 
desirable location.
Interested orthopaedic surgeons 
should forward a curriculum vitae 
and the names of three references 
to Dr. B. Johnstone, Medical 
Coordinator, Nanaimo Regional 
General Hospital, 1200 Dufferln 
C rescen t, N anaim o, B.C. 
V9S 2B7.
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Does Your Injectable H2 Antagonist Provide Prompt, Persistent Gastric pH Control?
The on set o f  a n tis e cr eto ry  e f f e c t  o f  PEPCID® 20 m g I. V. was n o ted  as ea r ly  as on e hou r a fter  
adm in istra tion  in a study of hypersecretor individuals.1 Mean gastric pH values were maintained above 
4.0 for up to 12 hours. The convenient ql2h dosage of PEPCID® I.V. may mean significant cost savings 
and a reduction in time needed to prepare medication. So for prompt, persistent pH control: PEPCID®. 
For many patients with pathological hypersecretory conditions or intractable 
ulcers, or for short term use in patients unable to take oral medication. __  / q!2h
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for deep cavity surgery
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